{"PMC7235495": [["As Dr Thomson eloquently notes in his valuable letter,1underlying respiratory diseases appear to be less of a risk factor for poor outcome in COVID\u201019 patients than either underlying cardiovascular disease or diabetes.", [["respiratory", "ANATOMY", 66, 77], ["cardiovascular", "ANATOMY", 183, 197], ["respiratory diseases", "DISEASE", 66, 86], ["cardiovascular disease", "DISEASE", 183, 205], ["diabetes", "DISEASE", 209, 217], ["patients", "ORGANISM", 151, 159], ["patients", "SPECIES", 151, 159], ["1underlying respiratory diseases", "PROBLEM", 54, 86], ["underlying cardiovascular disease", "PROBLEM", 172, 205], ["diabetes", "PROBLEM", 209, 217], ["respiratory", "ANATOMY", 66, 77], ["diseases", "OBSERVATION", 78, 86], ["cardiovascular", "ANATOMY", 183, 197], ["disease", "OBSERVATION", 198, 205], ["diabetes", "OBSERVATION", 209, 217]]], ["This intriguing finding emerged from several studies that examined underlying medical conditions in COVID\u201019 patients.", [["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 109, 117], ["several studies", "TEST", 37, 52], ["underlying medical conditions", "PROBLEM", 67, 96]]]], "PMC7457993": [["Financial support and sponsorshipNil.Conflicts of interestThere are no conflicts of interest.", [["Financial support", "TREATMENT", 0, 17], ["sponsorshipNil", "TREATMENT", 22, 36], ["no", "UNCERTAINTY", 68, 70], ["conflicts", "OBSERVATION", 71, 80]]]], "PMC7537022": [], "ea6c3d35646adfcd7e1c55d7d1f0998ba1107d89": [["nucleus are inhibited, and a number of viral nucleolar antigens accumulate in the nucleoli of infected cells (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) .", [["nucleus", "ANATOMY", 0, 7], ["nucleolar", "ANATOMY", 45, 54], ["nucleoli", "ANATOMY", 82, 90], ["cells", "ANATOMY", 103, 108], ["nucleus", "CELLULAR_COMPONENT", 0, 7], ["nucleolar antigens", "GENE_OR_GENE_PRODUCT", 45, 63], ["nucleoli", "CELLULAR_COMPONENT", 82, 90], ["cells", "CELL", 103, 108], ["viral nucleolar antigens", "PROTEIN", 39, 63], ["viral nucleolar antigens", "TEST", 39, 63], ["viral nucleolar antigens accumulate", "OBSERVATION", 39, 74], ["nucleoli", "OBSERVATION_MODIFIER", 82, 90], ["infected cells", "OBSERVATION", 94, 108]]], ["Moreover, two cellular nucleolar antigens, UBF 1 and B23.1, have been shown to be sequestered into viral DNA replication centers where they affect viral DNA replication (11) (12) (13) .", [["cellular nucleolar", "ANATOMY", 14, 32], ["cellular", "CELL", 14, 22], ["UBF 1", "GENE_OR_GENE_PRODUCT", 43, 48], ["B23.1", "GENE_OR_GENE_PRODUCT", 53, 58], ["DNA", "CELLULAR_COMPONENT", 105, 108], ["DNA", "CELLULAR_COMPONENT", 153, 156], ["cellular nucleolar antigens", "PROTEIN", 14, 41], ["UBF 1", "PROTEIN", 43, 48], ["B23.1", "PROTEIN", 53, 58], ["two cellular nucleolar antigens", "TEST", 10, 41], ["UBF", "TEST", 43, 46], ["viral DNA replication centers", "TREATMENT", 99, 128], ["viral DNA replication", "TREATMENT", 147, 168], ["cellular nucleolar antigens", "OBSERVATION", 14, 41]]], ["Thus, there is clear evidence that adenovirus infection has a substantial impact on the composition and function of the nucleolus.", [["nucleolus", "ANATOMY", 120, 129], ["adenovirus infection", "DISEASE", 35, 55], ["adenovirus", "ORGANISM", 35, 45], ["nucleolus", "CELLULAR_COMPONENT", 120, 129], ["adenovirus", "SPECIES", 35, 45], ["adenovirus infection", "PROBLEM", 35, 55], ["adenovirus", "OBSERVATION_MODIFIER", 35, 45], ["infection", "OBSERVATION", 46, 55], ["substantial", "OBSERVATION_MODIFIER", 62, 73], ["impact", "OBSERVATION_MODIFIER", 74, 80], ["nucleolus", "ANATOMY", 120, 129]]], ["What is not clear is whether the sequestration of cellular nucleolar antigens is limited to a small number of proteins or widespread.", [["cellular nucleolar", "ANATOMY", 50, 68], ["cellular", "CELL", 50, 58], ["cellular nucleolar antigens", "PROTEIN", 50, 77], ["the sequestration of cellular nucleolar antigens", "PROBLEM", 29, 77], ["a small number of proteins", "PROBLEM", 92, 118], ["cellular nucleolar antigens", "OBSERVATION", 50, 77], ["small", "OBSERVATION_MODIFIER", 94, 99], ["widespread", "OBSERVATION_MODIFIER", 122, 132]]], ["In addition, it is unclear whether adenovirus primarily modulates the nucleolus for replicative advantage or whether the effects on the nucleolus are a side effect of cellular proteins being sequestered into virally induced structures.", [["nucleolus", "ANATOMY", 70, 79], ["nucleolus", "ANATOMY", 136, 145], ["cellular", "ANATOMY", 167, 175], ["adenovirus", "ORGANISM", 35, 45], ["nucleolus", "CELLULAR_COMPONENT", 70, 79], ["nucleolus", "CELLULAR_COMPONENT", 136, 145], ["cellular", "CELL", 167, 175], ["cellular proteins", "PROTEIN", 167, 184], ["adenovirus", "PROBLEM", 35, 45], ["replicative advantage", "TREATMENT", 84, 105], ["the nucleolus", "PROBLEM", 132, 145], ["cellular proteins", "TREATMENT", 167, 184], ["unclear whether", "UNCERTAINTY", 19, 34], ["adenovirus", "OBSERVATION", 35, 45]]]], "59cb28c185c23948182e21e4598073cc4569e20a": [["77Dodecafluoropentane emulsion [NanO 2 TM , NuvOx Pharma (Tucson, AZ)] is one 78 such promising perfluorocarbon.", [["77Dodecafluoropentane", "CHEMICAL", 0, 21], ["NanO 2 TM", "CHEMICAL", 32, 41], ["perfluorocarbon", "CHEMICAL", 96, 111], ["77Dodecafluoropentane", "CHEMICAL", 0, 21], ["NuvOx", "CHEMICAL", 44, 49], ["perfluorocarbon", "CHEMICAL", 96, 111], ["77Dodecafluoropentane", "SIMPLE_CHEMICAL", 0, 21], ["Tucson, AZ", "SIMPLE_CHEMICAL", 58, 68], ["perfluorocarbon", "SIMPLE_CHEMICAL", 96, 111], ["77Dodecafluoropentane emulsion", "TREATMENT", 0, 30], ["NuvOx Pharma (Tucson, AZ)", "TREATMENT", 44, 69]]], ["The molecular characteristics of NanO 2, comprised of 79 2% weight/volume dodecafluoropentane emulsion (DDFPe)(9) make it highly effective at 80 oxygen delivery at extremely low doses,(10) and an ideal intravenous agent for O 2 delivery.7781 In this study, we aimed to evaluate the potential of NanO 2 to improve oxygenation in 82 conditions of low V/Q mismatch and high intrapulmonary shunt by using a preclinical 83 model of acute lung injury and measuring the difference in mean oxygen saturation after 84 injection of NanO 2 or saline and differences in BAL cell count and protein.88We used an established two-hit mouse model of acute lung injury for this", [["intravenous", "ANATOMY", 202, 213], ["intrapulmonary", "ANATOMY", 371, 385], ["lung", "ANATOMY", 433, 437], ["BAL cell", "ANATOMY", 558, 566], ["lung", "ANATOMY", 639, 643], ["NanO 2", "CHEMICAL", 33, 39], ["dodecafluoropentane", "CHEMICAL", 74, 93], ["DDFPe", "CHEMICAL", 104, 109], ["oxygen", "CHEMICAL", 145, 151], ["acute lung injury", "DISEASE", 427, 444], ["oxygen", "CHEMICAL", 482, 488], ["NanO 2", "CHEMICAL", 522, 528], ["acute lung injury", "DISEASE", 633, 650], ["NanO 2", "CHEMICAL", 33, 39], ["dodecafluoropentane", "CHEMICAL", 74, 93], ["oxygen", "CHEMICAL", 145, 151], ["O 2", "CHEMICAL", 224, 227], ["NanO 2", "CHEMICAL", 295, 301], ["oxygen", "CHEMICAL", 482, 488], ["NanO 2", "CHEMICAL", 522, 528], ["NanO 2", "SIMPLE_CHEMICAL", 33, 39], ["dodecafluoropentane emulsion", "SIMPLE_CHEMICAL", 74, 102], ["DDFPe", "SIMPLE_CHEMICAL", 104, 109], ["oxygen", "SIMPLE_CHEMICAL", 145, 151], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 202, 213], ["intrapulmonary", "MULTI-TISSUE_STRUCTURE", 371, 385], ["lung", "ORGAN", 433, 437], ["oxygen", "SIMPLE_CHEMICAL", 482, 488], ["NanO 2", "SIMPLE_CHEMICAL", 522, 528], ["saline", "SIMPLE_CHEMICAL", 532, 538], ["BAL cell", "CELL", 558, 566], ["mouse", "ORGANISM", 618, 623], ["lung", "ORGAN", 639, 643], ["mouse", "SPECIES", 618, 623], ["mouse", "SPECIES", 618, 623], ["weight", "TEST", 60, 66], ["volume dodecafluoropentane emulsion", "TEST", 67, 102], ["oxygen delivery", "TREATMENT", 145, 160], ["an ideal intravenous agent", "TREATMENT", 193, 219], ["this study", "TEST", 245, 255], ["NanO 2", "TREATMENT", 295, 301], ["oxygenation", "TEST", 313, 324], ["low V/Q mismatch", "PROBLEM", 345, 361], ["high intrapulmonary shunt", "TREATMENT", 366, 391], ["acute lung injury", "PROBLEM", 427, 444], ["mean oxygen saturation", "TEST", 477, 499], ["NanO", "TREATMENT", 522, 526], ["saline", "TREATMENT", 532, 538], ["BAL cell count", "TEST", 558, 572], ["protein", "TEST", 577, 584], ["acute lung injury", "PROBLEM", 633, 650], ["high", "OBSERVATION_MODIFIER", 366, 370], ["intrapulmonary shunt", "OBSERVATION", 371, 391], ["acute", "OBSERVATION_MODIFIER", 427, 432], ["lung", "ANATOMY", 433, 437], ["injury", "OBSERVATION", 438, 444], ["BAL cell count", "OBSERVATION", 558, 572], ["acute", "OBSERVATION_MODIFIER", 633, 638], ["lung", "ANATOMY", 639, 643], ["injury", "OBSERVATION", 644, 650]]]], "3012e3f833915e67993777c3a69d90013bff8c1e": [["M acroautophagy (subsequently referred to as autophagy) is a conserved cytosolic degradation process in eukaryotes that maintains macromolecule, energy and organelle homeostasis 1 .", [["cytosolic", "ANATOMY", 71, 80], ["organelle", "ANATOMY", 156, 165], ["organelle", "CELLULAR_COMPONENT", 156, 165], ["a conserved cytosolic degradation process", "PROBLEM", 59, 100], ["cytosolic degradation", "OBSERVATION", 71, 92], ["organelle homeostasis", "OBSERVATION", 156, 177]]], ["It requires a fine-tuned sequence of molecular actions largely executed by autophagy-related genes (ATGs).", [["ATGs", "GENE_OR_GENE_PRODUCT", 100, 104], ["autophagy-related genes", "DNA", 75, 98], ["ATGs", "DNA", 100, 104]]], ["In the initial steps, a phagophore consisting of a double-membrane sheet is nucleated, amplified and finally closed to form a vesicular structure called an autophagosome that engulfs cellular material for degradation 1 .", [["membrane sheet", "ANATOMY", 58, 72], ["vesicular", "ANATOMY", 126, 135], ["autophagosome", "ANATOMY", 156, 169], ["cellular", "ANATOMY", 183, 191], ["autophagosome", "CELLULAR_COMPONENT", 156, 169], ["cellular material", "CELLULAR_COMPONENT", 183, 200], ["a double-membrane sheet", "TREATMENT", 49, 72], ["a vesicular structure", "PROBLEM", 124, 145], ["vesicular structure", "OBSERVATION", 126, 145], ["cellular material", "OBSERVATION", 183, 200]]], ["Degradation is accomplished after the fusion of autophagosomes (AP) with lysosomes to form autolysosomes (AL).", [["autophagosomes", "ANATOMY", 48, 62], ["lysosomes", "ANATOMY", 73, 82], ["autolysosomes", "ANATOMY", 91, 104], ["autophagosomes", "CELLULAR_COMPONENT", 48, 62], ["AP", "CELLULAR_COMPONENT", 64, 66], ["lysosomes", "CELLULAR_COMPONENT", 73, 82], ["autolysosomes", "GENE_OR_GENE_PRODUCT", 91, 104], ["AP", "PROTEIN", 64, 66], ["the fusion of autophagosomes", "TREATMENT", 34, 62]]]], "f447475d6f4b4ab2a7c1be8e7cfd7b31fedcb0c8": [["IntroductionDrug-resistant tuberculosis (DR-TB) currently accounts for 500,000 of the 10 million new tuberculosis (TB) cases reported annually 1 , with incidence expected to rise substantially due to the ongoing Covid-19 pandemic 2 .", [["Drug-resistant tuberculosis (DR-TB", "DISEASE", 12, 46], ["tuberculosis", "DISEASE", 101, 113], ["TB", "DISEASE", 115, 117], ["Drug-resistant tuberculosis", "ORGANISM", 12, 39], ["resistant tuberculosis", "PROBLEM", 17, 39], ["the ongoing Covid", "TEST", 200, 217], ["pandemic", "PROBLEM", 221, 229], ["resistant", "OBSERVATION_MODIFIER", 17, 26], ["tuberculosis", "OBSERVATION", 27, 39], ["tuberculosis", "OBSERVATION", 101, 113]]], ["Treatment outcomes for multidrug-resistant TB (MDR-TB) resistant to at least rifampicin and isoniazid have historically been poor, with treatment success rates of only 50-60% in routine programmatic settings 1, 3 .", [["multidrug-resistant TB (MDR-TB", "DISEASE", 23, 53], ["rifampicin", "CHEMICAL", 77, 87], ["isoniazid", "CHEMICAL", 92, 101], ["rifampicin", "CHEMICAL", 77, 87], ["isoniazid", "CHEMICAL", 92, 101], ["rifampicin", "SIMPLE_CHEMICAL", 77, 87], ["isoniazid", "SIMPLE_CHEMICAL", 92, 101], ["multidrug-resistant TB", "PROBLEM", 23, 45], ["MDR", "PROBLEM", 47, 50], ["TB", "PROBLEM", 51, 53], ["rifampicin", "TREATMENT", 77, 87], ["isoniazid", "TREATMENT", 92, 101], ["treatment success rates", "TREATMENT", 136, 159]]], ["The discovery of bedaquiline, a diarylquinoline antimycobacterial active against ATP synthase, which is highly effective against Mycobacterium tuberculosis (Mtb) 4 Cohort studies of patients treated with bedaquiline-containing regimens against MDR-TB report success rates of 70-80% 7, 8 .", [["bedaquiline", "CHEMICAL", 17, 28], ["diarylquinoline", "CHEMICAL", 32, 47], ["ATP", "CHEMICAL", 81, 84], ["Mycobacterium tuberculosis", "DISEASE", 129, 155], ["bedaquiline", "CHEMICAL", 204, 215], ["MDR-TB", "DISEASE", 244, 250], ["bedaquiline", "CHEMICAL", 17, 28], ["diarylquinoline", "CHEMICAL", 32, 47], ["ATP", "CHEMICAL", 81, 84], ["bedaquiline", "CHEMICAL", 204, 215], ["bedaquiline", "SIMPLE_CHEMICAL", 17, 28], ["diarylquinoline", "SIMPLE_CHEMICAL", 32, 47], ["ATP synthase", "GENE_OR_GENE_PRODUCT", 81, 93], ["Mycobacterium tuberculosis", "ORGANISM", 129, 155], ["patients", "ORGANISM", 182, 190], ["bedaquiline", "SIMPLE_CHEMICAL", 204, 215], ["ATP synthase", "PROTEIN", 81, 93], ["Mycobacterium tuberculosis", "SPECIES", 129, 155], ["patients", "SPECIES", 182, 190], ["Mycobacterium tuberculosis", "SPECIES", 129, 155], ["bedaquiline", "TREATMENT", 17, 28], ["a diarylquinoline antimycobacterial", "TREATMENT", 30, 65], ["ATP synthase", "TREATMENT", 81, 93], ["Mycobacterium tuberculosis", "PROBLEM", 129, 155], ["Cohort studies", "TEST", 164, 178], ["bedaquiline", "TREATMENT", 204, 215], ["regimens", "TREATMENT", 227, 235], ["MDR", "PROBLEM", 244, 247], ["success rates", "TEST", 258, 271]]], ["Similar results have been achieved for extensively drug-resistant TB (XDR-TB, defined by additional resistance to fluoroquinolones and injectables), where treatment outcomes without bedaquiline are even worse 9, 10 .", [["TB", "DISEASE", 66, 68], ["XDR-TB", "DISEASE", 70, 76], ["fluoroquinolones", "CHEMICAL", 114, 130], ["bedaquiline", "CHEMICAL", 182, 193], ["fluoroquinolones", "CHEMICAL", 114, 130], ["bedaquiline", "CHEMICAL", 182, 193], ["bedaquiline", "SIMPLE_CHEMICAL", 182, 193], ["extensively drug-resistant TB", "PROBLEM", 39, 68], ["XDR", "PROBLEM", 70, 73], ["TB", "PROBLEM", 74, 76], ["fluoroquinolones", "TREATMENT", 114, 130], ["bedaquiline", "TREATMENT", 182, 193]]], ["In light of these promising results, the World Health Organization (WHO) now recommends that bedaquiline be included in all MDR-TB regimens 11 .", [["bedaquiline", "CHEMICAL", 93, 104], ["TB", "DISEASE", 128, 130], ["bedaquiline", "CHEMICAL", 93, 104], ["bedaquiline", "SIMPLE_CHEMICAL", 93, 104], ["bedaquiline", "TREATMENT", 93, 104], ["all MDR", "TREATMENT", 120, 127], ["TB regimens", "TREATMENT", 128, 139]]], ["In addition, bedaquiline is positioned as a key drug in multiple phase III clinical trials for drug-susceptible TB (SimpliciTB, ClinicalTrials.gov NCT03338621), MDR-TB (STREAM2, ClinicalTrials.gov NCT02409290) and XDR-TB (ZENIX-TB, ClinicalTrials.gov NCT03086486).IntroductionUnlike other major drug-resistant bacteria, Mtb reproduces strictly clonally and systematically acquires resistance by chromosomal mutations rather than via horizontal gene transfer or recombination 12 .IntroductionPhylogenetic reconstructions based on whole genome sequencing can therefore accurately infer the time of emergence and subsequent spread of Mtb resistance-associated variants (RAVs).", [["chromosomal", "ANATOMY", 395, 406], ["bedaquiline", "CHEMICAL", 13, 24], ["TB", "DISEASE", 112, 114], ["MDR-TB", "DISEASE", 161, 167], ["XDR-TB", "DISEASE", 214, 220], ["bedaquiline", "CHEMICAL", 13, 24], ["bedaquiline", "SIMPLE_CHEMICAL", 13, 24], ["Mtb", "ORGANISM", 320, 323], ["chromosomal", "CELLULAR_COMPONENT", 395, 406], ["Mtb", "GENE_OR_GENE_PRODUCT", 631, 634], ["RAVs", "DNA", 667, 671], ["bedaquiline", "TREATMENT", 13, 24], ["susceptible TB", "PROBLEM", 100, 114], ["XDR", "PROBLEM", 214, 217], ["TB", "PROBLEM", 218, 220], ["ZENIX", "TEST", 222, 227], ["resistant bacteria", "PROBLEM", 300, 318], ["Mtb", "PROBLEM", 320, 323], ["chromosomal mutations", "PROBLEM", 395, 416], ["IntroductionPhylogenetic reconstructions", "TREATMENT", 479, 519], ["whole genome sequencing", "TEST", 529, 552], ["Mtb resistance", "PROBLEM", 631, 645], ["bedaquiline", "OBSERVATION", 13, 24], ["resistant bacteria", "OBSERVATION", 300, 318], ["Mtb resistance", "OBSERVATION", 631, 645]]], ["Phylogenetic studies have demonstrated that there are often multiple Mtb lineages introduced into distinct geographical regions, with repeated independent drug resistance emergence events occurring locally [13] [14] [15] [16] .IntroductionMtb has demonstrated the ability to acquire resistance to every drug used against it until now.", [["Phylogenetic studies", "TEST", 0, 20], ["multiple Mtb lineages", "PROBLEM", 60, 81], ["repeated independent drug resistance emergence events", "PROBLEM", 134, 187], ["multiple", "OBSERVATION_MODIFIER", 60, 68], ["Mtb lineages", "OBSERVATION", 69, 81], ["distinct", "OBSERVATION_MODIFIER", 98, 106], ["geographical", "OBSERVATION_MODIFIER", 107, 119], ["drug resistance", "OBSERVATION", 155, 170]]], ["Resistance has been reported to occur soon after the introduction of a novel TB drug 17, 18 .", [["TB", "DISEASE", 77, 79], ["a novel TB drug", "TREATMENT", 69, 84]]], ["For example, mutations conferring resistance to isoniazid -one of the first antimycobacterials -tend to have emerged prior to resistance to rifampicin, the other major first-line drug.", [["isoniazid", "CHEMICAL", 48, 57], ["rifampicin", "CHEMICAL", 140, 150], ["isoniazid", "CHEMICAL", 48, 57], ["rifampicin", "CHEMICAL", 140, 150], ["isoniazid", "SIMPLE_CHEMICAL", 48, 57], ["rifampicin", "SIMPLE_CHEMICAL", 140, 150], ["mutations", "PROBLEM", 13, 22], ["isoniazid", "TREATMENT", 48, 57], ["the first antimycobacterials", "TREATMENT", 66, 94], ["rifampicin", "TREATMENT", 140, 150]]], ["These also predate resistance mutations to second-line drugs, so termed because they are used clinically to treat patients infected with strains already resistant to first-line drugs.", [["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 114, 122], ["resistance mutations", "PROBLEM", 19, 39], ["second-line drugs", "TREATMENT", 43, 60], ["strains", "PROBLEM", 137, 144], ["first-line drugs", "TREATMENT", 166, 182], ["resistance mutations", "OBSERVATION", 19, 39]]], ["This was observed, for example, in KwaZulu-Natal, South Africa, where resistance-associated mutations accumulated over decades prior to their identification, leading to the largest reported outbreak of extensively drug-resistant TB (XDR-TB) 18 .IntroductionMutations conferring resistance to bedaquiline were first selected in vitro, and were located in the atpE gene encoding the target F1F0 ATP synthase, the target of bedaquiline 19 .", [["extensively drug-resistant TB (XDR-TB", "DISEASE", 202, 239], ["bedaquiline", "CHEMICAL", 292, 303], ["ATP", "CHEMICAL", 393, 396], ["bedaquiline", "CHEMICAL", 421, 432], ["bedaquiline", "CHEMICAL", 292, 303], ["ATP", "CHEMICAL", 393, 396], ["bedaquiline", "CHEMICAL", 421, 432], ["bedaquiline", "SIMPLE_CHEMICAL", 292, 303], ["atpE", "GENE_OR_GENE_PRODUCT", 358, 362], ["F1F0 ATP synthase", "GENE_OR_GENE_PRODUCT", 388, 405], ["atpE gene", "DNA", 358, 367], ["F1F0 ATP synthase", "PROTEIN", 388, 405], ["bedaquiline 19", "PROTEIN", 421, 435], ["associated mutations", "PROBLEM", 81, 101], ["extensively drug-resistant TB", "PROBLEM", 202, 231], ["IntroductionMutations", "TREATMENT", 245, 266], ["bedaquiline", "TREATMENT", 292, 303], ["bedaquiline", "TREATMENT", 421, 432]]], ["Subsequently, resistanceconferring mutations have been found in pepQ in a murine model and potentially in a small number of patients 20 .", [["pepQ", "GENE_OR_GENE_PRODUCT", 64, 68], ["murine", "ORGANISM", 74, 80], ["patients", "ORGANISM", 124, 132], ["pepQ", "PROTEIN", 64, 68], ["murine", "SPECIES", 74, 80], ["patients", "SPECIES", 124, 132], ["resistanceconferring mutations", "PROBLEM", 14, 44], ["small", "OBSERVATION_MODIFIER", 108, 113]]], ["However, the vast majority of resistance observed in clinical isolates has been identified in the context of resistance-associated variants (RAVs) in the Rv0678 gene, a negative repressor of expression of the MmpL5 efflux pump.", [["Rv0678", "GENE_OR_GENE_PRODUCT", 154, 160], ["MmpL5 efflux pump", "GENE_OR_GENE_PRODUCT", 209, 226], ["RAVs", "DNA", 141, 145], ["Rv0678 gene", "DNA", 154, 165], ["MmpL5", "PROTEIN", 209, 214], ["resistance-associated variants", "PROBLEM", 109, 139], ["the MmpL5 efflux pump", "TREATMENT", 205, 226], ["resistance", "OBSERVATION", 30, 40], ["efflux pump", "OBSERVATION", 215, 226]]], ["Loss of function of Rv0678 leads to pump overexpression 21 and increased minimum inhibitory concentrations (MIC) to bedaquiline, as well as to the recently repurposed antimycobacterial clofazimine and the azole class of antifungal drugs (which also have antimycobacterial activity) 22 .IntroductionA diverse range of single nucleotide variants (SNVs) and frameshift Rv0678 mutations have been associated with resistance to bedaquiline, and are often present as heteroresistant alleles in patients [23] [24] [25] [26] [27] [28] [29] [30] .", [["Rv0678", "CHEMICAL", 20, 26], ["bedaquiline", "CHEMICAL", 116, 127], ["clofazimine", "CHEMICAL", 185, 196], ["azole", "CHEMICAL", 205, 210], ["bedaquiline", "CHEMICAL", 423, 434], ["bedaquiline", "CHEMICAL", 116, 127], ["clofazimine", "CHEMICAL", 185, 196], ["azole", "CHEMICAL", 205, 210], ["bedaquiline", "CHEMICAL", 423, 434], ["Rv0678", "GENE_OR_GENE_PRODUCT", 20, 26], ["bedaquiline", "SIMPLE_CHEMICAL", 116, 127], ["clofazimine", "SIMPLE_CHEMICAL", 185, 196], ["Rv0678", "GENE_OR_GENE_PRODUCT", 366, 372], ["bedaquiline", "SIMPLE_CHEMICAL", 423, 434], ["patients", "ORGANISM", 488, 496], ["[23] [24] [25] [26] [27] [28] [29] [30]", "SIMPLE_CHEMICAL", 497, 536], ["Rv0678", "PROTEIN", 20, 26], ["heteroresistant alleles", "DNA", 461, 484], ["patients", "SPECIES", 488, 496], ["Loss of function", "PROBLEM", 0, 16], ["pump overexpression", "TREATMENT", 36, 55], ["increased minimum inhibitory concentrations", "TREATMENT", 63, 106], ["bedaquiline", "TREATMENT", 116, 127], ["antimycobacterial clofazimine", "TREATMENT", 167, 196], ["the azole class", "TREATMENT", 201, 216], ["antifungal drugs", "TREATMENT", 220, 236], ["antimycobacterial activity)", "TREATMENT", 254, 281], ["single nucleotide variants", "TREATMENT", 317, 343], ["frameshift Rv0678 mutations", "PROBLEM", 355, 382], ["bedaquiline", "TREATMENT", 423, 434], ["antimycobacterial clofazimine", "OBSERVATION", 167, 196]]], ["In contrast to most other RAVs in Mtb, which often cause many-fold increases in MIC and clear-cut resistance, Rv0678 variants may be associated with normal MICs or subtle increases in bedaquiline MIC, although they may still be clinically important.", [["MIC", "CHEMICAL", 80, 83], ["bedaquiline", "CHEMICAL", 184, 195], ["bedaquiline", "CHEMICAL", 184, 195], ["RAVs", "GENE_OR_GENE_PRODUCT", 26, 30], ["Mtb", "GENE_OR_GENE_PRODUCT", 34, 37], ["MIC", "SIMPLE_CHEMICAL", 80, 83], ["Rv0678", "GENE_OR_GENE_PRODUCT", 110, 116], ["bedaquiline", "SIMPLE_CHEMICAL", 184, 195], ["Rv0678 variants", "DNA", 110, 125], ["many-fold increases in MIC", "PROBLEM", 57, 83], ["normal MICs", "PROBLEM", 149, 160], ["bedaquiline MIC", "TREATMENT", 184, 199], ["Mtb", "OBSERVATION", 34, 37], ["fold", "OBSERVATION_MODIFIER", 62, 66], ["increases", "OBSERVATION_MODIFIER", 67, 76], ["subtle", "OBSERVATION_MODIFIER", 164, 170], ["increases", "OBSERVATION_MODIFIER", 171, 180]]], ["These increases may not cross the current WHO critical concentrations used to classify resistant versus susceptible strains (0.25\u00b5g/mL on Middlebrook 7H11 agar, or 1\u00b5g/mL in Mycobacteria Growth Indicator Tube [MGIT] liquid media).", [["susceptible strains", "PROBLEM", 104, 123], ["agar", "TEST", 155, 159], ["Tube [MGIT] liquid media", "TREATMENT", 204, 228]]], ["Bedaquiline has a long terminal half-life of up to 5.5 months 6 , leading to the possibility of subtherapeutic concentrations, where adherence is suboptimal or treatment is interrupted, which could act as a further driver of resistance.IntroductionBedaquiline and clofazimine cross-resistance has now been reported across three continents following the rapid expansion in usage of both drugs 24, 29, 31, 32 , and is associated with poor adherence to therapy and inadequate regimens.", [["Bedaquiline", "CHEMICAL", 0, 11], ["Bedaquiline", "CHEMICAL", 248, 259], ["clofazimine", "CHEMICAL", 264, 275], ["Bedaquiline", "CHEMICAL", 0, 11], ["Bedaquiline", "CHEMICAL", 248, 259], ["clofazimine", "CHEMICAL", 264, 275], ["Bedaquiline", "SIMPLE_CHEMICAL", 0, 11], ["Bedaquiline", "SIMPLE_CHEMICAL", 248, 259], ["clofazimine", "SIMPLE_CHEMICAL", 264, 275], ["Bedaquiline", "TREATMENT", 0, 11], ["subtherapeutic concentrations", "PROBLEM", 96, 125], ["treatment", "TREATMENT", 160, 169], ["IntroductionBedaquiline", "TREATMENT", 236, 259], ["clofazimine cross-resistance", "TREATMENT", 264, 292], ["therapy", "TREATMENT", 450, 457], ["inadequate regimens", "TREATMENT", 462, 481], ["rapid", "OBSERVATION_MODIFIER", 353, 358], ["expansion", "OBSERVATION_MODIFIER", 359, 368]]], ["However, baseline isolates in 8/347 (2.3%) patients from phase IIb bedaquiline trials demonstrated Rv0678 RAVs and high bedaquiline MICs in the absence of prior documented use of bedaquiline or clofazimine 33 , suggesting that bedaquiline RAVs could pre-exist in many settings where bedaquiline will be used.", [["bedaquiline", "CHEMICAL", 120, 131], ["bedaquiline", "CHEMICAL", 179, 190], ["clofazimine", "CHEMICAL", 194, 205], ["bedaquiline", "CHEMICAL", 227, 238], ["bedaquiline", "CHEMICAL", 283, 294], ["bedaquiline", "CHEMICAL", 120, 131], ["bedaquiline", "CHEMICAL", 179, 190], ["clofazimine", "CHEMICAL", 194, 205], ["bedaquiline", "CHEMICAL", 227, 238], ["bedaquiline", "CHEMICAL", 283, 294], ["patients", "ORGANISM", 43, 51], ["bedaquiline", "SIMPLE_CHEMICAL", 120, 131], ["bedaquiline", "SIMPLE_CHEMICAL", 179, 190], ["clofazimine", "SIMPLE_CHEMICAL", 194, 205], ["bedaquiline RAVs", "SIMPLE_CHEMICAL", 227, 243], ["bedaquiline", "SIMPLE_CHEMICAL", 283, 294], ["patients", "SPECIES", 43, 51], ["baseline isolates", "TEST", 9, 26], ["phase IIb bedaquiline trials", "TREATMENT", 57, 85], ["Rv0678 RAVs", "PROBLEM", 99, 110], ["high bedaquiline MICs", "TREATMENT", 115, 136], ["bedaquiline", "TREATMENT", 179, 190], ["clofazimine", "TREATMENT", 194, 205], ["bedaquiline RAVs", "TREATMENT", 227, 243], ["bedaquiline", "TREATMENT", 283, 294]]], ["While there are isolated clinical reports from multiple geographical regions, the global situation regarding bedaquiline resistance emergence and spread has not yet been investigated.IntroductionIn this study, we characterised and dated the emergence of bedaquiline RAVs in the two global Mtb lineage 2 (L2) and lineage 4 (L4) lineages, which include the majority of drug resistance strains 17 .IntroductionPhylogenetic analyses of two datasets comprising 1,514 Mtb L2 and 2,168 L4 whole genome sequences revealed the emergence and spread of multiple Rv0678 RAVs prior to the use of bedaquiline or clofazimine, with some mutations having been in circulation already before the antibiotic era.", [["bedaquiline", "CHEMICAL", 109, 120], ["bedaquiline", "CHEMICAL", 254, 265], ["bedaquiline", "CHEMICAL", 583, 594], ["clofazimine", "CHEMICAL", 598, 609], ["bedaquiline", "CHEMICAL", 109, 120], ["bedaquiline", "CHEMICAL", 254, 265], ["bedaquiline", "CHEMICAL", 583, 594], ["clofazimine", "CHEMICAL", 598, 609], ["bedaquiline", "SIMPLE_CHEMICAL", 109, 120], ["bedaquiline", "GENE_OR_GENE_PRODUCT", 254, 265], ["bedaquiline", "SIMPLE_CHEMICAL", 583, 594], ["clofazimine", "SIMPLE_CHEMICAL", 598, 609], ["bedaquiline RAVs", "DNA", 254, 270], ["Mtb L2 and 2,168 L4 whole genome sequences", "DNA", 462, 504], ["bedaquiline resistance emergence", "PROBLEM", 109, 141], ["this study", "TEST", 198, 208], ["bedaquiline RAVs", "TREATMENT", 254, 270], ["lineage 4 (L4) lineages", "TREATMENT", 312, 335], ["drug resistance strains", "PROBLEM", 367, 390], ["Phylogenetic analyses", "TEST", 407, 428], ["two datasets", "TEST", 432, 444], ["Mtb L2", "TEST", 462, 468], ["L4 whole genome sequences", "TEST", 479, 504], ["bedaquiline", "TREATMENT", 583, 594], ["clofazimine", "TREATMENT", 598, 609], ["some mutations", "PROBLEM", 616, 630], ["the antibiotic era", "TREATMENT", 673, 691], ["multiple", "OBSERVATION_MODIFIER", 47, 55], ["bedaquiline resistance", "OBSERVATION", 109, 131], ["Mtb lineage", "OBSERVATION", 289, 300], ["L4", "ANATOMY", 323, 325], ["drug resistance", "OBSERVATION", 367, 382]]], ["This preexisting reservoir of bedaquiline/clofazimine-resistant Mtb strains suggests Rv0678 RAVs exert a relatively low fitness cost which could be rapidly selected for as bedaquiline and clofazimine are more widely used in the treatment of TB.The global diversity of Mtb lineage L2 and L4To investigate the global distribution of Mtb isolates with variants in Rv0678, we curated two large datasets of whole genomes from the two dominant global lineages L2 and L4.", [["bedaquiline", "CHEMICAL", 30, 41], ["clofazimine", "CHEMICAL", 42, 53], ["Rv0678", "CHEMICAL", 85, 91], ["bedaquiline", "CHEMICAL", 172, 183], ["clofazimine", "CHEMICAL", 188, 199], ["TB", "DISEASE", 241, 243], ["bedaquiline", "CHEMICAL", 30, 41], ["clofazimine", "CHEMICAL", 42, 53], ["bedaquiline", "CHEMICAL", 172, 183], ["clofazimine", "CHEMICAL", 188, 199], ["bedaquiline", "SIMPLE_CHEMICAL", 30, 41], ["clofazimine", "SIMPLE_CHEMICAL", 42, 53], ["Mtb strains", "ORGANISM", 64, 75], ["Rv0678 RAVs", "ORGANISM", 85, 96], ["bedaquiline", "SIMPLE_CHEMICAL", 172, 183], ["clofazimine", "SIMPLE_CHEMICAL", 188, 199], ["L4To", "GENE_OR_GENE_PRODUCT", 287, 291], ["Mtb", "GENE_OR_GENE_PRODUCT", 331, 334], ["L4To", "PROTEIN", 287, 291], ["Rv0678", "DNA", 361, 367], ["L4", "DNA", 461, 463], ["bedaquiline", "TREATMENT", 30, 41], ["clofazimine", "TREATMENT", 42, 53], ["resistant Mtb strains", "PROBLEM", 54, 75], ["a relatively low fitness cost", "PROBLEM", 103, 132], ["bedaquiline", "TREATMENT", 172, 183], ["clofazimine", "TREATMENT", 188, 199], ["TB", "PROBLEM", 241, 243], ["TB", "OBSERVATION", 241, 243], ["global", "OBSERVATION_MODIFIER", 248, 254], ["diversity", "OBSERVATION_MODIFIER", 255, 264], ["Mtb lineage L2", "OBSERVATION", 268, 282], ["global", "OBSERVATION_MODIFIER", 308, 314], ["distribution", "OBSERVATION_MODIFIER", 315, 327], ["Mtb isolates", "OBSERVATION", 331, 343], ["two", "OBSERVATION_MODIFIER", 380, 383], ["large", "OBSERVATION_MODIFIER", 384, 389], ["whole genomes", "OBSERVATION", 402, 415], ["two", "OBSERVATION_MODIFIER", 425, 428], ["dominant", "OBSERVATION_MODIFIER", 429, 437], ["global lineages", "OBSERVATION", 438, 453], ["L2", "ANATOMY_MODIFIER", 454, 456], ["L4", "ANATOMY_MODIFIER", 461, 463]]], ["Both datasets were selectively enriched for samples with variants in Rv0678 (see Methods) and those with accompanying Using the same approach for the L4 dataset we estimated a clock rate of 7.1x10 -8 (6.2x10 -8 -7.9x10 -8 ) substitutions per site per year resulting in an estimated tMRCA of 853CE (685CE -967CE) ( Figure 2 ).", [["samples", "ANATOMY", 44, 51], ["variants", "TEST", 57, 65], ["a clock rate", "TEST", 174, 186], ["an estimated tMRCA", "TEST", 269, 287], ["L4", "ANATOMY", 150, 152]]], ["We observed a slightly higher, yet statistically not significant, clock rate in L2 compared to L4 (Supplementary Table S3) , with all estimated substitution rates falling largely in line with previously published estimates 41 .Identification of Rv0678 variantsSince atpE and pepQ bedaquiline RAVs are found at very low prevalence, we focused on characterising the full mutational spectrum of Rv068 across both lineages.", [["bedaquiline", "CHEMICAL", 280, 291], ["Rv0678", "GENE_OR_GENE_PRODUCT", 245, 251], ["atpE", "GENE_OR_GENE_PRODUCT", 266, 270], ["pepQ", "GENE_OR_GENE_PRODUCT", 275, 279], ["Rv068", "GENE_OR_GENE_PRODUCT", 392, 397], ["Rv0678 variants", "DNA", 245, 260], ["atpE and pepQ bedaquiline RAVs", "DNA", 266, 296], ["Rv068", "DNA", 392, 397], ["significant, clock rate in L2", "PROBLEM", 53, 82], ["all estimated substitution rates", "PROBLEM", 130, 162], ["Rv0678 variants", "PROBLEM", 245, 260], ["atpE", "TREATMENT", 266, 270], ["pepQ bedaquiline RAVs", "TREATMENT", 275, 296], ["slightly", "OBSERVATION_MODIFIER", 14, 22], ["higher", "OBSERVATION_MODIFIER", 23, 29], ["significant", "OBSERVATION_MODIFIER", 53, 64], ["L2", "ANATOMY_MODIFIER", 80, 82], ["L4", "ANATOMY", 95, 97], ["substitution", "OBSERVATION", 144, 156], ["Rv0678 variants", "OBSERVATION", 245, 260]]], ["In total we identified the presence of non- Of the 198 L2 isolates identified as carrying variants in Rv0678, 18 samples had more than one variant in the same gene (10%).", [["samples", "ANATOMY", 113, 120], ["samples", "CANCER", 113, 120], ["Rv0678", "DNA", 102, 108], ["the 198 L2 isolates", "TEST", 47, 66]]], ["In L4, 14 samples (6%) were observed with more than one variant co-occurring in the Rv0678 gene.", [["L4", "ANATOMY", 3, 5], ["samples", "ANATOMY", 10, 17], ["samples", "CANCER", 10, 17], ["Rv0678", "GENE_OR_GENE_PRODUCT", 84, 90], ["Rv0678 gene", "DNA", 84, 95], ["L4", "ANATOMY", 3, 5]]], ["We identified a significant relationship between the presence of Rv0678 variants and drug resistance status in both the L2 and L4 datasets (Supplementary Figure S8-S9) , though in both cases we identified otherwise fully phenotypically susceptible isolates carrying Rv0678 RAVs (12 L2, 25 L4).Identification of Rv0678 variantsWe identified one L2 isolate (ERR2677436 sampled in Germany in 2016) which already had two Rv0678 RAVs at low allele frequency -Val7fs (11%) and Val20Phe (20%) -and also contained two low frequency atpE RAVs: Glu61Asp (3.2%) and Alal63Pro (3.7%).", [["Val", "CHEMICAL", 471, 474], ["Phe", "CHEMICAL", 476, 479], ["Rv0678", "GENE_OR_GENE_PRODUCT", 65, 71], ["Rv0678", "GENE_OR_GENE_PRODUCT", 311, 317], ["Glu61Asp", "GENE_OR_GENE_PRODUCT", 535, 543], ["Rv0678 RAVs", "DNA", 266, 277], ["Rv0678 variants", "DNA", 311, 326], ["Rv0678 RAVs", "DNA", 417, 428], ["atpE RAVs", "DNA", 524, 533], ["Alal63Pro", "DNA", 555, 564], ["Rv0678 variants", "PROBLEM", 65, 80], ["drug resistance status", "PROBLEM", 85, 107], ["Rv0678 variants", "PROBLEM", 311, 326], ["Val7fs", "TEST", 454, 460], ["Val", "TEST", 471, 474], ["Phe", "TEST", 476, 479], ["Glu61Asp", "TEST", 535, 543], ["Alal", "TEST", 555, 559], ["significant", "OBSERVATION_MODIFIER", 16, 27], ["drug resistance", "OBSERVATION", 85, 100], ["L2", "ANATOMY", 120, 122], ["L4", "ANATOMY", 127, 129], ["Rv0678 variants", "OBSERVATION", 311, 326], ["L2 isolate", "OBSERVATION_MODIFIER", 344, 354]]], ["We also identified three isolates obtained in 2007-08 from separate but neighbouring Chinese provinces carrying the Rv1979c Val52Gly RAV, which has been reported to be associated with clofazimine resistance in a study from China 24 but was associated with a normal MIC in another 42 .", [["clofazimine", "CHEMICAL", 184, 195], ["clofazimine", "CHEMICAL", 184, 195], ["Val52Gly", "GENE_OR_GENE_PRODUCT", 124, 132], ["clofazimine", "SIMPLE_CHEMICAL", 184, 195], ["Rv1979c Val52Gly RAV", "DNA", 116, 136], ["clofazimine resistance", "PROBLEM", 184, 206], ["a study", "TEST", 210, 217]]], ["Furthermore, several frameshift and premature stop mutations in pepQ have been previously associated with bedaquiline and clofazimine resistance.", [["bedaquiline", "CHEMICAL", 106, 117], ["clofazimine", "CHEMICAL", 122, 133], ["bedaquiline", "CHEMICAL", 106, 117], ["clofazimine", "CHEMICAL", 122, 133], ["pepQ", "GENE_OR_GENE_PRODUCT", 64, 68], ["bedaquiline", "SIMPLE_CHEMICAL", 106, 117], ["clofazimine", "SIMPLE_CHEMICAL", 122, 133], ["pepQ", "DNA", 64, 68], ["several frameshift", "PROBLEM", 13, 31], ["premature stop mutations in pepQ", "PROBLEM", 36, 68], ["bedaquiline", "TREATMENT", 106, 117], ["clofazimine resistance", "TREATMENT", 122, 144], ["several", "OBSERVATION_MODIFIER", 13, 20], ["frameshift", "OBSERVATION", 21, 31], ["premature", "OBSERVATION_MODIFIER", 36, 45], ["clofazimine resistance", "OBSERVATION", 122, 144]]], ["In this dataset, we identified 18 frameshift mutations in pepQ across 11 patients, one of which also had a Rv0678 frameshift mutation.", [["pepQ", "GENE_OR_GENE_PRODUCT", 58, 62], ["patients", "ORGANISM", 73, 81], ["Rv0678", "GENE_OR_GENE_PRODUCT", 107, 113], ["pepQ", "DNA", 58, 62], ["Rv0678 frameshift mutation", "DNA", 107, 133], ["patients", "SPECIES", 73, 81], ["18 frameshift mutations", "PROBLEM", 31, 54], ["a Rv0678 frameshift mutation", "PROBLEM", 105, 133], ["frameshift mutations", "OBSERVATION", 34, 54], ["frameshift mutation", "OBSERVATION", 114, 133]]], ["In one isolate the pepQ frameshift occurred at the Arg271 position previously reported to be associated with bedaquiline resistance 20 .Prediction of phenotype based on Rv0678 variantsAcross our datasets we identified 62 genomes with nonsynonymous Rv0678 variants of unknown phenotypic effect (12 L2, 50 L4), corresponding to 23 unique mutations or combinations of mutations.Prediction of phenotype based on Rv0678 variantsA gradient-boosted tree classifier was trained and optimised to determine if the amino acid properties of Rv0678 mutations associated to known bedaquiline resistance phenotypes can be used to predict the resistance status of mutations with no available phenotypic information.", [["bedaquiline", "CHEMICAL", 109, 120], ["amino acid", "CHEMICAL", 504, 514], ["bedaquiline", "CHEMICAL", 566, 577], ["bedaquiline", "CHEMICAL", 109, 120], ["amino acid", "CHEMICAL", 504, 514], ["bedaquiline", "CHEMICAL", 566, 577], ["pepQ", "GENE_OR_GENE_PRODUCT", 19, 23], ["bedaquiline", "SIMPLE_CHEMICAL", 109, 120], ["Rv0678", "GENE_OR_GENE_PRODUCT", 169, 175], ["Rv0678", "GENE_OR_GENE_PRODUCT", 248, 254], ["amino acid", "AMINO_ACID", 504, 514], ["Rv0678", "GENE_OR_GENE_PRODUCT", 529, 535], ["pepQ frameshift", "DNA", 19, 34], ["Arg271 position", "DNA", 51, 66], ["Rv0678 variants", "DNA", 169, 184], ["nonsynonymous Rv0678 variants", "DNA", 234, 263], ["Rv0678 variants", "DNA", 408, 423], ["the pepQ frameshift", "PROBLEM", 15, 34], ["bedaquiline resistance", "TREATMENT", 109, 131], ["unknown phenotypic effect", "PROBLEM", 267, 292], ["23 unique mutations", "PROBLEM", 326, 345], ["mutations", "PROBLEM", 365, 374], ["A gradient", "TEST", 423, 433], ["the amino acid properties", "TEST", 500, 525], ["Rv0678 mutations", "PROBLEM", 529, 545], ["known bedaquiline resistance phenotypes", "PROBLEM", 560, 599], ["the resistance status of mutations", "PROBLEM", 623, 657], ["pepQ frameshift", "OBSERVATION", 19, 34], ["unknown", "UNCERTAINTY", 267, 274], ["phenotypic effect", "OBSERVATION", 275, 292], ["bedaquiline resistance", "OBSERVATION", 566, 588]]], ["The optimised model provided an area under the precision-recall curve (AUPRC) of 0.805 (Supplementary Table S6 ), suggesting that the physiochemical properties of mutations can be used to successfully differentiate between resistance and susceptibility phenotypes (Supplementary Table S7 ).", [["AUPRC", "TEST", 71, 76], ["the physiochemical properties of mutations", "PROBLEM", 130, 172], ["resistance and susceptibility phenotypes", "PROBLEM", 223, 263]]], ["The features of the models were then interpreted using SHAP values (see Methods).", [["SHAP values", "TEST", 55, 66]]], ["Via this approach, we found that 5' end mutations, mutations in the DNA binding domain and polar and positively charged residues are associated with resistance.", [["DNA", "CELLULAR_COMPONENT", 68, 71], ["5' end mutations", "DNA", 33, 49], ["DNA binding domain", "PROTEIN", 68, 86], ["5' end mutations", "PROBLEM", 33, 49], ["mutations", "PROBLEM", 51, 60], ["the DNA binding domain", "PROBLEM", 64, 86], ["polar", "OBSERVATION_MODIFIER", 91, 96], ["charged residues", "OBSERVATION", 112, 128]]], ["Conversely, mutations in the dimerisation domains, transitions from negatively to positively charged residues, and mutations involving hydrophobic wild type or variant residues are associated with susceptibility (Supplementary Figure S10) .The time to emergence of Rv0678 variantsTo estimate the age of the emergence of different Rv0678 non-synonymous variants, we identified all nodes in the global time calibrated phylogenies delineating clades of isolates carrying a particularDiscussionOur work establishes that the emergence of variants in Rv0678, including RAVs, is not solely driven by the use of bedaquiline and clofazimine or azoles (which have also been proposed as a further potential selective force) 22 Prediction of phenotypic bedaquiline resistance from genomic data is further complicated by the existence of hyper-susceptibility variants.", [["bedaquiline", "CHEMICAL", 604, 615], ["clofazimine", "CHEMICAL", 620, 631], ["azoles", "CHEMICAL", 635, 641], ["bedaquiline", "CHEMICAL", 741, 752], ["bedaquiline", "CHEMICAL", 604, 615], ["clofazimine", "CHEMICAL", 620, 631], ["azoles", "CHEMICAL", 635, 641], ["Rv0678", "GENE_OR_GENE_PRODUCT", 265, 271], ["Rv0678", "GENE_OR_GENE_PRODUCT", 545, 551], ["RAVs", "GENE_OR_GENE_PRODUCT", 563, 567], ["bedaquiline", "SIMPLE_CHEMICAL", 604, 615], ["clofazimine", "SIMPLE_CHEMICAL", 620, 631], ["azoles", "SIMPLE_CHEMICAL", 635, 641], ["bedaquiline", "SIMPLE_CHEMICAL", 741, 752], ["dimerisation domains", "PROTEIN", 29, 49], ["Rv0678 variants", "DNA", 265, 280], ["Rv0678 non-synonymous variants", "DNA", 330, 360], ["Rv0678", "DNA", 545, 551], ["mutations in the dimerisation domains", "PROBLEM", 12, 49], ["mutations involving hydrophobic wild type or variant residues", "PROBLEM", 115, 176], ["different Rv0678 non-synonymous variants", "PROBLEM", 320, 360], ["all nodes", "PROBLEM", 376, 385], ["bedaquiline", "TREATMENT", 604, 615], ["clofazimine", "TREATMENT", 620, 631], ["azoles", "TREATMENT", 635, 641], ["a further potential selective force)", "TREATMENT", 676, 712], ["phenotypic bedaquiline resistance", "PROBLEM", 730, 763], ["genomic data", "TEST", 769, 781], ["hyper-susceptibility variants", "PROBLEM", 825, 854], ["non-synonymous variants", "OBSERVATION", 337, 360], ["all", "OBSERVATION_MODIFIER", 376, 379], ["nodes", "OBSERVATION", 380, 385], ["bedaquiline resistance", "OBSERVATION", 741, 763], ["hyper", "OBSERVATION", 825, 830], ["susceptibility variants", "OBSERVATION", 831, 854]]], ["For example, the C-11A variant located in the promoter ofDiscussionRv0678, which appears to increase susceptibly to bedaquiline 33 Bedaquiline resistance can also be conferred by other RAVs including in pepQ (bedaquiline and clofazimine), atpE (bedaquiline only) 44 and Rv1979c (clofazimine only).", [["bedaquiline", "CHEMICAL", 116, 127], ["Bedaquiline", "CHEMICAL", 131, 142], ["pepQ", "CHEMICAL", 203, 207], ["bedaquiline", "CHEMICAL", 209, 220], ["clofazimine", "CHEMICAL", 225, 236], ["atpE", "CHEMICAL", 239, 243], ["bedaquiline", "CHEMICAL", 245, 256], ["Rv1979c", "CHEMICAL", 270, 277], ["clofazimine", "CHEMICAL", 279, 290], ["bedaquiline", "CHEMICAL", 116, 127], ["Bedaquiline", "CHEMICAL", 131, 142], ["bedaquiline", "CHEMICAL", 209, 220], ["clofazimine", "CHEMICAL", 225, 236], ["atpE", "CHEMICAL", 239, 243], ["bedaquiline", "CHEMICAL", 245, 256], ["Rv1979c", "CHEMICAL", 270, 277], ["clofazimine", "CHEMICAL", 279, 290], ["C-11A", "GENE_OR_GENE_PRODUCT", 17, 22], ["bedaquiline 33", "SIMPLE_CHEMICAL", 116, 130], ["Bedaquiline", "SIMPLE_CHEMICAL", 131, 142], ["RAVs", "GENE_OR_GENE_PRODUCT", 185, 189], ["pepQ", "SIMPLE_CHEMICAL", 203, 207], ["bedaquiline", "SIMPLE_CHEMICAL", 209, 220], ["clofazimine", "SIMPLE_CHEMICAL", 225, 236], ["atpE", "SIMPLE_CHEMICAL", 239, 243], ["bedaquiline", "SIMPLE_CHEMICAL", 245, 256], ["Rv1979c", "SIMPLE_CHEMICAL", 270, 277], ["clofazimine", "SIMPLE_CHEMICAL", 279, 290], ["C-11A variant", "DNA", 17, 30], ["promoter ofDiscussionRv0678", "DNA", 46, 73], ["bedaquiline", "TREATMENT", 116, 127], ["Bedaquiline resistance", "TREATMENT", 131, 153], ["bedaquiline", "TREATMENT", 209, 220], ["clofazimine", "TREATMENT", 225, 236], ["atpE (bedaquiline", "TREATMENT", 239, 256], ["clofazimine", "TREATMENT", 279, 290], ["increase", "OBSERVATION_MODIFIER", 92, 100]]], ["We only found atpE RAVs at low allele frequency in one patient who also had Rv0678 variants (sample accession ERR2677436),Discussionwhich is in line with other evidence suggesting they rarely occur in clinical isolates, likely due to a high fitness cost.", [["atpE", "GENE_OR_GENE_PRODUCT", 14, 18], ["patient", "ORGANISM", 55, 62], ["atpE RAVs", "DNA", 14, 23], ["Rv0678 variants", "DNA", 76, 91], ["patient", "SPECIES", 55, 62], ["atpE RAVs", "PROBLEM", 14, 23], ["Rv0678 variants", "PROBLEM", 76, 91], ["a high fitness cost", "PROBLEM", 234, 253]]], ["Likewise, we only identified Rv1979c RAVs in three patients in China, although there were other variants in Rv1979c for which ability to cause phenotypic resistance has not been previously assessed.", [["Rv1979c", "GENE_OR_GENE_PRODUCT", 29, 36], ["patients", "ORGANISM", 51, 59], ["Rv1979c", "GENE_OR_GENE_PRODUCT", 108, 115], ["Rv1979c RAVs", "DNA", 29, 41], ["Rv1979c", "DNA", 108, 115], ["patients", "SPECIES", 51, 59], ["phenotypic resistance", "PROBLEM", 143, 164]]], ["Frameshift pepQ mutations that are potentially causative of resistance were identified in 11 patients, in keeping with its possible role as an additional rare resistance mechanism.DiscussionOur findings are of high clinical relevance as the presence of Rv0678 variants during therapy in clinical strains has been associated with substantially worse outcomes in patients treated with drug regimens including bedaquiline 31Sample collectionIn this study we curated large representative datasets of Mtb whole genome sequences encompassing the global genetic and geographic distribution of lineages 2 (L2) and L4 (Figure 1, Supplementary Tables S1-S2Reference mapping and variant callingOriginal fastq files for all included sequences were downloaded and paired reads mapped to the H37Rv reference genome with bwa mem v0.7.17 61 .", [["bedaquiline 31Sample", "CHEMICAL", 407, 427], ["bedaquiline", "CHEMICAL", 407, 418], ["pepQ", "GENE_OR_GENE_PRODUCT", 11, 15], ["patients", "ORGANISM", 93, 101], ["Rv0678", "GENE_OR_GENE_PRODUCT", 253, 259], ["patients", "ORGANISM", 361, 369], ["Rv0678 variants", "DNA", 253, 268], ["Mtb whole genome sequences", "DNA", 496, 522], ["L2", "DNA", 598, 600], ["L4", "DNA", 606, 608], ["Figure 1, Supplementary Tables S1-S2Reference mapping", "DNA", 610, 663], ["Original fastq files", "DNA", 683, 703], ["H37Rv reference genome", "DNA", 778, 800], ["bwa mem v0.7.17 61", "DNA", 806, 824], ["patients", "SPECIES", 93, 101], ["patients", "SPECIES", 361, 369], ["Frameshift pepQ mutations", "PROBLEM", 0, 25], ["an additional rare resistance mechanism", "PROBLEM", 140, 179], ["Rv0678 variants", "PROBLEM", 253, 268], ["therapy", "TREATMENT", 276, 283], ["clinical strains", "PROBLEM", 287, 303], ["drug regimens", "TREATMENT", 383, 396], ["bedaquiline", "TREATMENT", 407, 418], ["this study", "TEST", 441, 451], ["Mtb whole genome sequences", "TEST", 496, 522], ["large", "OBSERVATION_MODIFIER", 463, 468], ["geographic", "OBSERVATION_MODIFIER", 559, 569], ["distribution", "OBSERVATION_MODIFIER", 570, 582], ["lineages", "OBSERVATION_MODIFIER", 586, 594], ["L4", "ANATOMY", 606, 608]]], ["Mapped reads were sorted and de-duplicated using Picard Tools v2.20 followed by indel realignment with GATK v3.8 62 .", [["Mapped reads", "TEST", 0, 12], ["Picard Tools", "TEST", 49, 61], ["indel realignment", "TEST", 80, 97], ["GATK v", "TEST", 103, 109]]], ["Alignment quality and coverage was recorded with Qualimap v2.21 63 .", [["Qualimap v", "TEST", 49, 59]]], ["Variant calling was performed using bcftools v1.9, based on reads mapping with a minimum mapping quality of 20, base quality of 20, no evidence of strand or position bias, a minimum coverage depth of 10 reads, and a minimum of four reads supporting the alternate allele, with at least two of them on each strand.", [["alternate allele", "DNA", 253, 269], ["bcftools v", "TREATMENT", 36, 46], ["reads mapping", "TEST", 60, 73], ["a minimum mapping quality", "TEST", 79, 104], ["base quality", "TEST", 112, 124], ["strand or position bias", "PROBLEM", 147, 170], ["no evidence of", "UNCERTAINTY", 132, 146], ["strand", "OBSERVATION", 147, 153]]], ["Moreover, SNPs that were less than 2bp apart of an indel were excluded from the analysis.", [["SNPs", "TREATMENT", 10, 14], ["an indel", "TEST", 48, 56], ["the analysis", "TEST", 76, 88]]], ["Similarly, only indels 3bp apart of other indels were kept.Reference mapping and variant callingAll sites with insufficient coverage to identify a site as variant or reference were excluded (marked as 'N'), as were those in or within 100 bases of PE/PPE genes, or in insertion sequences or phages.", [["PPE", "GENE_OR_GENE_PRODUCT", 250, 253], ["PE/PPE genes", "DNA", 247, 259], ["insertion sequences", "DNA", 267, 286], ["indels", "TEST", 16, 22], ["bp", "TEST", 24, 26], ["other indels", "PROBLEM", 36, 48], ["Reference mapping", "TEST", 59, 76], ["insufficient coverage", "TREATMENT", 111, 132], ["PE/PPE genes", "PROBLEM", 247, 259], ["PE", "OBSERVATION", 247, 249], ["PPE genes", "OBSERVATION", 250, 259]]], ["SNPs present in the alignment with at least 90% frequency were used to generate a pseudoalignment of equal length to the H37Rv reference using a custom Python script for use in phylogenetic analysis.", [["H37Rv reference", "DNA", 121, 136], ["H37Rv", "SPECIES", 121, 126], ["SNPs", "TREATMENT", 0, 4], ["phylogenetic analysis", "TEST", 177, 198]]], ["Samples with more than 10% of the alignment represented by ambiguous bases were excluded.", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7], ["bases", "ANATOMY_MODIFIER", 69, 74]]], ["Those positions with more than 10% of ambiguous bases across all the samples were also removed.", [["samples", "ANATOMY", 69, 76], ["samples", "CANCER", 69, 76], ["bases", "ANATOMY_MODIFIER", 48, 53]]], ["In order to avoid bias on the tree structure, positions known to be associated with drug resistance were not included.Reference mapping and variant callingA more permissive variant calling pipeline was used to identify Rv0678 variants, as they are often present at <100% frequency with a high incidence of frameshift mutations.", [["Rv0678", "GENE_OR_GENE_PRODUCT", 219, 225], ["Rv0678 variants", "DNA", 219, 234], ["bias on the tree structure", "PROBLEM", 18, 44], ["drug resistance", "PROBLEM", 84, 99], ["Reference mapping", "TEST", 118, 135], ["frameshift mutations", "PROBLEM", 306, 326]]], ["Here we instead employed FreeBayes v1.2 64 to call all variants present in the Rv0678 gene (or up to 100 bases upstream) that were present at \u00b35% frequency (alternate allele fraction -F 0.05) and supported by at least four reads including one on each strand.Classification of resistance variantsAll raw fastq files were screened using the rapid resistance profiling tool TBProfiler 39,65 against a curated whole genome drug resistance mutations library.", [["TBProfiler 39,65", "CHEMICAL", 371, 387], ["Rv0678", "GENE_OR_GENE_PRODUCT", 79, 85], ["Rv0678 gene", "DNA", 79, 90], ["TBProfiler 39,65", "DNA", 371, 387], ["whole genome drug resistance mutations library", "DNA", 406, 452], ["resistance variants", "PROBLEM", 276, 295], ["resistance variants", "OBSERVATION", 276, 295]]], ["This allowed rapid assignment of polymorphisms associated with resistance to different antimycobacterial drugs and categorisation of MDR and XDR Mtb status (Supplementary Figure S2, Supplementary Figures S5-S9) .Classification of Rv0678 variantsThe diverse range of Rv0678 variants and paucity of widespread MIC testing means that there are limited data from which to infer the phenotypic consequences of identified Rv0678 variants.", [["Rv0678", "GENE_OR_GENE_PRODUCT", 230, 236], ["Rv0678", "GENE_OR_GENE_PRODUCT", 266, 272], ["Rv0678", "GENE_OR_GENE_PRODUCT", 416, 422], ["Rv0678 variants", "DNA", 230, 245], ["Rv0678 variants", "DNA", 266, 281], ["Rv0678 variants", "DNA", 416, 431], ["polymorphisms", "PROBLEM", 33, 46], ["different antimycobacterial drugs", "TREATMENT", 77, 110], ["MDR", "PROBLEM", 133, 136], ["XDR Mtb status", "PROBLEM", 141, 155], ["widespread MIC testing", "TEST", 297, 319], ["antimycobacterial drugs", "OBSERVATION", 87, 110], ["Rv0678 variants", "OBSERVATION", 230, 245], ["diverse", "OBSERVATION_MODIFIER", 249, 256], ["range", "OBSERVATION_MODIFIER", 257, 262]]], ["We were able to categorise 29/85 (34.1%) of the different non-synonymous and promoter mutations identified.", [["the different non-synonymous and promoter mutations", "PROBLEM", 44, 95], ["promoter mutations", "OBSERVATION", 77, 95]]], ["Supplementary Table S7 .Global phylogenetic inferenceThe alignments for phylogenetic inference were masked for the Rv0678 region using bedtools v2.", [["Rv0678 region", "DNA", 115, 128], ["Global phylogenetic inference", "PROBLEM", 24, 53], ["phylogenetic inference", "OBSERVATION", 31, 53]]], ["25 for the number of invariant sites using the ascertainment flag (ASC_STAM) and specifying a minimum branch length of 1x10 -9 reporting 12 decimal places (--precision 12).Estimating the age of emergence of Rv0678 variantsTo test whether the resulting phylogenies can be time-calibrated we first dropped the outgroups from the phylogeny and rescaled the trees so that branches were measured in unit of substitutions per genome.Estimating the age of emergence of Rv0678 variantsWe then computed a linear regression between root-to-tip distance and the time of sample collection using BactDating 72 , which additionally assesses the significance of the regression based on 10,000 date randomisations.", [["root", "ANATOMY", 522, 526], ["sample", "ANATOMY", 559, 565], ["Rv0678", "GENE_OR_GENE_PRODUCT", 207, 213], ["Rv0678", "GENE_OR_GENE_PRODUCT", 462, 468], ["Rv0678 variants", "DNA", 207, 222], ["Rv0678 variants", "DNA", 462, 477], ["invariant sites", "PROBLEM", 21, 36], ["the ascertainment flag (ASC_STAM)", "TREATMENT", 43, 76], ["the resulting phylogenies", "PROBLEM", 238, 263], ["a linear regression between root", "PROBLEM", 494, 526], ["sample collection", "TEST", 559, 576], ["the regression", "PROBLEM", 647, 661], ["minimum", "OBSERVATION_MODIFIER", 94, 101], ["branch", "OBSERVATION_MODIFIER", 102, 108], ["length", "OBSERVATION_MODIFIER", 109, 115], ["trees", "ANATOMY_MODIFIER", 354, 359], ["branches", "OBSERVATION_MODIFIER", 368, 376], ["linear", "OBSERVATION_MODIFIER", 496, 502], ["regression", "OBSERVATION", 503, 513], ["root", "OBSERVATION_MODIFIER", 522, 526], ["tip", "OBSERVATION_MODIFIER", 530, 533]]], ["We obtained a significant temporal correlation for both the L2 and L4 phylogenies, Figure S4) .Estimating the age of emergence of Rv0678 variantsBEAST2 v2.6.0 74 was run on both subsampled SNP alignments allowing for model averaging over possible choices of substitution models 75 .", [["SNP", "CHEMICAL", 189, 192], ["L2", "DNA", 60, 62], ["subsampled SNP alignments", "DNA", 178, 203], ["both subsampled SNP alignments", "TREATMENT", 173, 203], ["substitution models", "TEST", 258, 277], ["L2", "ANATOMY", 60, 62], ["L4", "ANATOMY", 67, 69]]], ["All models were run with either a relaxed or a strict prior on the evolutionary clock rate for three possible coalescent demographic models: exponential, constant and skyline.", [["relaxed", "OBSERVATION", 34, 41]]], ["In each case, the MCMC chain was run for 500,000,000 iterations, with the first 10% discarded as burn-in and sampling trees every 10,000Estimating the age of emergence of Rv0678 variantschains.", [["Rv0678", "GENE_OR_GENE_PRODUCT", 171, 177], ["Rv0678 variantschains", "PROTEIN", 171, 192]]], ["(Figure 2) .Estimating the age of emergence of Rv0678 variantsThe resulting phylogenetic trees were visualised and annotated for place of geographic sampling andEstimating the age of emergence of Rv0678 variantsRv0678 variant status using ggtree v1.14.6 77 .", [["Rv0678", "GENE_OR_GENE_PRODUCT", 47, 53], ["Rv0678 variants", "DNA", 47, 62], ["Rv0678 variants", "DNA", 196, 211], ["geographic sampling", "TEST", 138, 157], ["ggtree v", "TEST", 239, 247], ["phylogenetic trees", "OBSERVATION", 76, 94]]], ["All nonsynonymous mutations in Rv0678 were considered, with the phenotypic status assigned in Supplementary Table S4 .", [["Rv0678", "DNA", 31, 37], ["All nonsynonymous mutations", "TEST", 0, 27], ["nonsynonymous mutations", "OBSERVATION", 4, 27]]], ["For the purpose of this analysis, and to be conservative, 'unknown' variants classified using XGBoost were still considered 'unknown'.", [["this analysis", "TEST", 19, 32], ["XGBoost", "TREATMENT", 94, 101]]], ["Clades carrying shared variants in Rv0678 were identified and the age of the node (point estimates and 95% HPDs) extracted from the time-stamped phylogeny using the R package Ape v5.3 78 .", [["node", "ANATOMY", 77, 81], ["Rv0678", "GENE_OR_GENE_PRODUCT", 35, 41], ["node", "MULTI-TISSUE_STRUCTURE", 77, 81], ["Rv0678", "DNA", 35, 41], ["node", "OBSERVATION", 77, 81]]], ["For isolated samples (single emergences) exhibiting variants in Rv0678, the time of sample collection was extracted together with the date associated with the upper bound on the age of the next closest node of the tree (Figure 3, Supplementary Figures S11-S12) .", [["samples", "ANATOMY", 13, 20], ["sample", "ANATOMY", 84, 90], ["node", "ANATOMY", 202, 206], ["Rv0678", "DNA", 64, 70], ["isolated samples", "TEST", 4, 20], ["sample collection", "PROBLEM", 84, 101], ["the upper bound", "PROBLEM", 155, 170], ["upper", "ANATOMY_MODIFIER", 159, 164], ["node", "OBSERVATION", 202, 206], ["tree", "ANATOMY_MODIFIER", 214, 218]]], ["For the oldest bedaquiline resistance clade, which comprised Ile67fs carriers predominately from Peru, Bayesian skyline analysis was implemented through the skylineplot analysis functionality available in Ape v5.3 78 .Data availabilityRaw sequence data and full metadata for all newly generated isolates are available on NCBI SequencingData availabilityRead Archive under BioProject ID: XXXXX.Author ContributionsLvD, CN and FB conceived and designed the study.", [["bedaquiline", "CHEMICAL", 15, 26], ["bedaquiline", "CHEMICAL", 15, 26], ["Ile67fs", "GENE_OR_GENE_PRODUCT", 61, 68], ["the oldest bedaquiline resistance clade", "TREATMENT", 4, 43], ["Bayesian skyline analysis", "TEST", 103, 128], ["the skylineplot analysis", "TEST", 153, 177], ["Raw sequence data", "TEST", 235, 252], ["the study", "TEST", 451, 460], ["bedaquiline resistance", "OBSERVATION", 15, 37]]], ["JM, NP, AG, MO, AP, OBB, VE and LG provided sequence data.", [["MO", "GENE_OR_GENE_PRODUCT", 12, 14], ["AP", "GENE_OR_GENE_PRODUCT", 16, 18], ["AP, OBB, VE and LG provided sequence data", "TEST", 16, 57]]], ["ATO, JP, MA, CCST and XD performed and advised on computational analyses.", [["ATO", "CHEMICAL", 0, 3], ["ATO", "CHEMICAL", 0, 3], ["ATO", "SIMPLE_CHEMICAL", 0, 3], ["JP", "SIMPLE_CHEMICAL", 5, 7], ["computational analyses", "TEST", 50, 72], ["JP", "ANATOMY", 5, 7]]], ["LvD, CN and FB wrote the manuscript with input from all co-authors.", [["CN", "PROTEIN", 5, 7], ["LvD", "PROBLEM", 0, 3]]], ["Figures 11-12 and Supplementary Table S8.", [["Figures", "TEST", 0, 7]]]], "PMC3390060": [["IntroductionAcute lung injury (ALI) or acute respiratory distress syndrome (ARDS) is a serious clinical problem with high mortality.[1] In animals and humans, ALI can be induced by various causes such as brain injury,[1]\u2013[4] enterovirus,[5],[6] Japanese B encephalitis,[7] and coronavirus.[8],[9] The risk factors for ARDS included septicemia, acid aspiration, infection, traumatic injury, fat embolism, ischemia/reperfusion, and other caused.[1],[6],[8],[10]\u2013[18] Our cardiopulmonary laboratory has carried out experimental studies and clinical investigations on ALI and ARDS since 1973.[1]\u2013[3],[17],[19],[20] The purposes of this review article are: (1) To describe in brief the historical perspective of ARDS and ALI; (2) To draw attention of an important clinical issue of neurogenic ALI; (3) To present the experimental studies and clinical investigations from our laboratory from 1973 to 2009; (4) To elucidate the functional role of nitric oxide (NO) and other mediators involved in the pathogenesis of ARDS/ALI; (5) To define the risk factors for ARDS and ALI; and (6) To discuss the pathogenetic mechanisms and therapeutic regimen for ARDS/ALI.Neurogenic pulmonary edemaALI or pulmonary embolism (PE) has been reported in humans and animals with intracranial disorders such as head trauma, brain tumor, intracranial hypertension or cerebral compression.", [["lung", "ANATOMY", 18, 22], ["respiratory", "ANATOMY", 45, 56], ["brain", "ANATOMY", 204, 209], ["fat", "ANATOMY", 390, 393], ["pulmonary", "ANATOMY", 1164, 1173], ["pulmonary", "ANATOMY", 1186, 1195], ["intracranial", "ANATOMY", 1255, 1267], ["head", "ANATOMY", 1286, 1290], ["brain tumor", "ANATOMY", 1299, 1310], ["intracranial", "ANATOMY", 1312, 1324], ["cerebral", "ANATOMY", 1341, 1349], ["IntroductionAcute lung injury", "DISEASE", 0, 29], ["ALI", "DISEASE", 31, 34], ["acute respiratory distress syndrome", "DISEASE", 39, 74], ["ARDS", "DISEASE", 76, 80], ["ALI", "DISEASE", 159, 162], ["brain injury", "DISEASE", 204, 216], ["[1]\u2013[4] enterovirus,[5],[6] Japanese B", "CHEMICAL", 217, 255], ["encephalitis", "DISEASE", 256, 268], ["ARDS", "DISEASE", 318, 322], ["septicemia", "DISEASE", 332, 342], ["infection", "DISEASE", 361, 370], ["traumatic injury", "DISEASE", 372, 388], ["fat embolism", "DISEASE", 390, 402], ["ischemia", "DISEASE", 404, 412], ["ALI", "DISEASE", 564, 567], ["ARDS", "DISEASE", 572, 576], ["ARDS", "DISEASE", 707, 711], ["ALI", "DISEASE", 716, 719], ["ALI", "DISEASE", 788, 791], ["nitric oxide", "CHEMICAL", 940, 952], ["NO", "CHEMICAL", 954, 956], ["ARDS", "DISEASE", 1010, 1014], ["ALI", "DISEASE", 1015, 1018], ["ARDS", "DISEASE", 1055, 1059], ["ALI", "DISEASE", 1064, 1067], ["ARDS", "DISEASE", 1144, 1148], ["ALI", "DISEASE", 1149, 1152], ["Neurogenic pulmonary edemaALI", "DISEASE", 1153, 1182], ["pulmonary embolism", "DISEASE", 1186, 1204], ["PE", "DISEASE", 1206, 1208], ["intracranial disorders", "DISEASE", 1255, 1277], ["head trauma", "DISEASE", 1286, 1297], ["brain tumor", "DISEASE", 1299, 1310], ["intracranial hypertension", "DISEASE", 1312, 1337], ["cerebral compression", "DISEASE", 1341, 1361], ["[1],[6],[8],[10]\u2013[18]", "CHEMICAL", 443, 464], ["nitric oxide", "CHEMICAL", 940, 952], ["NO", "CHEMICAL", 954, 956], ["lung", "ORGAN", 18, 22], ["animals", "ORGANISM", 139, 146], ["humans", "ORGANISM", 151, 157], ["brain", "ORGAN", 204, 209], ["[1]\u2013[4] enterovirus", "SIMPLE_CHEMICAL", 217, 236], ["[5],[6] Japanese B encephalitis", "ORGANISM", 237, 268], ["coronavirus", "ORGANISM", 277, 288], ["fat", "TISSUE", 390, 393], ["[1],[6],[8]", "SIMPLE_CHEMICAL", 443, 454], ["[1]\u2013[3],[17],[19]", "SIMPLE_CHEMICAL", 588, 605], ["nitric oxide", "SIMPLE_CHEMICAL", 940, 952], ["NO", "SIMPLE_CHEMICAL", 954, 956], ["pulmonary", "ORGAN", 1164, 1173], ["pulmonary", "ORGAN", 1186, 1195], ["humans", "ORGANISM", 1231, 1237], ["head", "ORGANISM_SUBDIVISION", 1286, 1290], ["brain tumor", "CANCER", 1299, 1310], ["cerebral", "ORGAN", 1341, 1349], ["humans", "SPECIES", 151, 157], ["humans", "SPECIES", 1231, 1237], ["humans", "SPECIES", 151, 157], ["humans", "SPECIES", 1231, 1237], ["IntroductionAcute lung injury (ALI)", "PROBLEM", 0, 35], ["acute respiratory distress syndrome", "PROBLEM", 39, 74], ["ARDS", "PROBLEM", 76, 80], ["a serious clinical problem", "PROBLEM", 85, 111], ["high mortality", "PROBLEM", 117, 131], ["brain injury", "PROBLEM", 204, 216], ["enterovirus", "PROBLEM", 225, 236], ["Japanese B encephalitis", "PROBLEM", 245, 268], ["coronavirus", "PROBLEM", 277, 288], ["The risk factors", "PROBLEM", 297, 313], ["ARDS", "PROBLEM", 318, 322], ["septicemia", "PROBLEM", 332, 342], ["acid aspiration", "PROBLEM", 344, 359], ["infection", "PROBLEM", 361, 370], ["traumatic injury", "PROBLEM", 372, 388], ["fat embolism", "PROBLEM", 390, 402], ["ischemia", "PROBLEM", 404, 412], ["reperfusion", "PROBLEM", 413, 424], ["Our cardiopulmonary laboratory", "TEST", 465, 495], ["experimental studies", "TEST", 512, 532], ["clinical investigations", "TEST", 537, 560], ["ALI", "PROBLEM", 564, 567], ["ARDS", "PROBLEM", 572, 576], ["ARDS", "PROBLEM", 707, 711], ["ALI", "PROBLEM", 716, 719], ["neurogenic ALI", "PROBLEM", 777, 791], ["the experimental studies", "TEST", 808, 832], ["clinical investigations", "TEST", 837, 860], ["nitric oxide", "TREATMENT", 940, 952], ["ARDS", "PROBLEM", 1010, 1014], ["ALI", "PROBLEM", 1015, 1018], ["ARDS", "PROBLEM", 1055, 1059], ["ALI", "PROBLEM", 1064, 1067], ["the pathogenetic mechanisms", "PROBLEM", 1088, 1115], ["therapeutic regimen", "TREATMENT", 1120, 1139], ["ARDS", "PROBLEM", 1144, 1148], ["ALI", "PROBLEM", 1149, 1152], ["Neurogenic pulmonary edemaALI", "PROBLEM", 1153, 1182], ["pulmonary embolism", "PROBLEM", 1186, 1204], ["PE", "PROBLEM", 1206, 1208], ["intracranial disorders", "PROBLEM", 1255, 1277], ["head trauma", "PROBLEM", 1286, 1297], ["brain tumor", "PROBLEM", 1299, 1310], ["intracranial hypertension", "PROBLEM", 1312, 1337], ["cerebral compression", "PROBLEM", 1341, 1361], ["lung", "ANATOMY", 18, 22], ["injury", "OBSERVATION", 23, 29], ["ALI", "ANATOMY", 31, 34], ["acute", "OBSERVATION_MODIFIER", 39, 44], ["respiratory distress", "OBSERVATION", 45, 65], ["ALI", "ANATOMY", 159, 162], ["encephalitis", "OBSERVATION", 256, 268], ["ARDS", "OBSERVATION", 318, 322], ["septicemia", "OBSERVATION", 332, 342], ["infection", "OBSERVATION", 361, 370], ["traumatic", "OBSERVATION_MODIFIER", 372, 381], ["fat embolism", "OBSERVATION", 390, 402], ["ischemia", "OBSERVATION", 404, 412], ["reperfusion", "OBSERVATION", 413, 424], ["cardiopulmonary", "ANATOMY", 469, 484], ["ARDS", "OBSERVATION", 572, 576], ["ARDS", "OBSERVATION", 707, 711], ["neurogenic ALI", "OBSERVATION", 777, 791], ["ARDS", "OBSERVATION", 1010, 1014], ["ALI", "OBSERVATION", 1149, 1152], ["pulmonary", "ANATOMY", 1164, 1173], ["edemaALI", "OBSERVATION", 1174, 1182], ["pulmonary", "ANATOMY", 1186, 1195], ["embolism", "OBSERVATION", 1196, 1204], ["PE", "OBSERVATION", 1206, 1208], ["head", "ANATOMY", 1286, 1290], ["brain", "ANATOMY", 1299, 1304], ["tumor", "OBSERVATION", 1305, 1310], ["intracranial", "ANATOMY", 1312, 1324], ["hypertension", "OBSERVATION", 1325, 1337], ["cerebral", "ANATOMY", 1341, 1349], ["compression", "OBSERVATION", 1350, 1361]]], ["Early studies in our laboratory demonstrated that acute PE of hemorrhagic and fulminant type occurred accompanying severe hypertension and bradycardia (Cushing responses) in rats following cerebral compression (CC) or intracranial hypertension (ICH).", [["cerebral", "ANATOMY", 189, 197], ["intracranial", "ANATOMY", 218, 230], ["hemorrhagic", "DISEASE", 62, 73], ["hypertension", "DISEASE", 122, 134], ["bradycardia", "DISEASE", 139, 150], ["Cushing", "DISEASE", 152, 159], ["cerebral compression", "DISEASE", 189, 209], ["CC", "CHEMICAL", 211, 213], ["intracranial hypertension", "DISEASE", 218, 243], ["ICH", "DISEASE", 245, 248], ["rats", "ORGANISM", 174, 178], ["cerebral", "ORGAN", 189, 197], ["rats", "SPECIES", 174, 178], ["Early studies", "TEST", 0, 13], ["acute PE", "PROBLEM", 50, 58], ["hemorrhagic", "PROBLEM", 62, 73], ["fulminant type", "PROBLEM", 78, 92], ["severe hypertension", "PROBLEM", 115, 134], ["bradycardia", "PROBLEM", 139, 150], ["cerebral compression (CC)", "PROBLEM", 189, 214], ["intracranial hypertension (ICH)", "PROBLEM", 218, 249], ["acute", "OBSERVATION_MODIFIER", 50, 55], ["PE", "OBSERVATION", 56, 58], ["hemorrhagic", "OBSERVATION_MODIFIER", 62, 73], ["fulminant", "OBSERVATION_MODIFIER", 78, 87], ["severe", "OBSERVATION_MODIFIER", 115, 121], ["hypertension", "OBSERVATION", 122, 134], ["bradycardia", "OBSERVATION", 139, 150], ["cerebral", "ANATOMY", 189, 197], ["compression", "OBSERVATION", 198, 209], ["intracranial", "ANATOMY", 218, 230], ["hypertension", "OBSERVATION", 231, 243]]], ["The lung pathology was characterized by intravascular congestion and disruption of pulmonary large and small vessels leading to severe alveolar hemorrhage (alveolar flooding).", [["lung", "ANATOMY", 4, 8], ["intravascular", "ANATOMY", 40, 53], ["pulmonary", "ANATOMY", 83, 92], ["small vessels", "ANATOMY", 103, 116], ["alveolar", "ANATOMY", 135, 143], ["alveolar", "ANATOMY", 156, 164], ["intravascular congestion", "DISEASE", 40, 64], ["alveolar hemorrhage", "DISEASE", 135, 154], ["lung", "ORGAN", 4, 8], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 40, 53], ["pulmonary", "ORGAN", 83, 92], ["vessels", "MULTI-TISSUE_STRUCTURE", 109, 116], ["alveolar", "MULTI-TISSUE_STRUCTURE", 135, 143], ["alveolar", "MULTI-TISSUE_STRUCTURE", 156, 164], ["The lung pathology", "TEST", 0, 18], ["intravascular congestion", "PROBLEM", 40, 64], ["disruption of pulmonary large and small vessels", "PROBLEM", 69, 116], ["severe alveolar hemorrhage", "PROBLEM", 128, 154], ["alveolar flooding)", "PROBLEM", 156, 174], ["lung", "ANATOMY", 4, 8], ["pathology", "OBSERVATION", 9, 18], ["intravascular", "OBSERVATION_MODIFIER", 40, 53], ["congestion", "OBSERVATION", 54, 64], ["pulmonary", "ANATOMY", 83, 92], ["large", "OBSERVATION_MODIFIER", 93, 98], ["small", "OBSERVATION_MODIFIER", 103, 108], ["vessels", "ANATOMY", 109, 116], ["severe", "OBSERVATION_MODIFIER", 128, 134], ["alveolar", "ANATOMY_MODIFIER", 135, 143], ["hemorrhage", "OBSERVATION", 144, 154], ["alveolar flooding", "OBSERVATION", 156, 173]]], ["These changes was prevented by spinal transection, sympathectomy and sympathoadrenergic blocking agents, but was not affected by decerebration, adrenalectomy, vagotomy and atropine.", [["spinal", "ANATOMY", 31, 37], ["atropine", "CHEMICAL", 172, 180], ["atropine", "CHEMICAL", 172, 180], ["atropine", "SIMPLE_CHEMICAL", 172, 180], ["spinal transection", "TREATMENT", 31, 49], ["sympathectomy", "TREATMENT", 51, 64], ["sympathoadrenergic blocking agents", "TREATMENT", 69, 103], ["decerebration", "PROBLEM", 129, 142], ["adrenalectomy", "TREATMENT", 144, 157], ["vagotomy", "TREATMENT", 159, 167], ["atropine", "TREATMENT", 172, 180], ["spinal", "ANATOMY", 31, 37], ["transection", "OBSERVATION", 38, 49], ["sympathectomy", "OBSERVATION", 51, 64], ["adrenalectomy", "OBSERVATION", 144, 157], ["vagotomy", "OBSERVATION", 159, 167]]], ["These results suggest that sympathetic nervous system is pivotal in the neurogenic PE.", [["sympathetic nervous system", "ANATOMY", 27, 53], ["sympathetic nervous system", "ANATOMICAL_SYSTEM", 27, 53], ["sympathetic nervous system", "PROBLEM", 27, 53], ["the neurogenic PE", "PROBLEM", 68, 85], ["sympathetic nervous", "OBSERVATION", 27, 46], ["neurogenic", "ANATOMY", 72, 82], ["PE", "OBSERVATION", 83, 85]]], ["Brain areas above the medulla oblongata and parasympathetic nervous system play little role.[2]Neurogenic pulmonary edemaA series of studies was carried out to elucidate the hemodynamic events involved in the neurogenic PE.", [["Brain areas", "ANATOMY", 0, 11], ["medulla oblongata", "ANATOMY", 22, 39], ["parasympathetic nervous system", "ANATOMY", 44, 74], ["pulmonary", "ANATOMY", 106, 115], ["PE", "DISEASE", 220, 222], ["Brain areas", "MULTI-TISSUE_STRUCTURE", 0, 11], ["medulla oblongata", "MULTI-TISSUE_STRUCTURE", 22, 39], ["parasympathetic nervous system", "ANATOMICAL_SYSTEM", 44, 74], ["pulmonary", "ORGAN", 106, 115], ["Neurogenic pulmonary edemaA", "PROBLEM", 95, 122], ["studies", "TEST", 133, 140], ["the hemodynamic events", "PROBLEM", 170, 192], ["the neurogenic PE", "PROBLEM", 205, 222], ["medulla oblongata", "ANATOMY", 22, 39], ["parasympathetic nervous", "ANATOMY", 44, 67], ["pulmonary", "ANATOMY", 106, 115], ["neurogenic", "ANATOMY", 209, 219], ["PE", "OBSERVATION", 220, 222]]], ["In anesthetized rats, we measured the aortic and pulmonary blood flow and used techniques of right and left heart bypass.", [["aortic", "ANATOMY", 38, 44], ["pulmonary blood", "ANATOMY", 49, 64], ["right", "ANATOMY", 93, 98], ["left heart", "ANATOMY", 103, 113], ["rats", "ORGANISM", 16, 20], ["aortic", "MULTI-TISSUE_STRUCTURE", 38, 44], ["pulmonary", "ORGAN", 49, 58], ["blood", "ORGANISM_SUBSTANCE", 59, 64], ["right", "ORGANISM_SUBDIVISION", 93, 98], ["heart", "ORGAN", 108, 113], ["rats", "SPECIES", 16, 20], ["right and left heart bypass", "TREATMENT", 93, 120], ["aortic", "ANATOMY", 38, 44], ["pulmonary blood", "ANATOMY", 49, 64], ["right", "ANATOMY_MODIFIER", 93, 98], ["left", "ANATOMY_MODIFIER", 103, 107], ["heart", "ANATOMY", 108, 113], ["bypass", "OBSERVATION", 114, 120]]], ["The imbalance in the right and left ventricular output was characterized by a rapid and dramatic decline in aortic flow accompanying a gradual decrease in pulmonary arterial flow.", [["right", "ANATOMY", 21, 26], ["left ventricular", "ANATOMY", 31, 47], ["aortic", "ANATOMY", 108, 114], ["pulmonary arterial", "ANATOMY", 155, 173], ["right", "ORGANISM_SUBDIVISION", 21, 26], ["left ventricular", "MULTI-TISSUE_STRUCTURE", 31, 47], ["aortic", "MULTI-TISSUE_STRUCTURE", 108, 114], ["pulmonary arterial", "MULTI-TISSUE_STRUCTURE", 155, 173], ["The imbalance in the right and left ventricular output", "PROBLEM", 0, 54], ["a rapid and dramatic decline in aortic flow", "PROBLEM", 76, 119], ["a gradual decrease in pulmonary arterial flow", "PROBLEM", 133, 178], ["imbalance", "OBSERVATION", 4, 13], ["right", "ANATOMY_MODIFIER", 21, 26], ["left ventricular", "ANATOMY", 31, 47], ["output", "OBSERVATION", 48, 54], ["rapid", "OBSERVATION_MODIFIER", 78, 83], ["dramatic", "OBSERVATION_MODIFIER", 88, 96], ["decline", "OBSERVATION", 97, 104], ["aortic", "ANATOMY", 108, 114], ["flow", "OBSERVATION", 115, 119], ["gradual", "OBSERVATION_MODIFIER", 135, 142], ["decrease", "OBSERVATION_MODIFIER", 143, 151], ["pulmonary arterial", "ANATOMY", 155, 173], ["flow", "OBSERVATION", 174, 178]]], ["In rats with a right heart bypass, ICH produced severe pulmonary hypertension and PE.", [["right heart", "ANATOMY", 15, 26], ["pulmonary", "ANATOMY", 55, 64], ["ICH", "DISEASE", 35, 38], ["pulmonary hypertension", "DISEASE", 55, 77], ["PE", "DISEASE", 82, 84], ["rats", "ORGANISM", 3, 7], ["heart", "ORGAN", 21, 26], ["pulmonary", "ORGAN", 55, 64], ["rats", "SPECIES", 3, 7], ["a right heart bypass", "TREATMENT", 13, 33], ["ICH", "PROBLEM", 35, 38], ["severe pulmonary hypertension", "PROBLEM", 48, 77], ["PE", "PROBLEM", 82, 84], ["right", "ANATOMY_MODIFIER", 15, 20], ["heart", "ANATOMY", 21, 26], ["bypass", "OBSERVATION", 27, 33], ["ICH", "OBSERVATION", 35, 38], ["severe", "OBSERVATION_MODIFIER", 48, 54], ["pulmonary", "ANATOMY", 55, 64], ["hypertension", "OBSERVATION", 65, 77], ["PE", "OBSERVATION", 82, 84]]], ["In the left heart-bypassed rats, ICH induced systemic hypertension, whereas no significant changes occurred in the lungs.[4] In anesthetized dogs with a total heart bypass preparation, ICH produced constriction of the systemic and pulmonary resistance and capacitance vessels.[21]\u2013[24] The implications of these findings are: (1) Central sympathetic activation elicits increase in the systemic and pulmonary vascular resistance associated with decreases in vascular capacity in both circulations; (2) The major cause of volume and pressure loading in the pulmonary circulation is acute left ventricular failure resulting in a marked decrease in aortic flow; and (3) Systemic venous constriction causes a shift of blood from the systemic to the pulmonary circulation (Figure 1).", [["left heart", "ANATOMY", 7, 17], ["lungs", "ANATOMY", 115, 120], ["heart", "ANATOMY", 159, 164], ["pulmonary", "ANATOMY", 231, 240], ["capacitance vessels", "ANATOMY", 256, 275], ["pulmonary vascular", "ANATOMY", 398, 416], ["vascular", "ANATOMY", 457, 465], ["pulmonary", "ANATOMY", 555, 564], ["left ventricular", "ANATOMY", 586, 602], ["aortic", "ANATOMY", 645, 651], ["venous", "ANATOMY", 675, 681], ["blood", "ANATOMY", 713, 718], ["pulmonary", "ANATOMY", 744, 753], ["ICH", "DISEASE", 33, 36], ["hypertension", "DISEASE", 54, 66], ["ICH", "DISEASE", 185, 188], ["left ventricular failure", "DISEASE", 586, 610], ["heart", "ORGAN", 12, 17], ["rats", "ORGANISM", 27, 31], ["lungs", "ORGAN", 115, 120], ["dogs", "ORGANISM", 141, 145], ["heart", "ORGAN", 159, 164], ["pulmonary", "ORGAN", 231, 240], ["capacitance vessels", "MULTI-TISSUE_STRUCTURE", 256, 275], ["pulmonary vascular", "MULTI-TISSUE_STRUCTURE", 398, 416], ["vascular", "MULTI-TISSUE_STRUCTURE", 457, 465], ["pulmonary", "ORGAN", 555, 564], ["ventricular", "ORGAN", 591, 602], ["aortic", "MULTI-TISSUE_STRUCTURE", 645, 651], ["venous", "MULTI-TISSUE_STRUCTURE", 675, 681], ["blood", "ORGANISM_SUBSTANCE", 713, 718], ["pulmonary", "ORGAN", 744, 753], ["rats", "SPECIES", 27, 31], ["dogs", "SPECIES", 141, 145], ["ICH", "PROBLEM", 33, 36], ["systemic hypertension", "PROBLEM", 45, 66], ["significant changes", "PROBLEM", 79, 98], ["anesthetized dogs", "TREATMENT", 128, 145], ["a total heart bypass preparation", "TREATMENT", 151, 183], ["ICH", "PROBLEM", 185, 188], ["constriction of the systemic and pulmonary resistance and capacitance vessels", "PROBLEM", 198, 275], ["Central sympathetic activation", "PROBLEM", 330, 360], ["the systemic and pulmonary vascular resistance", "PROBLEM", 381, 427], ["decreases in vascular capacity", "PROBLEM", 444, 474], ["pressure loading in the pulmonary circulation", "PROBLEM", 531, 576], ["acute left ventricular failure", "PROBLEM", 580, 610], ["a marked decrease in aortic flow", "PROBLEM", 624, 656], ["Systemic venous constriction", "PROBLEM", 666, 694], ["a shift of blood", "PROBLEM", 702, 718], ["left", "ANATOMY_MODIFIER", 7, 11], ["heart", "ANATOMY", 12, 17], ["bypassed rats", "OBSERVATION", 18, 31], ["ICH", "OBSERVATION", 33, 36], ["systemic", "OBSERVATION_MODIFIER", 45, 53], ["hypertension", "OBSERVATION", 54, 66], ["no", "UNCERTAINTY", 76, 78], ["significant", "OBSERVATION_MODIFIER", 79, 90], ["changes", "OBSERVATION", 91, 98], ["lungs", "ANATOMY", 115, 120], ["heart", "ANATOMY", 159, 164], ["bypass", "OBSERVATION", 165, 171], ["constriction", "OBSERVATION", 198, 210], ["systemic", "OBSERVATION_MODIFIER", 218, 226], ["pulmonary", "ANATOMY", 231, 240], ["resistance", "OBSERVATION", 241, 251], ["capacitance vessels", "OBSERVATION", 256, 275], ["increase", "OBSERVATION_MODIFIER", 369, 377], ["systemic", "OBSERVATION_MODIFIER", 385, 393], ["pulmonary vascular", "ANATOMY", 398, 416], ["resistance", "OBSERVATION", 417, 427], ["decreases", "OBSERVATION_MODIFIER", 444, 453], ["vascular", "ANATOMY", 457, 465], ["capacity", "OBSERVATION_MODIFIER", 466, 474], ["both", "ANATOMY_MODIFIER", 478, 482], ["circulations", "ANATOMY_MODIFIER", 483, 495], ["volume", "OBSERVATION", 520, 526], ["pressure loading", "OBSERVATION", 531, 547], ["pulmonary circulation", "ANATOMY", 555, 576], ["acute", "OBSERVATION_MODIFIER", 580, 585], ["left ventricular", "ANATOMY", 586, 602], ["failure", "OBSERVATION", 603, 610], ["marked", "OBSERVATION_MODIFIER", 626, 632], ["decrease", "OBSERVATION_MODIFIER", 633, 641], ["aortic", "ANATOMY", 645, 651], ["flow", "OBSERVATION", 652, 656], ["venous", "ANATOMY", 675, 681], ["constriction", "OBSERVATION", 682, 694], ["shift", "OBSERVATION_MODIFIER", 704, 709], ["pulmonary circulation", "ANATOMY", 744, 765]]], ["A schematic representation summarizes the neural and hemodynamic consequence caused by cerebral compression (Figure 2).Neurogenic pulmonary edemaSpectral analysis of the aortic flow and pressure wave was employed to evaluate the hemodynamics of steady and pulsatile components.", [["neural", "ANATOMY", 42, 48], ["cerebral", "ANATOMY", 87, 95], ["pulmonary", "ANATOMY", 130, 139], ["aortic", "ANATOMY", 170, 176], ["cerebral compression", "DISEASE", 87, 107], ["cerebral", "ORGAN", 87, 95], ["pulmonary", "ORGAN", 130, 139], ["aortic", "MULTI-TISSUE_STRUCTURE", 170, 176], ["cerebral compression", "PROBLEM", 87, 107], ["Neurogenic pulmonary edemaSpectral analysis", "PROBLEM", 119, 162], ["the aortic flow", "TEST", 166, 181], ["pressure wave", "TEST", 186, 199], ["cerebral", "ANATOMY", 87, 95], ["compression", "OBSERVATION", 96, 107], ["pulmonary", "ANATOMY", 130, 139], ["edemaSpectral", "OBSERVATION", 140, 153], ["aortic", "ANATOMY", 170, 176], ["flow", "OBSERVATION", 177, 181], ["pressure", "OBSERVATION_MODIFIER", 186, 194], ["pulsatile components", "OBSERVATION", 256, 276]]], ["In anesthetized dogs, ICH caused significant increases in characteristic impedance, pulse wave reflection and total peripheral resistance with decrease in arterial compliance and cardiac output.", [["arterial", "ANATOMY", 155, 163], ["cardiac", "ANATOMY", 179, 186], ["ICH", "DISEASE", 22, 25], ["dogs", "ORGANISM", 16, 20], ["arterial", "MULTI-TISSUE_STRUCTURE", 155, 163], ["cardiac", "ORGAN", 179, 186], ["dogs", "SPECIES", 16, 20], ["ICH", "PROBLEM", 22, 25], ["characteristic impedance", "PROBLEM", 58, 82], ["pulse wave reflection", "PROBLEM", 84, 105], ["total peripheral resistance", "PROBLEM", 110, 137], ["arterial compliance", "TEST", 155, 174], ["cardiac output", "TEST", 179, 193], ["significant", "OBSERVATION_MODIFIER", 33, 44], ["increases", "OBSERVATION_MODIFIER", 45, 54], ["total", "OBSERVATION_MODIFIER", 110, 115], ["peripheral resistance", "OBSERVATION", 116, 137], ["decrease", "OBSERVATION_MODIFIER", 143, 151], ["arterial compliance", "OBSERVATION", 155, 174], ["cardiac", "ANATOMY", 179, 186], ["output", "OBSERVATION", 187, 193]]], ["The ventricular work was elevated.[25] Clinical study in patients with head injury of various severities, analysis of the heart rate variability with frequency analysis revealed increased low frequency percentage, and low to high frequency ratio with decrease in high frequency.", [["ventricular", "ANATOMY", 4, 15], ["head", "ANATOMY", 71, 75], ["heart", "ANATOMY", 122, 127], ["head injury", "DISEASE", 71, 82], ["ventricular", "MULTI-TISSUE_STRUCTURE", 4, 15], ["patients", "ORGANISM", 57, 65], ["head", "ORGANISM_SUBDIVISION", 71, 75], ["heart", "ORGAN", 122, 127], ["patients", "SPECIES", 57, 65], ["The ventricular work", "TEST", 0, 20], ["elevated", "PROBLEM", 25, 33], ["Clinical study", "TEST", 39, 53], ["head injury of various severities", "PROBLEM", 71, 104], ["the heart rate variability", "TEST", 118, 144], ["frequency analysis", "TEST", 150, 168], ["increased low frequency percentage", "PROBLEM", 178, 212], ["ventricular", "ANATOMY", 4, 15], ["elevated", "OBSERVATION", 25, 33], ["heart", "ANATOMY", 122, 127], ["increased", "OBSERVATION_MODIFIER", 178, 187], ["low frequency", "OBSERVATION_MODIFIER", 188, 201], ["decrease", "OBSERVATION_MODIFIER", 251, 259], ["high frequency", "OBSERVATION_MODIFIER", 263, 277]]], ["The findings indicate augmented sympathetic and attenuated parasympathetic drive.", [["augmented sympathetic and attenuated parasympathetic drive", "PROBLEM", 22, 80], ["augmented sympathetic", "OBSERVATION", 22, 43], ["attenuated", "OBSERVATION_MODIFIER", 48, 58], ["parasympathetic drive", "OBSERVATION", 59, 80]]], ["These autonomic functional changes were related to the severity of brain-stem damage.[26] These two studies further support the contention that central sympathetic activation is involved in the Cushing pressor response and consequent hemodynamic and autonomic alterations.The mediators involved in ALI and pulmonary hypertensionIn 1990s, my associates and I were interested in the study of chest disorders.", [["brain-stem", "ANATOMY", 67, 77], ["pulmonary", "ANATOMY", 306, 315], ["chest", "ANATOMY", 390, 395], ["brain-stem damage", "DISEASE", 67, 84], ["ALI", "DISEASE", 298, 301], ["chest disorders", "DISEASE", 390, 405], ["brain-stem", "TISSUE", 67, 77], ["pulmonary", "ORGAN", 306, 315], ["chest", "ORGANISM_SUBDIVISION", 390, 395], ["These autonomic functional changes", "PROBLEM", 0, 34], ["brain-stem damage", "PROBLEM", 67, 84], ["These two studies", "TEST", 90, 107], ["central sympathetic activation", "PROBLEM", 144, 174], ["consequent hemodynamic and autonomic alterations", "PROBLEM", 223, 271], ["ALI", "PROBLEM", 298, 301], ["the study", "TEST", 377, 386], ["chest disorders", "PROBLEM", 390, 405], ["autonomic functional", "OBSERVATION", 6, 26], ["brain", "ANATOMY", 67, 72], ["stem damage", "OBSERVATION", 73, 84], ["central", "OBSERVATION_MODIFIER", 144, 151], ["sympathetic activation", "OBSERVATION", 152, 174], ["autonomic alterations", "OBSERVATION", 250, 271], ["ALI", "ANATOMY", 298, 301], ["pulmonary", "ANATOMY", 306, 315], ["chest", "ANATOMY", 390, 395]]], ["We developed an isolated perfused rat's lung in situ preparation (Figure 3).", [["lung", "ANATOMY", 40, 44], ["rat", "ORGANISM", 34, 37], ["lung", "ORGAN", 40, 44], ["rat", "SPECIES", 34, 37], ["rat", "SPECIES", 34, 37], ["an isolated perfused rat's lung", "PROBLEM", 13, 44], ["isolated", "OBSERVATION_MODIFIER", 16, 24], ["perfused", "OBSERVATION_MODIFIER", 25, 33], ["rat", "OBSERVATION_MODIFIER", 34, 37], ["lung", "ANATOMY", 40, 44]]], ["Previous method involved removing the isolated lungs from the body and placing the organ on a force-displacement transducer to record the changes in lung weight and these procedures were rather complicated and unstable.", [["lungs", "ANATOMY", 47, 52], ["body", "ANATOMY", 62, 66], ["organ", "ANATOMY", 83, 88], ["lung", "ANATOMY", 149, 153], ["lungs", "ORGAN", 47, 52], ["body", "ORGANISM_SUBDIVISION", 62, 66], ["organ", "ORGAN", 83, 88], ["lung", "ORGAN", 149, 153], ["a force-displacement transducer", "TREATMENT", 92, 123], ["the changes in lung weight", "PROBLEM", 134, 160], ["these procedures", "TREATMENT", 165, 181], ["lungs", "ANATOMY", 47, 52], ["body", "ANATOMY_MODIFIER", 62, 66], ["organ", "ANATOMY", 83, 88], ["lung", "ANATOMY", 149, 153], ["unstable", "OBSERVATION_MODIFIER", 210, 218]]], ["Our in situ preparation does not require removing the lungs.", [["lungs", "ANATOMY", 54, 59], ["lungs", "ORGAN", 54, 59], ["lungs", "ANATOMY", 54, 59]]], ["Instead, the isolated lungs were left in situ.", [["lungs", "ANATOMY", 22, 27], ["lungs", "ORGAN", 22, 27], ["isolated", "OBSERVATION_MODIFIER", 13, 21], ["lungs", "ANATOMY", 22, 27], ["left", "ANATOMY_MODIFIER", 33, 37], ["situ", "OBSERVATION_MODIFIER", 41, 45]]], ["The whole rat was placed in a scale platform to measure the change in body weight (BW).", [["body", "ANATOMY", 70, 74], ["rat", "ORGANISM", 10, 13], ["body", "ORGANISM_SUBDIVISION", 70, 74], ["rat", "SPECIES", 10, 13], ["rat", "SPECIES", 10, 13], ["The whole rat", "TREATMENT", 0, 13], ["a scale platform", "TREATMENT", 28, 44], ["change", "OBSERVATION_MODIFIER", 60, 66]]], ["Since the lungs are completely isolated from the body, the changes in BW reflect the lung weight (LW) changes.", [["lungs", "ANATOMY", 10, 15], ["body", "ANATOMY", 49, 53], ["lung", "ANATOMY", 85, 89], ["lungs", "ORGAN", 10, 15], ["body", "ORGANISM_SUBDIVISION", 49, 53], ["lung", "ORGAN", 85, 89], ["the lung weight (LW) changes", "PROBLEM", 81, 109], ["lungs", "ANATOMY", 10, 15], ["completely", "OBSERVATION_MODIFIER", 20, 30], ["isolated", "OBSERVATION", 31, 39], ["body", "OBSERVATION_MODIFIER", 49, 53], ["lung", "ANATOMY", 85, 89], ["weight", "OBSERVATION", 90, 96]]], ["We used a digital-analogue converter to transfer the weight change from the scale platform to a recorder.", [["a digital-analogue converter", "TREATMENT", 8, 36], ["the weight change", "TREATMENT", 49, 66]]], ["In this model, we can obtain the lung weight gain, LW/BW ratio, the changes in pulmonary arterial, capillary and venous pressures, the microvascular permeability (capillary filtration coefficient, Kfc), protein concentration in bronchoalveolar lavage (PCBAL), dye leakage, and exhaled nitric oxide (NO).", [["lung", "ANATOMY", 33, 37], ["pulmonary arterial", "ANATOMY", 79, 97], ["capillary", "ANATOMY", 99, 108], ["venous", "ANATOMY", 113, 119], ["microvascular", "ANATOMY", 135, 148], ["capillary", "ANATOMY", 163, 172], ["bronchoalveolar lavage", "ANATOMY", 228, 250], ["nitric oxide", "CHEMICAL", 285, 297], ["NO", "CHEMICAL", 299, 301], ["nitric oxide", "CHEMICAL", 285, 297], ["NO", "CHEMICAL", 299, 301], ["lung", "ORGAN", 33, 37], ["pulmonary arterial", "MULTI-TISSUE_STRUCTURE", 79, 97], ["capillary", "TISSUE", 99, 108], ["venous", "MULTI-TISSUE_STRUCTURE", 113, 119], ["microvascular", "TISSUE", 135, 148], ["capillary", "TISSUE", 163, 172], ["bronchoalveolar lavage", "MULTI-TISSUE_STRUCTURE", 228, 250], ["PCBAL", "SIMPLE_CHEMICAL", 252, 257], ["exhaled nitric oxide", "SIMPLE_CHEMICAL", 277, 297], ["NO", "SIMPLE_CHEMICAL", 299, 301], ["the lung weight gain", "TEST", 29, 49], ["LW/BW ratio", "TEST", 51, 62], ["venous pressures", "TEST", 113, 129], ["the microvascular permeability", "TEST", 131, 161], ["capillary filtration coefficient", "TEST", 163, 195], ["Kfc", "TEST", 197, 200], ["protein concentration", "TEST", 203, 224], ["bronchoalveolar lavage", "TEST", 228, 250], ["dye leakage", "PROBLEM", 260, 271], ["exhaled nitric oxide", "TREATMENT", 277, 297], ["lung", "ANATOMY", 33, 37], ["pulmonary arterial", "ANATOMY", 79, 97], ["capillary", "ANATOMY_MODIFIER", 99, 108], ["venous", "ANATOMY", 113, 119], ["pressures", "ANATOMY_MODIFIER", 120, 129], ["microvascular permeability", "OBSERVATION", 135, 161], ["bronchoalveolar lavage", "OBSERVATION", 228, 250], ["dye leakage", "OBSERVATION", 260, 271]]], ["The concentration of nitrate/nitrite, methyl guanidine (an index for hydroxyl radical), proinflammatory cytokines [tumor necrosis factor \u03b1 (TNF\u03b1) and interleukin-1\u03b2 (IL-1\u03b2)] and other factors in the lung perfusate can also be detected.", [["lung", "ANATOMY", 199, 203], ["nitrate", "CHEMICAL", 21, 28], ["nitrite", "CHEMICAL", 29, 36], ["methyl guanidine", "CHEMICAL", 38, 54], ["hydroxyl", "CHEMICAL", 69, 77], ["necrosis", "DISEASE", 121, 129], ["nitrate", "CHEMICAL", 21, 28], ["nitrite", "CHEMICAL", 29, 36], ["methyl guanidine", "CHEMICAL", 38, 54], ["hydroxyl", "CHEMICAL", 69, 77], ["nitrate", "SIMPLE_CHEMICAL", 21, 28], ["nitrite", "SIMPLE_CHEMICAL", 29, 36], ["methyl guanidine", "SIMPLE_CHEMICAL", 38, 54], ["hydroxyl radical", "SIMPLE_CHEMICAL", 69, 85], ["tumor necrosis factor \u03b1", "GENE_OR_GENE_PRODUCT", 115, 138], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 140, 144], ["interleukin-1\u03b2", "GENE_OR_GENE_PRODUCT", 150, 164], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 166, 171], ["lung", "ORGAN", 199, 203], ["perfusate", "ORGANISM_SUBSTANCE", 204, 213], ["proinflammatory cytokines", "PROTEIN", 88, 113], ["tumor necrosis factor \u03b1", "PROTEIN", 115, 138], ["TNF\u03b1", "PROTEIN", 140, 144], ["interleukin-1\u03b2 (IL-1\u03b2", "PROTEIN", 150, 171], ["The concentration of nitrate", "TREATMENT", 0, 28], ["nitrite", "TREATMENT", 29, 36], ["methyl guanidine", "TREATMENT", 38, 54], ["hydroxyl radical)", "TREATMENT", 69, 86], ["proinflammatory cytokines", "PROBLEM", 88, 113], ["tumor necrosis factor", "TEST", 115, 136], ["TNF", "TEST", 140, 143], ["interleukin", "TEST", 150, 161], ["other factors in the lung perfusate", "PROBLEM", 178, 213], ["lung", "ANATOMY", 199, 203], ["perfusate", "OBSERVATION", 204, 213]]], ["Early animal experimentations investigated the pathogenesis, modulators and mediators involved in the ALI induced by phorphol, air embolism, platelets, hypoxia, ischemia/reperfusion, endotoxin [lipopolysaccharide (LPS)].", [["platelets", "ANATOMY", 141, 150], ["ALI", "DISEASE", 102, 105], ["phorphol", "CHEMICAL", 117, 125], ["embolism", "DISEASE", 131, 139], ["hypoxia", "DISEASE", 152, 159], ["ischemia", "DISEASE", 161, 169], ["endotoxin", "CHEMICAL", 183, 192], ["lipopolysaccharide", "CHEMICAL", 194, 212], ["LPS", "CHEMICAL", 214, 217], ["phorphol", "CHEMICAL", 117, 125], ["phorphol", "SIMPLE_CHEMICAL", 117, 125], ["platelets", "CELL", 141, 150], ["endotoxin", "SIMPLE_CHEMICAL", 183, 192], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 194, 212], ["LPS", "SIMPLE_CHEMICAL", 214, 217], ["platelets", "CELL_TYPE", 141, 150], ["Early animal experimentations", "PROBLEM", 0, 29], ["the ALI", "PROBLEM", 98, 105], ["air embolism", "PROBLEM", 127, 139], ["platelets", "PROBLEM", 141, 150], ["hypoxia", "PROBLEM", 152, 159], ["ischemia", "PROBLEM", 161, 169], ["reperfusion", "PROBLEM", 170, 181], ["endotoxin [lipopolysaccharide (LPS", "TREATMENT", 183, 217], ["ALI", "ANATOMY", 102, 105], ["air embolism", "OBSERVATION", 127, 139], ["hypoxia", "OBSERVATION_MODIFIER", 152, 159], ["ischemia", "OBSERVATION", 161, 169], ["reperfusion", "OBSERVATION_MODIFIER", 170, 181]]], ["The major finding is that cyclooxygenase products of arachidonic acid, thromboxane A2 in particular is involved in the ALI and pulmonary hypertension caused by phorbol, platelets and air embolism.[27],[28] Furthermore, we found that L-arginine and inhaled NO enhanced the lung injury caused by air embolism, while blockade of NO synthase (NOS) with N\u03c9-nitro-L-arginine methyl ester (L-NAME) attenuated the ALI.[28] The result suggests that NO is also involved.The detrimental role of NO via the iNOS isoform in the ALI/ARDSDuring the summers from 2001\u20132003, we encountered a total of 48 children suffering from hand, foot, and mouth disease.[6] Chest radiography on admission revealed clear lung.", [["pulmonary", "ANATOMY", 127, 136], ["platelets", "ANATOMY", 169, 178], ["lung", "ANATOMY", 272, 276], ["hand", "ANATOMY", 611, 615], ["foot", "ANATOMY", 617, 621], ["mouth", "ANATOMY", 627, 632], ["lung", "ANATOMY", 691, 695], ["arachidonic acid", "CHEMICAL", 53, 69], ["thromboxane", "CHEMICAL", 71, 82], ["ALI", "DISEASE", 119, 122], ["pulmonary hypertension", "DISEASE", 127, 149], ["phorbol", "CHEMICAL", 160, 167], ["air embolism", "DISEASE", 183, 195], ["L-arginine", "CHEMICAL", 233, 243], ["NO", "CHEMICAL", 256, 258], ["lung injury", "DISEASE", 272, 283], ["air embolism", "DISEASE", 294, 306], ["NO", "CHEMICAL", 326, 328], ["N\u03c9-nitro-L-arginine methyl ester", "CHEMICAL", 349, 381], ["L-NAME", "CHEMICAL", 383, 389], ["ALI", "DISEASE", 406, 409], ["NO", "CHEMICAL", 440, 442], ["NO", "CHEMICAL", 484, 486], ["ALI", "DISEASE", 515, 518], ["hand, foot, and mouth disease", "DISEASE", 611, 640], ["arachidonic acid", "CHEMICAL", 53, 69], ["thromboxane A2", "CHEMICAL", 71, 85], ["phorbol", "CHEMICAL", 160, 167], ["L-arginine", "CHEMICAL", 233, 243], ["NO", "CHEMICAL", 256, 258], ["NO", "CHEMICAL", 326, 328], ["N\u03c9-nitro-L-arginine methyl ester", "CHEMICAL", 349, 381], ["L-NAME", "CHEMICAL", 383, 389], ["NO", "CHEMICAL", 440, 442], ["NO", "CHEMICAL", 484, 486], ["cyclooxygenase", "GENE_OR_GENE_PRODUCT", 26, 40], ["arachidonic acid", "SIMPLE_CHEMICAL", 53, 69], ["thromboxane A2", "GENE_OR_GENE_PRODUCT", 71, 85], ["pulmonary", "ORGAN", 127, 136], ["phorbol", "SIMPLE_CHEMICAL", 160, 167], ["platelets", "CELL", 169, 178], ["L-arginine", "SIMPLE_CHEMICAL", 233, 243], ["NO", "SIMPLE_CHEMICAL", 256, 258], ["lung", "ORGAN", 272, 276], ["NO synthase", "GENE_OR_GENE_PRODUCT", 326, 337], ["NOS", "GENE_OR_GENE_PRODUCT", 339, 342], ["N\u03c9-nitro-L-arginine methyl ester", "SIMPLE_CHEMICAL", 349, 381], ["L-NAME", "SIMPLE_CHEMICAL", 383, 389], ["NO", "SIMPLE_CHEMICAL", 440, 442], ["NO", "SIMPLE_CHEMICAL", 484, 486], ["iNOS", "GENE_OR_GENE_PRODUCT", 495, 499], ["children", "ORGANISM", 587, 595], ["hand", "ORGANISM_SUBDIVISION", 611, 615], ["foot", "ORGANISM_SUBDIVISION", 617, 621], ["mouth", "ORGANISM_SUBDIVISION", 627, 632], ["lung", "ORGAN", 691, 695], ["cyclooxygenase products", "PROTEIN", 26, 49], ["NO synthase", "PROTEIN", 326, 337], ["NOS", "PROTEIN", 339, 342], ["iNOS isoform", "PROTEIN", 495, 507], ["children", "SPECIES", 587, 595], ["cyclooxygenase products", "TREATMENT", 26, 49], ["arachidonic acid", "TEST", 53, 69], ["thromboxane A2", "TREATMENT", 71, 85], ["the ALI", "PROBLEM", 115, 122], ["pulmonary hypertension", "PROBLEM", 127, 149], ["phorbol", "TEST", 160, 167], ["platelets", "TEST", 169, 178], ["air embolism", "PROBLEM", 183, 195], ["L-arginine", "TREATMENT", 233, 243], ["the lung injury", "PROBLEM", 268, 283], ["air embolism", "PROBLEM", 294, 306], ["N\u03c9-nitro", "TREATMENT", 349, 357], ["L-arginine methyl ester (L-NAME)", "TREATMENT", 358, 390], ["the ALI", "PROBLEM", 402, 409], ["hand, foot, and mouth disease", "PROBLEM", 611, 640], ["Chest radiography", "TEST", 645, 662], ["arachidonic acid", "OBSERVATION", 53, 69], ["ALI", "ANATOMY", 119, 122], ["pulmonary", "ANATOMY", 127, 136], ["hypertension", "OBSERVATION", 137, 149], ["air embolism", "OBSERVATION", 183, 195], ["lung", "ANATOMY", 272, 276], ["injury", "OBSERVATION", 277, 283], ["air embolism", "OBSERVATION", 294, 306], ["ALI", "ANATOMY", 406, 409], ["iNOS", "OBSERVATION", 495, 499], ["ALI", "ANATOMY", 515, 518], ["hand", "ANATOMY", 611, 615], ["foot", "ANATOMY", 617, 621], ["mouth", "ANATOMY", 627, 632], ["disease", "OBSERVATION", 633, 640], ["Chest", "ANATOMY", 645, 650], ["clear", "OBSERVATION", 685, 690], ["lung", "ANATOMY", 691, 695]]], ["However, 21 out of 48 cases developed severe dyspnea, hyperglycemia, leukocytosis, and decreased blood oxygen tension.", [["blood", "ANATOMY", 97, 102], ["dyspnea", "DISEASE", 45, 52], ["hyperglycemia", "DISEASE", 54, 67], ["leukocytosis", "DISEASE", 69, 81], ["oxygen", "CHEMICAL", 103, 109], ["oxygen", "CHEMICAL", 103, 109], ["blood", "ORGANISM_SUBSTANCE", 97, 102], ["oxygen", "SIMPLE_CHEMICAL", 103, 109], ["severe dyspnea", "PROBLEM", 38, 52], ["hyperglycemia", "PROBLEM", 54, 67], ["leukocytosis", "PROBLEM", 69, 81], ["decreased blood oxygen tension", "PROBLEM", 87, 117], ["severe", "OBSERVATION_MODIFIER", 38, 44], ["dyspnea", "OBSERVATION", 45, 52], ["hyperglycemia", "OBSERVATION", 54, 67], ["leukocytosis", "OBSERVATION", 69, 81], ["decreased", "OBSERVATION_MODIFIER", 87, 96], ["blood", "OBSERVATION", 97, 102], ["oxygen tension", "OBSERVATION", 103, 117]]], ["Arterial pressure (AP) and heart rate (HR) fluctuation ensued.", [["Arterial", "ANATOMY", 0, 8], ["heart", "ANATOMY", 27, 32], ["Arterial", "MULTI-TISSUE_STRUCTURE", 0, 8], ["heart", "ORGAN", 27, 32], ["Arterial pressure", "TEST", 0, 17], ["heart rate", "TEST", 27, 37], ["pressure", "OBSERVATION_MODIFIER", 9, 17], ["heart", "ANATOMY", 27, 32]]], ["Spectral analysis of the AP and HR variabilities showed elevation in sympathetic activity at the onset of respiratory stress.", [["respiratory", "ANATOMY", 106, 117], ["Spectral analysis", "TEST", 0, 17], ["the AP and HR variabilities", "TEST", 21, 48], ["elevation in sympathetic activity", "PROBLEM", 56, 89], ["respiratory stress", "PROBLEM", 106, 124], ["elevation", "OBSERVATION", 56, 65], ["sympathetic activity", "OBSERVATION", 69, 89], ["respiratory stress", "OBSERVATION", 106, 124]]], ["Thereafter, parasympathetic drive increased with declines in AP and HR.", [["parasympathetic drive", "TREATMENT", 12, 33], ["AP and HR", "TEST", 61, 70], ["parasympathetic drive", "OBSERVATION", 12, 33], ["increased", "OBSERVATION_MODIFIER", 34, 43]]], ["These children died within 4 h after the onset of ARDS.", [["ARDS", "DISEASE", 50, 54], ["children", "ORGANISM", 6, 14], ["children", "SPECIES", 6, 14], ["ARDS", "PROBLEM", 50, 54], ["ARDS", "OBSERVATION", 50, 54]]], ["Before death, chest radiography revealed severe lung infiltration.", [["chest", "ANATOMY", 14, 19], ["lung", "ANATOMY", 48, 52], ["death", "DISEASE", 7, 12], ["lung infiltration", "DISEASE", 48, 65], ["lung", "ORGAN", 48, 52], ["chest radiography", "TEST", 14, 31], ["severe lung infiltration", "PROBLEM", 41, 65], ["chest", "ANATOMY", 14, 19], ["severe", "OBSERVATION_MODIFIER", 41, 47], ["lung", "ANATOMY", 48, 52], ["infiltration", "OBSERVATION", 53, 65]]], ["Similar to Japanese B encephalitis, destruction of the medullary depressor area caused initial sympathetic activation.", [["medullary depressor area", "ANATOMY", 55, 79], ["Japanese B encephalitis", "DISEASE", 11, 34], ["Japanese B encephalitis", "ORGANISM", 11, 34], ["medullary depressor area", "MULTI-TISSUE_STRUCTURE", 55, 79], ["Japanese B encephalitis", "SPECIES", 11, 34], ["Japanese B encephalitis", "PROBLEM", 11, 34], ["destruction of the medullary depressor area", "PROBLEM", 36, 79], ["initial sympathetic activation", "PROBLEM", 87, 117], ["encephalitis", "OBSERVATION", 22, 34], ["medullary", "ANATOMY_MODIFIER", 55, 64], ["depressor", "ANATOMY", 65, 74], ["initial", "OBSERVATION_MODIFIER", 87, 94], ["sympathetic activation", "OBSERVATION", 95, 117]]], ["Reverse-transcriptase polymerase chain reaction (RT-PCR) found marked iNOS mRNA expression in the lung parenchyma, suggesting iNOS may also be involved in the pathogenesis of ARDS in patients with enterovirus 71 infection.", [["lung parenchyma", "ANATOMY", 98, 113], ["ARDS", "DISEASE", 175, 179], ["enterovirus 71 infection", "DISEASE", 197, 221], ["iNOS", "GENE_OR_GENE_PRODUCT", 70, 74], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 98, 113], ["iNOS", "GENE_OR_GENE_PRODUCT", 126, 130], ["patients", "ORGANISM", 183, 191], ["enterovirus 71", "ORGANISM", 197, 211], ["iNOS mRNA", "RNA", 70, 79], ["iNOS", "PROTEIN", 126, 130], ["patients", "SPECIES", 183, 191], ["enterovirus 71", "SPECIES", 197, 211], ["Reverse-transcriptase polymerase chain reaction", "PROBLEM", 0, 47], ["RT-PCR", "TEST", 49, 55], ["marked iNOS mRNA expression in the lung parenchyma", "PROBLEM", 63, 113], ["iNOS", "PROBLEM", 126, 130], ["ARDS", "PROBLEM", 175, 179], ["enterovirus 71 infection", "PROBLEM", 197, 221], ["marked", "OBSERVATION_MODIFIER", 63, 69], ["iNOS mRNA expression", "OBSERVATION", 70, 90], ["lung", "ANATOMY", 98, 102], ["parenchyma", "ANATOMY_MODIFIER", 103, 113], ["suggesting", "UNCERTAINTY", 115, 125], ["iNOS", "OBSERVATION", 126, 130], ["may also be", "UNCERTAINTY", 131, 142], ["ARDS", "OBSERVATION", 175, 179], ["infection", "OBSERVATION", 212, 221]]], ["Furthermore, we have reported ARDS in patients with leptospirosis.[18] In leptospirosis-induced ARDS, histochemical stain demonstrated spirochetes bacteria in the alveolar space.", [["alveolar space", "ANATOMY", 163, 177], ["ARDS", "DISEASE", 30, 34], ["leptospirosis", "DISEASE", 52, 65], ["leptospirosis", "DISEASE", 74, 87], ["ARDS", "DISEASE", 96, 100], ["patients", "ORGANISM", 38, 46], ["alveolar space", "MULTI-TISSUE_STRUCTURE", 163, 177], ["patients", "SPECIES", 38, 46], ["ARDS", "PROBLEM", 30, 34], ["leptospirosis", "PROBLEM", 52, 65], ["leptospirosis", "PROBLEM", 74, 87], ["ARDS", "PROBLEM", 96, 100], ["histochemical stain", "TEST", 102, 121], ["spirochetes bacteria in the alveolar space", "PROBLEM", 135, 177], ["ARDS", "OBSERVATION", 30, 34], ["leptospirosis", "OBSERVATION", 52, 65], ["ARDS", "OBSERVATION", 96, 100], ["spirochetes bacteria", "OBSERVATION", 135, 155], ["alveolar space", "ANATOMY", 163, 177]]], ["The pathology included alveolar hemorrhage, myocarditis, portal inflammation and interstitial nephritis.", [["alveolar", "ANATOMY", 23, 31], ["portal", "ANATOMY", 57, 63], ["interstitial", "ANATOMY", 81, 93], ["alveolar hemorrhage", "DISEASE", 23, 42], ["myocarditis", "DISEASE", 44, 55], ["portal inflammation", "DISEASE", 57, 76], ["interstitial nephritis", "DISEASE", 81, 103], ["alveolar", "MULTI-TISSUE_STRUCTURE", 23, 31], ["portal", "MULTI-TISSUE_STRUCTURE", 57, 63], ["The pathology", "TEST", 0, 13], ["alveolar hemorrhage", "PROBLEM", 23, 42], ["myocarditis", "PROBLEM", 44, 55], ["portal inflammation", "PROBLEM", 57, 76], ["interstitial nephritis", "PROBLEM", 81, 103], ["alveolar", "ANATOMY", 23, 31], ["hemorrhage", "OBSERVATION", 32, 42], ["myocarditis", "OBSERVATION", 44, 55], ["portal", "ANATOMY", 57, 63], ["inflammation", "OBSERVATION", 64, 76], ["interstitial", "ANATOMY_MODIFIER", 81, 93], ["nephritis", "OBSERVATION", 94, 103]]], ["Antigen retrieval immunohistochemical stain disclosed iNOS expression in the alveolar type 1 cells, myocardium, hepatocytes and renal tubules.", [["alveolar type 1 cells", "ANATOMY", 77, 98], ["myocardium", "ANATOMY", 100, 110], ["hepatocytes", "ANATOMY", 112, 123], ["renal tubules", "ANATOMY", 128, 141], ["iNOS", "GENE_OR_GENE_PRODUCT", 54, 58], ["alveolar type 1 cells", "CELL", 77, 98], ["myocardium", "MULTI-TISSUE_STRUCTURE", 100, 110], ["hepatocytes", "CELL", 112, 123], ["renal tubules", "TISSUE", 128, 141], ["iNOS", "PROTEIN", 54, 58], ["alveolar type 1 cells", "CELL_TYPE", 77, 98], ["hepatocytes", "CELL_TYPE", 112, 123], ["Antigen retrieval immunohistochemical stain", "TEST", 0, 43], ["iNOS expression in the alveolar type 1 cells", "PROBLEM", 54, 98], ["iNOS expression", "OBSERVATION", 54, 69], ["alveolar", "ANATOMY_MODIFIER", 77, 85], ["myocardium", "ANATOMY", 100, 110], ["hepatocytes", "ANATOMY", 112, 123], ["renal", "ANATOMY", 128, 133], ["tubules", "ANATOMY_MODIFIER", 134, 141]]], ["Spectral analysis of AP and HR variabilities indicated decreased sympathetic drive with increased parasympathetic activity.", [["AP", "MULTI-TISSUE_STRUCTURE", 21, 23], ["Spectral analysis", "TEST", 0, 17], ["AP and HR variabilities", "TEST", 21, 44], ["decreased sympathetic drive", "PROBLEM", 55, 82], ["increased parasympathetic activity", "PROBLEM", 88, 122], ["decreased", "OBSERVATION_MODIFIER", 55, 64], ["sympathetic drive", "OBSERVATION", 65, 82], ["increased", "OBSERVATION_MODIFIER", 88, 97], ["parasympathetic activity", "OBSERVATION", 98, 122]]], ["The changes in autonomic functions led to severe hypotension and bradycardia.", [["hypotension", "DISEASE", 49, 60], ["bradycardia", "DISEASE", 65, 76], ["The changes in autonomic functions", "PROBLEM", 0, 34], ["severe hypotension", "PROBLEM", 42, 60], ["bradycardia", "PROBLEM", 65, 76], ["autonomic functions", "OBSERVATION", 15, 34], ["severe", "OBSERVATION_MODIFIER", 42, 48], ["hypotension", "OBSERVATION", 49, 60], ["bradycardia", "OBSERVATION", 65, 76]]], ["Biochemical determinations suggested multiple organ damage.", [["organ", "ANATOMY", 46, 51], ["organ damage", "DISEASE", 46, 58], ["organ", "ORGAN", 46, 51], ["Biochemical determinations", "TEST", 0, 26], ["multiple organ damage", "PROBLEM", 37, 58], ["multiple", "OBSERVATION_MODIFIER", 37, 45], ["organ", "ANATOMY", 46, 51], ["damage", "OBSERVATION", 52, 58]]], ["The pathogenesis of lung and other organ injury might also involve iNOS and NO production.[18],[29] In subjects with scrub typhus, Orientia tsutsugamushi infection caused alveolar injury.", [["lung", "ANATOMY", 20, 24], ["organ", "ANATOMY", 35, 40], ["alveolar", "ANATOMY", 171, 179], ["lung and other organ injury", "DISEASE", 20, 47], ["NO", "CHEMICAL", 76, 78], ["scrub typhus", "DISEASE", 117, 129], ["Orientia tsutsugamushi infection", "DISEASE", 131, 163], ["alveolar injury", "DISEASE", 171, 186], ["NO", "CHEMICAL", 76, 78], ["lung", "ORGAN", 20, 24], ["organ", "ORGAN", 35, 40], ["iNOS", "GENE_OR_GENE_PRODUCT", 67, 71], ["NO", "SIMPLE_CHEMICAL", 76, 78], ["typhus", "ORGANISM", 123, 129], ["Orientia tsutsugamushi", "ORGANISM", 131, 153], ["alveolar", "MULTI-TISSUE_STRUCTURE", 171, 179], ["iNOS", "PROTEIN", 67, 71], ["Orientia tsutsugamushi", "SPECIES", 131, 153], ["scrub typhus", "SPECIES", 117, 129], ["Orientia tsutsugamushi", "SPECIES", 131, 153], ["The pathogenesis of lung and other organ injury", "PROBLEM", 0, 47], ["iNOS", "PROBLEM", 67, 71], ["production", "PROBLEM", 79, 89], ["scrub typhus", "PROBLEM", 117, 129], ["Orientia tsutsugamushi infection", "PROBLEM", 131, 163], ["alveolar injury", "PROBLEM", 171, 186], ["lung", "ANATOMY", 20, 24], ["organ", "ANATOMY", 35, 40], ["injury", "OBSERVATION", 41, 47], ["iNOS", "OBSERVATION", 67, 71], ["NO", "UNCERTAINTY", 76, 78], ["production", "OBSERVATION_MODIFIER", 79, 89], ["alveolar", "ANATOMY", 171, 179], ["injury", "OBSERVATION", 180, 186]]], ["Marked iNOS expression was found in the alveolar macrophages with increase in plasma nitrate/nitrite, suggesting that NO production from the alveolar macrophages accounts for the ALI.[30] The victim from rabies was a woman bitten by a wild dog.", [["alveolar macrophages", "ANATOMY", 40, 60], ["plasma", "ANATOMY", 78, 84], ["alveolar macrophages", "ANATOMY", 141, 161], ["nitrate", "CHEMICAL", 85, 92], ["nitrite", "CHEMICAL", 93, 100], ["NO", "CHEMICAL", 118, 120], ["ALI", "DISEASE", 179, 182], ["rabies", "DISEASE", 204, 210], ["nitrate", "CHEMICAL", 85, 92], ["nitrite", "CHEMICAL", 93, 100], ["NO", "CHEMICAL", 118, 120], ["iNOS", "GENE_OR_GENE_PRODUCT", 7, 11], ["alveolar macrophages", "CELL", 40, 60], ["plasma", "ORGANISM_SUBSTANCE", 78, 84], ["nitrate", "SIMPLE_CHEMICAL", 85, 92], ["nitrite", "SIMPLE_CHEMICAL", 93, 100], ["NO", "SIMPLE_CHEMICAL", 118, 120], ["alveolar macrophages", "CELL", 141, 161], ["rabies", "ORGANISM", 204, 210], ["woman", "ORGANISM", 217, 222], ["dog", "ORGANISM", 240, 243], ["iNOS", "PROTEIN", 7, 11], ["alveolar macrophages", "CELL_TYPE", 40, 60], ["alveolar macrophages", "CELL_TYPE", 141, 161], ["woman", "SPECIES", 217, 222], ["dog", "SPECIES", 240, 243], ["Marked iNOS expression", "PROBLEM", 0, 22], ["the alveolar macrophages", "PROBLEM", 36, 60], ["increase in plasma nitrate/nitrite", "PROBLEM", 66, 100], ["the alveolar macrophages", "PROBLEM", 137, 161], ["the ALI", "PROBLEM", 175, 182], ["iNOS expression", "OBSERVATION", 7, 22], ["alveolar", "ANATOMY_MODIFIER", 40, 48], ["macrophages", "ANATOMY", 49, 60], ["increase", "OBSERVATION_MODIFIER", 66, 74], ["plasma nitrate", "OBSERVATION", 78, 92], ["nitrite", "OBSERVATION", 93, 100], ["NO", "UNCERTAINTY", 118, 120], ["production", "OBSERVATION_MODIFIER", 121, 131], ["alveolar macrophages", "OBSERVATION", 141, 161], ["ALI", "OBSERVATION", 179, 182]]], ["In addition to sign of hydrophobia, hypoxia, hypercapnia, hyperglycemia and increased plasma nitrate/nitrite were observed.", [["plasma", "ANATOMY", 86, 92], ["hydrophobia", "DISEASE", 23, 34], ["hypoxia", "DISEASE", 36, 43], ["hypercapnia", "DISEASE", 45, 56], ["hyperglycemia", "DISEASE", 58, 71], ["nitrate", "CHEMICAL", 93, 100], ["nitrite", "CHEMICAL", 101, 108], ["nitrate", "CHEMICAL", 93, 100], ["nitrite", "CHEMICAL", 101, 108], ["plasma", "ORGANISM_SUBSTANCE", 86, 92], ["nitrate", "SIMPLE_CHEMICAL", 93, 100], ["nitrite", "SIMPLE_CHEMICAL", 101, 108], ["hydrophobia", "PROBLEM", 23, 34], ["hypoxia", "PROBLEM", 36, 43], ["hypercapnia", "PROBLEM", 45, 56], ["hyperglycemia", "PROBLEM", 58, 71], ["increased plasma nitrate/nitrite", "PROBLEM", 76, 108], ["hydrophobia", "OBSERVATION", 23, 34], ["hypoxia", "OBSERVATION", 36, 43], ["hypercapnia", "OBSERVATION", 45, 56], ["hyperglycemia", "OBSERVATION_MODIFIER", 58, 71], ["increased", "OBSERVATION_MODIFIER", 76, 85], ["plasma nitrate", "OBSERVATION", 86, 100]]], ["The woman died of alveolar hemorrhage shortly after admission.[31] Recently, we encountered five cases with long-term malignancy.", [["alveolar", "ANATOMY", 18, 26], ["alveolar hemorrhage", "DISEASE", 18, 37], ["malignancy", "DISEASE", 118, 128], ["woman", "ORGANISM", 4, 9], ["alveolar", "MULTI-TISSUE_STRUCTURE", 18, 26], ["woman", "SPECIES", 4, 9], ["alveolar hemorrhage", "PROBLEM", 18, 37], ["long-term malignancy", "PROBLEM", 108, 128], ["alveolar", "ANATOMY", 18, 26], ["hemorrhage", "OBSERVATION", 27, 37], ["long-term", "OBSERVATION_MODIFIER", 108, 117], ["malignancy", "OBSERVATION", 118, 128]]], ["These subjects displayed signs of respiratory distress following an episode of hypercalcemia.", [["respiratory", "ANATOMY", 34, 45], ["respiratory distress", "DISEASE", 34, 54], ["hypercalcemia", "DISEASE", 79, 92], ["respiratory distress", "PROBLEM", 34, 54], ["hypercalcemia", "PROBLEM", 79, 92], ["respiratory distress", "OBSERVATION", 34, 54], ["hypercalcemia", "OBSERVATION", 79, 92]]], ["Two cases died of ARDS after the plasma calcium was increased above 6 mmol/L. Search of literatures revealed that Holmes et al.[32] reported a patient who died of ARDS following a hypercalcemia crisis caused by a parathyroid adenoma.", [["plasma", "ANATOMY", 33, 39], ["parathyroid adenoma", "ANATOMY", 213, 232], ["ARDS", "DISEASE", 18, 22], ["calcium", "CHEMICAL", 40, 47], ["ARDS", "DISEASE", 163, 167], ["hypercalcemia", "DISEASE", 180, 193], ["parathyroid adenoma", "DISEASE", 213, 232], ["calcium", "CHEMICAL", 40, 47], ["plasma", "ORGANISM_SUBSTANCE", 33, 39], ["calcium", "SIMPLE_CHEMICAL", 40, 47], ["patient", "ORGANISM", 143, 150], ["parathyroid adenoma", "CANCER", 213, 232], ["patient", "SPECIES", 143, 150], ["ARDS", "PROBLEM", 18, 22], ["the plasma calcium", "TEST", 29, 47], ["Search of literatures", "TEST", 78, 99], ["ARDS", "PROBLEM", 163, 167], ["a hypercalcemia crisis", "PROBLEM", 178, 200], ["a parathyroid adenoma", "PROBLEM", 211, 232], ["ARDS", "OBSERVATION", 18, 22], ["ARDS", "OBSERVATION", 163, 167], ["hypercalcemia", "OBSERVATION", 180, 193], ["parathyroid", "ANATOMY", 213, 224], ["adenoma", "OBSERVATION", 225, 232]]], ["We conducted animal experiments in whole rodent and isolated perfused rat's lungs.", [["lungs", "ANATOMY", 76, 81], ["rodent", "ORGANISM", 41, 47], ["rat", "ORGANISM", 70, 73], ["lungs", "ORGAN", 76, 81], ["rodent", "SPECIES", 41, 47], ["rat", "SPECIES", 70, 73], ["rat", "SPECIES", 70, 73], ["isolated perfused rat's lungs", "PROBLEM", 52, 81], ["perfused", "OBSERVATION", 61, 69], ["lungs", "ANATOMY", 76, 81]]], ["Our results indicated that hypercalcemia (calcium concentration > 5 mmol/L) caused severe ALI in conscious rats and isolated lungs.", [["lungs", "ANATOMY", 125, 130], ["hypercalcemia", "DISEASE", 27, 40], ["calcium", "CHEMICAL", 42, 49], ["ALI", "DISEASE", 90, 93], ["calcium", "CHEMICAL", 42, 49], ["calcium", "SIMPLE_CHEMICAL", 42, 49], ["rats", "ORGANISM", 107, 111], ["lungs", "ORGAN", 125, 130], ["rats", "SPECIES", 107, 111], ["hypercalcemia", "PROBLEM", 27, 40], ["calcium concentration", "TEST", 42, 63], ["severe ALI in conscious rats", "PROBLEM", 83, 111], ["isolated lungs", "PROBLEM", 116, 130], ["hypercalcemia", "OBSERVATION", 27, 40], ["severe", "OBSERVATION_MODIFIER", 83, 89], ["ALI", "OBSERVATION", 90, 93], ["lungs", "ANATOMY", 125, 130]]], ["Immunohistochemical staining showed iNOS activity in the alveolar macrophages and epithelial cells.", [["alveolar macrophages", "ANATOMY", 57, 77], ["epithelial cells", "ANATOMY", 82, 98], ["iNOS", "GENE_OR_GENE_PRODUCT", 36, 40], ["alveolar macrophages", "CELL", 57, 77], ["epithelial cells", "CELL", 82, 98], ["iNOS", "PROTEIN", 36, 40], ["alveolar macrophages", "CELL_TYPE", 57, 77], ["epithelial cells", "CELL_TYPE", 82, 98], ["Immunohistochemical staining", "TEST", 0, 28], ["iNOS activity in the alveolar macrophages", "PROBLEM", 36, 77], ["epithelial cells", "PROBLEM", 82, 98], ["iNOS activity", "OBSERVATION", 36, 49], ["alveolar macrophages", "OBSERVATION", 57, 77], ["epithelial cells", "OBSERVATION", 82, 98]]], ["Reverse-transcriptase polymerase chain reaction (RT-PCR) found marked increase in iNOS mRNA expression in lung parenchyma.", [["lung parenchyma", "ANATOMY", 106, 121], ["iNOS", "GENE_OR_GENE_PRODUCT", 82, 86], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 106, 121], ["iNOS mRNA", "RNA", 82, 91], ["Reverse-transcriptase polymerase chain reaction", "PROBLEM", 0, 47], ["RT-PCR", "TEST", 49, 55], ["marked increase in iNOS mRNA expression in lung parenchyma", "PROBLEM", 63, 121], ["marked", "OBSERVATION_MODIFIER", 63, 69], ["increase", "OBSERVATION_MODIFIER", 70, 78], ["iNOS mRNA expression", "OBSERVATION", 82, 102], ["lung", "ANATOMY", 106, 110], ["parenchyma", "ANATOMY_MODIFIER", 111, 121]]], ["Hypercalcemia also increased nitrate/nitrite, methyl guanidine, proinflammatory cytokines and procalcitonin.", [["Hypercalcemia", "DISEASE", 0, 13], ["nitrate", "CHEMICAL", 29, 36], ["nitrite", "CHEMICAL", 37, 44], ["methyl guanidine", "CHEMICAL", 46, 62], ["nitrate", "CHEMICAL", 29, 36], ["nitrite", "CHEMICAL", 37, 44], ["methyl guanidine", "CHEMICAL", 46, 62], ["nitrate", "SIMPLE_CHEMICAL", 29, 36], ["nitrite", "SIMPLE_CHEMICAL", 37, 44], ["methyl guanidine", "SIMPLE_CHEMICAL", 46, 62], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 94, 107], ["proinflammatory cytokines", "PROTEIN", 64, 89], ["procalcitonin", "PROTEIN", 94, 107], ["Hypercalcemia", "PROBLEM", 0, 13], ["increased nitrate", "TREATMENT", 19, 36], ["nitrite", "TREATMENT", 37, 44], ["methyl guanidine", "TREATMENT", 46, 62], ["proinflammatory cytokines", "TREATMENT", 64, 89], ["procalcitonin", "TREATMENT", 94, 107]]], ["Pretreatment with calcitonin or L-N[6] (1-iminoethyl)-lysine (L-Nil, an iNOS inhibitor) attenuated the hypercalcemia-induced changes.", [["calcitonin", "CHEMICAL", 18, 28], ["L-N[6] (1-iminoethyl)-lysine", "CHEMICAL", 32, 60], ["L-Nil", "CHEMICAL", 62, 67], ["hypercalcemia", "DISEASE", 103, 116], ["L-N[6] (1-iminoethyl)-lysine", "CHEMICAL", 32, 60], ["L-Nil", "CHEMICAL", 62, 67], ["calcitonin", "GENE_OR_GENE_PRODUCT", 18, 28], ["L-N[6] (1-iminoethyl)-lysine", "SIMPLE_CHEMICAL", 32, 60], ["L-Nil", "SIMPLE_CHEMICAL", 62, 67], ["iNOS", "GENE_OR_GENE_PRODUCT", 72, 76], ["iNOS", "PROTEIN", 72, 76], ["Pretreatment", "TEST", 0, 12], ["calcitonin", "TREATMENT", 18, 28], ["lysine", "TREATMENT", 54, 60], ["Nil", "TREATMENT", 64, 67], ["an iNOS inhibitor", "TREATMENT", 69, 86], ["the hypercalcemia", "PROBLEM", 99, 116], ["hypercalcemia", "OBSERVATION", 103, 116]]], ["We proposed that hypercalcemia produced a sepsis-like syndrome.", [["hypercalcemia", "DISEASE", 17, 30], ["sepsis", "DISEASE", 42, 48], ["hypercalcemia", "PROBLEM", 17, 30], ["a sepsis-like syndrome", "PROBLEM", 40, 62], ["hypercalcemia", "OBSERVATION", 17, 30], ["sepsis", "OBSERVATION", 42, 48]]], ["The ALI caused by hypercalcemia may involve NO and iNOS.[33],[34]The detrimental role of NO via the iNOS isoform in the ALI/ARDSIn addition to the aforementioned animal experimentations and clinical observations that NO production through the iNOS may be involved in the lung injury due to various causes, our research team demonstrated that endotoxemia produced in anesthetized rats by intravenous administration of lipopolysaccharide (LPS, endotoxin) provoked systemic hypotension, endothelial damage and ALI accompanied by increased plasma nitrate/nitrite and expression of iNOS mRNA, TNF\u03b1 and IL-1\u03b2.", [["lung", "ANATOMY", 271, 275], ["intravenous", "ANATOMY", 387, 398], ["endothelial", "ANATOMY", 484, 495], ["plasma", "ANATOMY", 536, 542], ["ALI", "DISEASE", 4, 7], ["hypercalcemia", "DISEASE", 18, 31], ["NO", "CHEMICAL", 44, 46], ["NO", "CHEMICAL", 89, 91], ["ALI", "DISEASE", 120, 123], ["NO", "CHEMICAL", 217, 219], ["lung injury", "DISEASE", 271, 282], ["endotoxemia", "DISEASE", 342, 353], ["lipopolysaccharide", "CHEMICAL", 417, 435], ["LPS", "CHEMICAL", 437, 440], ["endotoxin", "CHEMICAL", 442, 451], ["hypotension", "DISEASE", 471, 482], ["endothelial damage", "DISEASE", 484, 502], ["ALI", "DISEASE", 507, 510], ["nitrate", "CHEMICAL", 543, 550], ["nitrite", "CHEMICAL", 551, 558], ["NO", "CHEMICAL", 44, 46], ["NO", "CHEMICAL", 89, 91], ["NO", "CHEMICAL", 217, 219], ["nitrate", "CHEMICAL", 543, 550], ["nitrite", "CHEMICAL", 551, 558], ["NO", "SIMPLE_CHEMICAL", 44, 46], ["iNOS", "GENE_OR_GENE_PRODUCT", 51, 55], ["[34]", "SIMPLE_CHEMICAL", 61, 65], ["NO", "SIMPLE_CHEMICAL", 89, 91], ["iNOS", "GENE_OR_GENE_PRODUCT", 100, 104], ["NO", "SIMPLE_CHEMICAL", 217, 219], ["iNOS", "GENE_OR_GENE_PRODUCT", 243, 247], ["lung", "ORGAN", 271, 275], ["rats", "ORGANISM", 379, 383], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 387, 398], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 417, 435], ["LPS", "SIMPLE_CHEMICAL", 437, 440], ["endotoxin", "SIMPLE_CHEMICAL", 442, 451], ["endothelial", "TISSUE", 484, 495], ["plasma", "ORGANISM_SUBSTANCE", 536, 542], ["nitrate", "SIMPLE_CHEMICAL", 543, 550], ["nitrite", "SIMPLE_CHEMICAL", 551, 558], ["iNOS", "GENE_OR_GENE_PRODUCT", 577, 581], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 588, 592], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 597, 602], ["iNOS", "PROTEIN", 51, 55], ["iNOS isoform", "PROTEIN", 100, 112], ["iNOS", "PROTEIN", 243, 247], ["iNOS mRNA", "RNA", 577, 586], ["TNF\u03b1 and IL-1\u03b2", "PROTEIN", 588, 602], ["rats", "SPECIES", 379, 383], ["The ALI", "PROBLEM", 0, 7], ["hypercalcemia", "PROBLEM", 18, 31], ["iNOS", "PROBLEM", 51, 55], ["the iNOS isoform", "PROBLEM", 96, 112], ["the lung injury", "PROBLEM", 267, 282], ["endotoxemia", "PROBLEM", 342, 353], ["lipopolysaccharide (LPS", "TREATMENT", 417, 440], ["endotoxin", "TREATMENT", 442, 451], ["systemic hypotension", "PROBLEM", 462, 482], ["endothelial damage", "PROBLEM", 484, 502], ["ALI", "PROBLEM", 507, 510], ["increased plasma nitrate/nitrite", "TREATMENT", 526, 558], ["iNOS mRNA", "TEST", 577, 586], ["TNF", "TEST", 588, 591], ["IL", "TEST", 597, 599], ["ALI", "ANATOMY", 4, 7], ["hypercalcemia", "OBSERVATION", 18, 31], ["iNOS", "OBSERVATION", 51, 55], ["ALI", "ANATOMY", 120, 123], ["lung", "ANATOMY", 271, 275], ["injury", "OBSERVATION", 276, 282], ["endotoxemia", "OBSERVATION", 342, 353], ["systemic", "OBSERVATION_MODIFIER", 462, 470], ["hypotension", "OBSERVATION", 471, 482], ["endothelial damage", "OBSERVATION", 484, 502], ["ALI", "ANATOMY", 507, 510], ["iNOS mRNA", "OBSERVATION", 577, 586]]], ["The LPS-induced changes were abolished by nonspecific and specific iNOS inhibitors such as N\u03c9-monomethyl-L-arginine (L-NMMA), L-NAME, aminoguanine and dexamethosone.[35] This study suggested that NO/iNOS, TNF\u03b1 and IL-1\u03b2 were involved in the endotoxemia-induced ALI.", [["LPS", "CHEMICAL", 4, 7], ["N\u03c9-monomethyl-L-arginine", "CHEMICAL", 91, 115], ["L-NMMA", "CHEMICAL", 117, 123], ["L-NAME", "CHEMICAL", 126, 132], ["aminoguanine", "CHEMICAL", 134, 146], ["dexamethosone", "CHEMICAL", 151, 164], ["NO", "CHEMICAL", 196, 198], ["endotoxemia", "DISEASE", 241, 252], ["ALI", "DISEASE", 261, 264], ["N\u03c9-monomethyl-L-arginine", "CHEMICAL", 91, 115], ["L-NMMA", "CHEMICAL", 117, 123], ["L-NAME", "CHEMICAL", 126, 132], ["aminoguanine", "CHEMICAL", 134, 146], ["dexamethosone", "CHEMICAL", 151, 164], ["NO", "CHEMICAL", 196, 198], ["LPS", "SIMPLE_CHEMICAL", 4, 7], ["iNOS", "GENE_OR_GENE_PRODUCT", 67, 71], ["N\u03c9-monomethyl-L-arginine", "SIMPLE_CHEMICAL", 91, 115], ["L-NMMA", "SIMPLE_CHEMICAL", 117, 123], ["L-NAME", "SIMPLE_CHEMICAL", 126, 132], ["aminoguanine", "SIMPLE_CHEMICAL", 134, 146], ["dexamethosone", "SIMPLE_CHEMICAL", 151, 164], ["NO", "GENE_OR_GENE_PRODUCT", 196, 198], ["iNOS", "GENE_OR_GENE_PRODUCT", 199, 203], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 205, 209], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 214, 219], ["iNOS", "PROTEIN", 67, 71], ["iNOS", "PROTEIN", 199, 203], ["TNF\u03b1", "PROTEIN", 205, 209], ["IL-1\u03b2", "PROTEIN", 214, 219], ["The LPS", "TEST", 0, 7], ["nonspecific and specific iNOS inhibitors", "PROBLEM", 42, 82], ["N\u03c9-monomethyl-L-arginine (L-NMMA)", "TREATMENT", 91, 124], ["L-NAME", "TREATMENT", 126, 132], ["aminoguanine", "TREATMENT", 134, 146], ["dexamethosone", "TREATMENT", 151, 164], ["This study", "TEST", 170, 180], ["iNOS", "PROBLEM", 199, 203], ["TNF", "TEST", 205, 208], ["IL", "TEST", 214, 216], ["ALI", "PROBLEM", 261, 264], ["NO", "UNCERTAINTY", 196, 198], ["endotoxemia", "OBSERVATION", 241, 252], ["ALI", "OBSERVATION", 261, 264]]], ["Generation of NO from the activated neutrophil caused alveolar injury from smoke inhalation.[36] Experiments in many laboratories using specific iNOS inhibitors and/or iNOS-knockout animals have supported the contention that NO/iNOS is responsible for the oxidative stress and endothelial damage in the ARDS/ALI caused by endotoxin, ozone exposure, carrageenan treatment, hypoxia, acute hyperoxia, bleomaycin administration, acid aspiration and other causes.[37]\u2013[46] Our laboratory further provided evidence to suggest that the NO/iNOS system is involved in the pathogenesis of ALI caused by air embolism,[47] fat embolism,[48]\u2013[50] ischemia/reperfusion,[51]\u2013[53] oleic acid[54] and phorbol myristate acetate.[55] In these recent studies, various insults caused increase in nitrate/nitrite in plasma or lung perfusate, upregulation of iNOS mRNA in lung parenchyma accompanied with elevation of proinflammatory cytokines such as TNF\u03b1, IL-1\u03b2 and IL-6.", [["neutrophil", "ANATOMY", 36, 46], ["alveolar", "ANATOMY", 54, 62], ["endothelial", "ANATOMY", 277, 288], ["plasma", "ANATOMY", 794, 800], ["lung", "ANATOMY", 804, 808], ["lung parenchyma", "ANATOMY", 849, 864], ["NO", "CHEMICAL", 14, 16], ["alveolar injury", "DISEASE", 54, 69], ["NO", "CHEMICAL", 225, 227], ["ARDS", "DISEASE", 303, 307], ["ALI", "DISEASE", 308, 311], ["endotoxin", "CHEMICAL", 322, 331], ["ozone", "CHEMICAL", 333, 338], ["carrageenan", "CHEMICAL", 349, 360], ["hypoxia", "DISEASE", 372, 379], ["bleomaycin", "CHEMICAL", 398, 408], ["NO", "CHEMICAL", 529, 531], ["ALI", "DISEASE", 579, 582], ["air embolism", "DISEASE", 593, 605], ["embolism", "DISEASE", 615, 623], ["[48]\u2013[50]", "CHEMICAL", 624, 633], ["ischemia", "DISEASE", 634, 642], ["[51]\u2013[53] oleic acid", "CHEMICAL", 655, 675], ["phorbol myristate acetate", "CHEMICAL", 684, 709], ["nitrate", "CHEMICAL", 775, 782], ["nitrite", "CHEMICAL", 783, 790], ["NO", "CHEMICAL", 14, 16], ["NO", "CHEMICAL", 225, 227], ["ozone", "CHEMICAL", 333, 338], ["bleomaycin", "CHEMICAL", 398, 408], ["NO", "CHEMICAL", 529, 531], ["[51]\u2013[53] oleic acid", "CHEMICAL", 655, 675], ["phorbol myristate acetate", "CHEMICAL", 684, 709], ["nitrate", "CHEMICAL", 775, 782], ["nitrite", "CHEMICAL", 783, 790], ["NO", "SIMPLE_CHEMICAL", 14, 16], ["neutrophil", "CELL", 36, 46], ["alveolar", "MULTI-TISSUE_STRUCTURE", 54, 62], ["iNOS", "GENE_OR_GENE_PRODUCT", 145, 149], ["iNOS", "GENE_OR_GENE_PRODUCT", 168, 172], ["NO", "SIMPLE_CHEMICAL", 225, 227], ["iNOS", "GENE_OR_GENE_PRODUCT", 228, 232], ["endothelial", "TISSUE", 277, 288], ["endotoxin", "SIMPLE_CHEMICAL", 322, 331], ["ozone", "SIMPLE_CHEMICAL", 333, 338], ["carrageenan", "SIMPLE_CHEMICAL", 349, 360], ["bleomaycin", "SIMPLE_CHEMICAL", 398, 408], ["NO", "GENE_OR_GENE_PRODUCT", 529, 531], ["iNOS", "GENE_OR_GENE_PRODUCT", 532, 536], ["[47] fat", "SIMPLE_CHEMICAL", 606, 614], ["[48]\u2013[50]", "SIMPLE_CHEMICAL", 624, 633], ["[51]\u2013[53] oleic acid[54]", "SIMPLE_CHEMICAL", 655, 679], ["phorbol myristate acetate", "SIMPLE_CHEMICAL", 684, 709], ["nitrate", "SIMPLE_CHEMICAL", 775, 782], ["nitrite", "SIMPLE_CHEMICAL", 783, 790], ["plasma", "ORGANISM_SUBSTANCE", 794, 800], ["lung", "ORGAN", 804, 808], ["perfusate", "ORGANISM_SUBSTANCE", 809, 818], ["iNOS", "GENE_OR_GENE_PRODUCT", 836, 840], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 849, 864], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 929, 933], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 935, 940], ["IL-6", "GENE_OR_GENE_PRODUCT", 945, 949], ["activated neutrophil", "CELL_TYPE", 26, 46], ["iNOS", "PROTEIN", 145, 149], ["iNOS", "PROTEIN", 168, 172], ["iNOS", "PROTEIN", 228, 232], ["iNOS", "PROTEIN", 532, 536], ["iNOS mRNA", "RNA", 836, 845], ["proinflammatory cytokines", "PROTEIN", 895, 920], ["TNF\u03b1", "PROTEIN", 929, 933], ["IL-1\u03b2 and IL-6", "PROTEIN", 935, 949], ["alveolar injury", "PROBLEM", 54, 69], ["specific iNOS inhibitors", "TREATMENT", 136, 160], ["iNOS", "TEST", 168, 172], ["the oxidative stress", "PROBLEM", 252, 272], ["endothelial damage", "PROBLEM", 277, 295], ["the ARDS/ALI", "PROBLEM", 299, 311], ["endotoxin", "PROBLEM", 322, 331], ["carrageenan treatment", "TREATMENT", 349, 370], ["hypoxia", "PROBLEM", 372, 379], ["acute hyperoxia", "PROBLEM", 381, 396], ["bleomaycin administration", "TREATMENT", 398, 423], ["acid aspiration", "PROBLEM", 425, 440], ["other causes", "PROBLEM", 445, 457], ["Our laboratory", "TEST", 468, 482], ["the NO/iNOS system", "PROBLEM", 525, 543], ["ALI", "PROBLEM", 579, 582], ["air embolism", "PROBLEM", 593, 605], ["fat embolism", "PROBLEM", 611, 623], ["ischemia", "PROBLEM", 634, 642], ["reperfusion", "TEST", 643, 654], ["oleic acid", "TEST", 665, 675], ["phorbol myristate acetate", "TREATMENT", 684, 709], ["these recent studies", "TEST", 718, 738], ["various insults", "PROBLEM", 740, 755], ["increase in nitrate/nitrite in plasma or lung perfusate", "PROBLEM", 763, 818], ["iNOS mRNA in lung parenchyma", "PROBLEM", 836, 864], ["elevation of proinflammatory cytokines", "PROBLEM", 882, 920], ["TNF", "TEST", 929, 932], ["IL", "TEST", 935, 937], ["NO from", "UNCERTAINTY", 14, 21], ["alveolar", "ANATOMY", 54, 62], ["injury", "OBSERVATION", 63, 69], ["smoke inhalation", "OBSERVATION", 75, 91], ["endothelial damage", "OBSERVATION", 277, 295], ["ARDS", "OBSERVATION", 303, 307], ["ALI", "ANATOMY", 308, 311], ["acute", "OBSERVATION_MODIFIER", 381, 386], ["hyperoxia", "OBSERVATION", 387, 396], ["ALI", "ANATOMY", 579, 582], ["air embolism", "OBSERVATION", 593, 605], ["increase", "OBSERVATION_MODIFIER", 763, 771], ["lung", "ANATOMY", 804, 808], ["perfusate", "OBSERVATION", 809, 818], ["iNOS mRNA", "OBSERVATION", 836, 845], ["lung", "ANATOMY", 849, 853], ["parenchyma", "ANATOMY_MODIFIER", 854, 864], ["elevation", "OBSERVATION_MODIFIER", 882, 891], ["proinflammatory cytokines", "OBSERVATION", 895, 920]]], ["Lin et al.[56] have suggested that an increase in iNOS mRNA triggers the release of proinflammatory cytokines in septic and conscious rats.", [["septic", "DISEASE", 113, 119], ["iNOS", "GENE_OR_GENE_PRODUCT", 50, 54], ["rats", "ORGANISM", 134, 138], ["iNOS mRNA", "RNA", 50, 59], ["proinflammatory cytokines", "PROTEIN", 84, 109], ["rats", "SPECIES", 134, 138], ["an increase in iNOS mRNA", "PROBLEM", 35, 59], ["proinflammatory cytokines", "PROBLEM", 84, 109], ["septic and conscious rats", "PROBLEM", 113, 138], ["increase", "OBSERVATION_MODIFIER", 38, 46], ["iNOS mRNA", "OBSERVATION", 50, 59], ["proinflammatory cytokines", "OBSERVATION", 84, 109], ["septic", "OBSERVATION", 113, 119]]], ["The inflammatory responses results in multiple organ damage including ALI.", [["organ", "ANATOMY", 47, 52], ["organ damage", "DISEASE", 47, 59], ["ALI", "DISEASE", 70, 73], ["organ", "ORGAN", 47, 52], ["The inflammatory responses", "PROBLEM", 0, 26], ["multiple organ damage", "PROBLEM", 38, 59], ["ALI", "PROBLEM", 70, 73], ["inflammatory", "OBSERVATION_MODIFIER", 4, 16], ["multiple", "OBSERVATION_MODIFIER", 38, 46], ["organ", "ANATOMY", 47, 52], ["damage", "OBSERVATION", 53, 59], ["ALI", "OBSERVATION", 70, 73]]], ["Inhibition of iNOS with S-methylisothiourea (SMT) or L-Nil attenuated the inflammatory changes, release of NO and cytokines and prevented the organ dysfunction and ALI.[52]Risk factors and pathogenetic mechanismsIn animal experiments and clinical investigations, the risk factors causing ALI/ARDS include head injury, intracranial hypertension,[2]\u2013[4],[57]\u2013[62] sepsis,[12],[17],[35],[37],[39],[42],[44],[63]\u2013[66] and infections.[6]\u2013[8],[10]\u2013[12],[17],[18],[29]\u2013[31],[67] Pulmonary embolic disorders such as fat and air embolism are less common causes.[7],[15],[28],[47],[68]\u2013[70] Ischemia/reperfusion lung injury may develop as a consequence of several pulmonary disorders such as pulmonary artery thromboendarterectomy, thrombolysis after pulmonary embolism and lung transplantation.[13],[51]\u2013[53],[71]\u2013[74] Gastric aspiration occurs frequently in surgical patients under anesthesia and other causes such as blunt thoracic trauma, impaired glottis competency, and pregnancy.[73],[75],[76] It is one of the major causes of acute respiratory syndrome (ARDS).[77],[78] Intratracheal instillation of hydrochloric acid (HCI) or gastric particles has been employed as experimental model of acute lung injury (ALI).[16],[79]\u2013[81] In addition, amphetamine, phorbal myristate acetate, oleic acid have been employed for the induction of ALI.[82]\u2013[86] Phorbol myristate acetate (PMA, 12-O-tetradecanoyl-phorbol-13-acetate), an ester derivative from croton oil has been used to induce ALI.[65],[83],[86],[87] Experiments in vivo and in vitro have demonstrated that PMA is a strong neutrophil activator.[87]\u2013[90] Activation and recruitment of neutrophil that lead to release of neutrophil elastase and other mediators may play an initial role in the pathogenesis of ALI.[91],[92] The oleic acid-induced ALI has several clinical implications.", [["organ", "ANATOMY", 142, 147], ["head", "ANATOMY", 305, 309], ["intracranial", "ANATOMY", 318, 330], ["fat", "ANATOMY", 508, 511], ["lung", "ANATOMY", 602, 606], ["pulmonary", "ANATOMY", 654, 663], ["pulmonary artery", "ANATOMY", 682, 698], ["pulmonary", "ANATOMY", 741, 750], ["lung", "ANATOMY", 764, 768], ["thoracic", "ANATOMY", 916, 924], ["glottis", "ANATOMY", 942, 949], ["gastric particles", "ANATOMY", 1125, 1142], ["lung", "ANATOMY", 1192, 1196], ["neutrophil", "ANATOMY", 1571, 1581], ["neutrophil", "ANATOMY", 1632, 1642], ["neutrophil", "ANATOMY", 1667, 1677], ["S-methylisothiourea", "CHEMICAL", 24, 43], ["SMT", "CHEMICAL", 45, 48], ["L-Nil", "CHEMICAL", 53, 58], ["NO", "CHEMICAL", 107, 109], ["organ dysfunction", "DISEASE", 142, 159], ["ALI", "DISEASE", 164, 167], ["ALI", "DISEASE", 288, 291], ["ARDS", "DISEASE", 292, 296], ["head injury", "DISEASE", 305, 316], ["intracranial hypertension", "DISEASE", 318, 343], ["sepsis", "DISEASE", 362, 368], ["infections", "DISEASE", 418, 428], ["[6]\u2013[8],[10]\u2013[12", "CHEMICAL", 429, 445], ["embolic disorders", "DISEASE", 482, 499], ["air embolism", "DISEASE", 516, 528], ["Ischemia", "DISEASE", 581, 589], ["lung injury", "DISEASE", 602, 613], ["pulmonary disorders", "DISEASE", 654, 673], ["pulmonary artery thromboendarterectomy", "DISEASE", 682, 720], ["pulmonary embolism", "DISEASE", 741, 759], ["blunt thoracic trauma", "DISEASE", 910, 931], ["impaired glottis competency", "DISEASE", 933, 960], ["acute respiratory syndrome", "DISEASE", 1024, 1050], ["ARDS", "DISEASE", 1052, 1056], ["hydrochloric acid", "CHEMICAL", 1098, 1115], ["HCI", "CHEMICAL", 1117, 1120], ["acute lung injury", "DISEASE", 1186, 1203], ["ALI", "DISEASE", 1205, 1208], ["amphetamine", "CHEMICAL", 1238, 1249], ["phorbal myristate acetate", "CHEMICAL", 1251, 1276], ["oleic acid", "CHEMICAL", 1278, 1288], ["ALI", "DISEASE", 1329, 1332], ["[82]\u2013[86] Phorbol myristate acetate", "CHEMICAL", 1333, 1368], ["PMA", "CHEMICAL", 1370, 1373], ["12-O-tetradecanoyl-phorbol-13-acetate", "CHEMICAL", 1375, 1412], ["ester", "CHEMICAL", 1418, 1423], ["croton", "CHEMICAL", 1440, 1446], ["ALI", "DISEASE", 1475, 1478], ["PMA", "CHEMICAL", 1555, 1558], ["ALI", "DISEASE", 1755, 1758], ["oleic", "CHEMICAL", 1773, 1778], ["ALI", "DISEASE", 1792, 1795], ["S-methylisothiourea", "CHEMICAL", 24, 43], ["SMT", "CHEMICAL", 45, 48], ["L-Nil", "CHEMICAL", 53, 58], ["NO", "CHEMICAL", 107, 109], ["hydrochloric acid", "CHEMICAL", 1098, 1115], ["HCI", "CHEMICAL", 1117, 1120], ["[16],[79]\u2013[81] In", "CHEMICAL", 1210, 1227], ["amphetamine", "CHEMICAL", 1238, 1249], ["phorbal myristate acetate", "CHEMICAL", 1251, 1276], ["oleic acid", "CHEMICAL", 1278, 1288], ["[82]\u2013[86] Phorbol myristate acetate", "CHEMICAL", 1333, 1368], ["PMA", "CHEMICAL", 1370, 1373], ["12-O-tetradecanoyl-phorbol-13-acetate", "CHEMICAL", 1375, 1412], ["ester", "CHEMICAL", 1418, 1423], ["PMA", "CHEMICAL", 1555, 1558], ["oleic acid-induced", "CHEMICAL", 1773, 1791], ["iNOS", "GENE_OR_GENE_PRODUCT", 14, 18], ["S-methylisothiourea", "SIMPLE_CHEMICAL", 24, 43], ["SMT", "SIMPLE_CHEMICAL", 45, 48], ["L-Nil", "SIMPLE_CHEMICAL", 53, 58], ["NO", "SIMPLE_CHEMICAL", 107, 109], ["organ", "ORGAN", 142, 147], ["head", "ORGANISM_SUBDIVISION", 305, 309], ["[2]\u2013[4]", "SIMPLE_CHEMICAL", 344, 351], ["[57]\u2013[62] sepsis", "SIMPLE_CHEMICAL", 352, 368], ["[12],[17],[35],[37],[39],[42],[44]", "SIMPLE_CHEMICAL", 369, 403], ["[63]\u2013[66]", "SIMPLE_CHEMICAL", 404, 413], ["[6]\u2013[8],[10]\u2013[12],[17],[18],[29]\u2013[31]", "SIMPLE_CHEMICAL", 429, 466], ["[67", "SIMPLE_CHEMICAL", 467, 470], ["fat", "TISSUE", 508, 511], ["[15],[28]", "SIMPLE_CHEMICAL", 556, 565], ["[47]", "SIMPLE_CHEMICAL", 566, 570], ["[68]\u2013[70]", "SIMPLE_CHEMICAL", 571, 580], ["lung", "ORGAN", 602, 606], ["pulmonary", "ORGAN", 654, 663], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 682, 698], ["pulmonary", "ORGAN", 741, 750], ["lung", "ORGAN", 764, 768], ["[13],[51]\u2013[53]", "SIMPLE_CHEMICAL", 785, 799], ["[71]\u2013", "SIMPLE_CHEMICAL", 800, 805], ["patients", "ORGANISM", 859, 867], ["thoracic", "ORGANISM_SUBDIVISION", 916, 924], ["glottis", "MULTI-TISSUE_STRUCTURE", 942, 949], ["[78] Intratracheal", "SIMPLE_CHEMICAL", 1063, 1081], ["hydrochloric acid", "SIMPLE_CHEMICAL", 1098, 1115], ["HCI", "SIMPLE_CHEMICAL", 1117, 1120], ["gastric particles", "SIMPLE_CHEMICAL", 1125, 1142], ["lung", "ORGAN", 1192, 1196], ["[16]", "SIMPLE_CHEMICAL", 1210, 1214], ["[79]\u2013[81] In", "SIMPLE_CHEMICAL", 1215, 1227], ["amphetamine", "SIMPLE_CHEMICAL", 1238, 1249], ["phorbal myristate acetate", "SIMPLE_CHEMICAL", 1251, 1276], ["oleic acid", "SIMPLE_CHEMICAL", 1278, 1288], ["[82]\u2013[86] Phorbol myristate acetate", "SIMPLE_CHEMICAL", 1333, 1368], ["PMA, 12-O-tetradecanoyl-phorbol-13-acetate", "SIMPLE_CHEMICAL", 1370, 1412], ["ester derivative", "SIMPLE_CHEMICAL", 1418, 1434], ["croton oil", "SIMPLE_CHEMICAL", 1440, 1450], ["[83]", "SIMPLE_CHEMICAL", 1484, 1488], ["[86]", "SIMPLE_CHEMICAL", 1489, 1493], ["PMA", "SIMPLE_CHEMICAL", 1555, 1558], ["neutrophil", "CELL", 1571, 1581], ["neutrophil", "CELL", 1632, 1642], ["neutrophil elastase", "GENE_OR_GENE_PRODUCT", 1667, 1686], ["[92]", "SIMPLE_CHEMICAL", 1764, 1768], ["oleic acid-induced", "SIMPLE_CHEMICAL", 1773, 1791], ["iNOS", "PROTEIN", 14, 18], ["cytokines", "PROTEIN", 114, 123], ["neutrophil activator", "PROTEIN", 1571, 1591], ["neutrophil", "CELL_TYPE", 1632, 1642], ["neutrophil elastase", "PROTEIN", 1667, 1686], ["patients", "SPECIES", 859, 867], ["S-methylisothiourea (SMT)", "TREATMENT", 24, 49], ["the inflammatory changes", "PROBLEM", 70, 94], ["cytokines", "TREATMENT", 114, 123], ["the organ dysfunction", "PROBLEM", 138, 159], ["ALI", "PROBLEM", 164, 167], ["Risk factors", "PROBLEM", 172, 184], ["pathogenetic mechanisms", "PROBLEM", 189, 212], ["clinical investigations", "TEST", 238, 261], ["ALI", "PROBLEM", 288, 291], ["ARDS", "PROBLEM", 292, 296], ["head injury", "PROBLEM", 305, 316], ["intracranial hypertension", "PROBLEM", 318, 343], ["sepsis", "PROBLEM", 362, 368], ["infections", "PROBLEM", 418, 428], ["Pulmonary embolic disorders", "PROBLEM", 472, 499], ["air embolism", "PROBLEM", 516, 528], ["Ischemia/reperfusion lung injury", "PROBLEM", 581, 613], ["several pulmonary disorders", "PROBLEM", 646, 673], ["pulmonary artery thromboendarterectomy", "TREATMENT", 682, 720], ["thrombolysis", "TREATMENT", 722, 734], ["pulmonary embolism", "PROBLEM", 741, 759], ["lung transplantation", "TREATMENT", 764, 784], ["Gastric aspiration", "PROBLEM", 810, 828], ["anesthesia", "TREATMENT", 874, 884], ["other causes", "PROBLEM", 889, 901], ["blunt thoracic trauma", "PROBLEM", 910, 931], ["impaired glottis competency", "PROBLEM", 933, 960], ["pregnancy", "PROBLEM", 966, 975], ["acute respiratory syndrome", "PROBLEM", 1024, 1050], ["ARDS", "PROBLEM", 1052, 1056], ["Intratracheal instillation of hydrochloric acid (HCI", "TREATMENT", 1068, 1120], ["gastric particles", "TREATMENT", 1125, 1142], ["acute lung injury", "PROBLEM", 1186, 1203], ["amphetamine", "TREATMENT", 1238, 1249], ["phorbal myristate acetate", "TREATMENT", 1251, 1276], ["oleic acid", "TREATMENT", 1278, 1288], ["ALI", "PROBLEM", 1329, 1332], ["Phorbol myristate acetate", "TREATMENT", 1343, 1368], ["PMA", "TEST", 1370, 1373], ["tetradecanoyl", "TREATMENT", 1380, 1393], ["phorbol", "TREATMENT", 1394, 1401], ["acetate", "TREATMENT", 1405, 1412], ["an ester derivative from croton oil", "TREATMENT", 1415, 1450], ["ALI", "PROBLEM", 1475, 1478], ["recruitment of neutrophil", "PROBLEM", 1617, 1642], ["neutrophil elastase", "TREATMENT", 1667, 1686], ["ALI", "PROBLEM", 1755, 1758], ["The oleic acid-induced ALI", "PROBLEM", 1769, 1795], ["iNOS", "OBSERVATION", 14, 18], ["inflammatory", "OBSERVATION", 74, 86], ["organ", "ANATOMY", 142, 147], ["dysfunction", "OBSERVATION", 148, 159], ["ALI", "OBSERVATION", 164, 167], ["ARDS", "OBSERVATION", 292, 296], ["intracranial", "ANATOMY", 318, 330], ["hypertension", "OBSERVATION", 331, 343], ["infections", "OBSERVATION", 418, 428], ["Pulmonary", "ANATOMY", 472, 481], ["embolic", "OBSERVATION", 482, 489], ["fat", "ANATOMY", 508, 511], ["air embolism", "OBSERVATION", 516, 528], ["lung", "ANATOMY", 602, 606], ["injury", "OBSERVATION", 607, 613], ["pulmonary", "ANATOMY", 654, 663], ["disorders", "OBSERVATION", 664, 673], ["pulmonary artery", "ANATOMY", 682, 698], ["thromboendarterectomy", "OBSERVATION", 699, 720], ["thrombolysis", "OBSERVATION", 722, 734], ["pulmonary", "ANATOMY", 741, 750], ["embolism", "OBSERVATION", 751, 759], ["lung", "ANATOMY", 764, 768], ["transplantation", "OBSERVATION", 769, 784], ["Gastric", "ANATOMY", 810, 817], ["aspiration", "OBSERVATION", 818, 828], ["thoracic", "ANATOMY", 916, 924], ["trauma", "OBSERVATION", 925, 931], ["glottis", "ANATOMY", 942, 949], ["acute", "OBSERVATION_MODIFIER", 1024, 1029], ["respiratory syndrome", "OBSERVATION", 1030, 1050], ["ARDS", "OBSERVATION", 1052, 1056], ["gastric", "ANATOMY", 1125, 1132], ["particles", "OBSERVATION", 1133, 1142], ["acute", "OBSERVATION_MODIFIER", 1186, 1191], ["lung", "ANATOMY", 1192, 1196], ["injury", "OBSERVATION", 1197, 1203], ["ALI", "OBSERVATION", 1205, 1208], ["ALI", "OBSERVATION", 1329, 1332], ["ALI", "OBSERVATION", 1475, 1478], ["neutrophil elastase", "OBSERVATION", 1667, 1686], ["ALI", "OBSERVATION", 1755, 1758]]], ["First, the blood level of oleic acid was significantly elevated in patients with ARDS.[93],[94] Second, the proportion of oleic acid incorporated into surfactant phospholipids was also increased in patients with ARDS and sepsis.[95],[96] These observations have provided evidence to suggest that serum level of oleic acid as a prediction or prognostic factor for ARDS.[84],[93] Early studies focused on the potential toxic effects of high oxygen fractions on inspired air.[97] Ventilator-induced ALI was attributed to the deleterious effects on capillary stress due to alveolar overdistension.", [["blood", "ANATOMY", 11, 16], ["serum", "ANATOMY", 296, 301], ["capillary", "ANATOMY", 545, 554], ["alveolar", "ANATOMY", 569, 577], ["oleic acid", "CHEMICAL", 26, 36], ["ARDS", "DISEASE", 81, 85], ["oleic acid", "CHEMICAL", 122, 132], ["ARDS", "DISEASE", 212, 216], ["sepsis", "DISEASE", 221, 227], ["oleic acid", "CHEMICAL", 311, 321], ["ARDS", "DISEASE", 363, 367], ["oxygen", "CHEMICAL", 439, 445], ["Ventilator", "CHEMICAL", 477, 487], ["ALI", "DISEASE", 496, 499], ["oleic acid", "CHEMICAL", 26, 36], ["oleic acid", "CHEMICAL", 122, 132], ["oleic acid", "CHEMICAL", 311, 321], ["oxygen", "CHEMICAL", 439, 445], ["blood", "ORGANISM_SUBSTANCE", 11, 16], ["oleic acid", "SIMPLE_CHEMICAL", 26, 36], ["patients", "ORGANISM", 67, 75], ["oleic acid", "SIMPLE_CHEMICAL", 122, 132], ["surfactant phospholipids", "SIMPLE_CHEMICAL", 151, 175], ["patients", "ORGANISM", 198, 206], ["serum", "ORGANISM_SUBSTANCE", 296, 301], ["oleic acid", "SIMPLE_CHEMICAL", 311, 321], ["oxygen", "SIMPLE_CHEMICAL", 439, 445], ["[97] Ventilator", "SIMPLE_CHEMICAL", 472, 487], ["capillary", "TISSUE", 545, 554], ["alveolar", "MULTI-TISSUE_STRUCTURE", 569, 577], ["patients", "SPECIES", 67, 75], ["patients", "SPECIES", 198, 206], ["the blood level of oleic acid", "TEST", 7, 36], ["significantly elevated", "PROBLEM", 41, 63], ["ARDS", "PROBLEM", 81, 85], ["oleic acid", "TREATMENT", 122, 132], ["surfactant phospholipids", "TREATMENT", 151, 175], ["ARDS", "PROBLEM", 212, 216], ["sepsis", "PROBLEM", 221, 227], ["serum level", "TEST", 296, 307], ["oleic acid", "PROBLEM", 311, 321], ["prognostic factor", "PROBLEM", 341, 358], ["ARDS", "PROBLEM", 363, 367], ["Early studies", "TEST", 378, 391], ["high oxygen fractions", "PROBLEM", 434, 455], ["Ventilator", "TREATMENT", 477, 487], ["ALI", "PROBLEM", 496, 499], ["the deleterious effects", "PROBLEM", 518, 541], ["capillary stress", "PROBLEM", 545, 561], ["alveolar overdistension", "PROBLEM", 569, 592], ["ARDS", "OBSERVATION", 81, 85], ["increased", "OBSERVATION_MODIFIER", 185, 194], ["ARDS", "OBSERVATION", 212, 216], ["sepsis", "OBSERVATION", 221, 227], ["high", "OBSERVATION_MODIFIER", 434, 438], ["oxygen fractions", "OBSERVATION", 439, 455], ["inspired air", "OBSERVATION", 459, 471], ["deleterious", "OBSERVATION", 522, 533], ["alveolar", "ANATOMY_MODIFIER", 569, 577], ["overdistension", "OBSERVATION", 578, 592]]], ["Cyclic opening and closing of atelectatic alveoli during mechanical ventilation might cause lung injury and enhance the injured alveoli.", [["alveoli", "ANATOMY", 42, 49], ["lung", "ANATOMY", 92, 96], ["alveoli", "ANATOMY", 128, 135], ["lung injury", "DISEASE", 92, 103], ["alveoli", "MULTI-TISSUE_STRUCTURE", 42, 49], ["lung", "ORGAN", 92, 96], ["alveoli", "MULTI-TISSUE_STRUCTURE", 128, 135], ["Cyclic opening", "PROBLEM", 0, 14], ["atelectatic alveoli", "PROBLEM", 30, 49], ["mechanical ventilation", "TREATMENT", 57, 79], ["lung injury", "PROBLEM", 92, 103], ["the injured alveoli", "PROBLEM", 116, 135], ["atelectatic", "OBSERVATION_MODIFIER", 30, 41], ["alveoli", "OBSERVATION", 42, 49], ["mechanical ventilation", "OBSERVATION", 57, 79], ["lung", "ANATOMY", 92, 96], ["injury", "OBSERVATION", 97, 103], ["injured", "OBSERVATION_MODIFIER", 120, 127], ["alveoli", "OBSERVATION", 128, 135]]], ["Recent evidence indicated that over distension coupled with repeated collapse and reopening of alveoli initiated an inflammatory cascade of proinflammatory cytokines release.[68],[98]\u2013[100]Risk factors and pathogenetic mechanismsIn spite of the risk factors and causes, the pathophysiology of ARDS/ALI has generally considered to be initiated by formation of alveolar edema (even hemorrhage) that is enriched with protein, inflammatory cells or red blood cells.", [["alveoli", "ANATOMY", 95, 102], ["alveolar edema", "ANATOMY", 359, 373], ["inflammatory cells", "ANATOMY", 423, 441], ["red blood cells", "ANATOMY", 445, 460], ["ARDS", "DISEASE", 293, 297], ["ALI", "DISEASE", 298, 301], ["alveolar edema", "DISEASE", 359, 373], ["hemorrhage", "DISEASE", 380, 390], ["alveoli", "MULTI-TISSUE_STRUCTURE", 95, 102], ["alveolar edema", "PATHOLOGICAL_FORMATION", 359, 373], ["inflammatory cells", "CELL", 423, 441], ["red blood cells", "CELL", 445, 460], ["proinflammatory cytokines", "PROTEIN", 140, 165], ["inflammatory cells", "CELL_TYPE", 423, 441], ["red blood cells", "CELL_TYPE", 445, 460], ["over distension", "PROBLEM", 31, 46], ["repeated collapse", "PROBLEM", 60, 77], ["alveoli", "PROBLEM", 95, 102], ["an inflammatory cascade of proinflammatory cytokines release", "TREATMENT", 113, 173], ["pathogenetic mechanisms", "PROBLEM", 206, 229], ["the risk factors", "PROBLEM", 241, 257], ["ARDS", "PROBLEM", 293, 297], ["ALI", "PROBLEM", 298, 301], ["alveolar edema", "PROBLEM", 359, 373], ["hemorrhage", "PROBLEM", 380, 390], ["protein, inflammatory cells", "PROBLEM", 414, 441], ["red blood cells", "TEST", 445, 460], ["collapse", "OBSERVATION", 69, 77], ["alveoli", "ANATOMY", 95, 102], ["inflammatory", "OBSERVATION_MODIFIER", 116, 128], ["proinflammatory cytokines", "OBSERVATION", 140, 165], ["ARDS", "OBSERVATION", 293, 297], ["alveolar", "ANATOMY", 359, 367], ["edema", "OBSERVATION", 368, 373], ["hemorrhage", "OBSERVATION", 380, 390], ["inflammatory cells", "OBSERVATION", 423, 441], ["red blood cells", "OBSERVATION", 445, 460]]], ["After damage of alveolar-capillary barrier, impairment of gas exchange occurs, with decrease in lung compliance and increases in dispersion of ventilation and perfusion and intrapulmonary shunt.", [["alveolar-capillary barrier", "ANATOMY", 16, 42], ["lung", "ANATOMY", 96, 100], ["intrapulmonary", "ANATOMY", 173, 187], ["alveolar-capillary barrier", "TISSUE", 16, 42], ["lung", "ORGAN", 96, 100], ["alveolar-capillary barrier", "TREATMENT", 16, 42], ["impairment of gas exchange", "PROBLEM", 44, 70], ["decrease in lung compliance", "PROBLEM", 84, 111], ["ventilation", "TREATMENT", 143, 154], ["perfusion", "TEST", 159, 168], ["intrapulmonary shunt", "TREATMENT", 173, 193], ["alveolar", "ANATOMY_MODIFIER", 16, 24], ["capillary barrier", "OBSERVATION", 25, 42], ["gas exchange", "OBSERVATION", 58, 70], ["decrease", "OBSERVATION_MODIFIER", 84, 92], ["lung", "ANATOMY", 96, 100], ["compliance", "OBSERVATION", 101, 111], ["increases", "OBSERVATION_MODIFIER", 116, 125], ["ventilation", "OBSERVATION", 143, 154], ["intrapulmonary shunt", "OBSERVATION", 173, 193]]], ["Hypoxia, reduction in arterial oxygen partial pressure to fraction of oxygen in inspired air PaO2/FiO2, hypercapnia ensued despite ventilation with high oxygen.[1],[2],[67],[68],[101],[102] In addition to the potential toxic effects of NO and free radicals, certain chemokines, cytokines, neutrophil elastase, myeloperoxidase and malondialdehyde have been shown to be associated with several types of ARDS/ALI.[50],[54],[55],[91],[103]\u2013[105] The balance between proinflammatory and anti-inflammatory mediators is regulated by transcriptional factors mainly nuclear factor-\u039aB (NF-\u039aB).[106] Pulmonary fluid clearance and ion transport are important factors to determine the extent of lung edema.", [["arterial", "ANATOMY", 22, 30], ["lung", "ANATOMY", 682, 686], ["Hypoxia", "DISEASE", 0, 7], ["oxygen", "CHEMICAL", 31, 37], ["oxygen", "CHEMICAL", 70, 76], ["hypercapnia", "DISEASE", 104, 115], ["oxygen", "CHEMICAL", 153, 159], ["NO", "CHEMICAL", 236, 238], ["malondialdehyde", "CHEMICAL", 330, 345], ["ARDS", "DISEASE", 401, 405], ["ALI", "DISEASE", 406, 409], ["lung edema", "DISEASE", 682, 692], ["oxygen", "CHEMICAL", 31, 37], ["oxygen", "CHEMICAL", 70, 76], ["PaO2", "CHEMICAL", 93, 97], ["FiO2", "CHEMICAL", 98, 102], ["oxygen", "CHEMICAL", 153, 159], ["NO", "CHEMICAL", 236, 238], ["malondialdehyde", "CHEMICAL", 330, 345], ["arterial", "MULTI-TISSUE_STRUCTURE", 22, 30], ["oxygen", "SIMPLE_CHEMICAL", 31, 37], ["oxygen", "SIMPLE_CHEMICAL", 70, 76], ["oxygen", "SIMPLE_CHEMICAL", 153, 159], ["[1],[2]", "SIMPLE_CHEMICAL", 160, 167], ["[67]", "SIMPLE_CHEMICAL", 168, 172], ["[68]", "SIMPLE_CHEMICAL", 173, 177], ["[101]", "SIMPLE_CHEMICAL", 178, 183], ["[102]", "SIMPLE_CHEMICAL", 184, 189], ["NO", "SIMPLE_CHEMICAL", 236, 238], ["free radicals", "SIMPLE_CHEMICAL", 243, 256], ["neutrophil elastase", "GENE_OR_GENE_PRODUCT", 289, 308], ["myeloperoxidase", "SIMPLE_CHEMICAL", 310, 325], ["malondialdehyde", "SIMPLE_CHEMICAL", 330, 345], ["[54],[55]", "SIMPLE_CHEMICAL", 415, 424], ["[91]", "SIMPLE_CHEMICAL", 425, 429], ["nuclear factor-\u039aB", "GENE_OR_GENE_PRODUCT", 557, 574], ["NF-\u039aB", "GENE_OR_GENE_PRODUCT", 576, 581], ["ion", "SIMPLE_CHEMICAL", 619, 622], ["lung", "ORGAN", 682, 686], ["edema", "PATHOLOGICAL_FORMATION", 687, 692], ["chemokines", "PROTEIN", 266, 276], ["cytokines", "PROTEIN", 278, 287], ["neutrophil elastase", "PROTEIN", 289, 308], ["myeloperoxidase", "PROTEIN", 310, 325], ["proinflammatory and anti-inflammatory mediators", "PROTEIN", 462, 509], ["transcriptional factors", "PROTEIN", 526, 549], ["nuclear factor-\u039aB", "PROTEIN", 557, 574], ["NF-\u039aB", "PROTEIN", 576, 581], ["Hypoxia", "PROBLEM", 0, 7], ["arterial oxygen partial pressure", "TREATMENT", 22, 54], ["oxygen", "TREATMENT", 70, 76], ["inspired air PaO2", "TEST", 80, 97], ["FiO2", "TREATMENT", 98, 102], ["hypercapnia", "PROBLEM", 104, 115], ["ventilation", "TREATMENT", 131, 142], ["high oxygen", "TREATMENT", 148, 159], ["free radicals", "PROBLEM", 243, 256], ["cytokines", "TEST", 278, 287], ["neutrophil elastase", "TEST", 289, 308], ["myeloperoxidase", "TEST", 310, 325], ["ARDS", "PROBLEM", 401, 405], ["ALI", "PROBLEM", 406, 409], ["proinflammatory and anti-inflammatory mediators", "TREATMENT", 462, 509], ["nuclear factor", "TEST", 557, 571], ["\u039aB", "TEST", 572, 574], ["Pulmonary fluid clearance", "TEST", 589, 614], ["lung edema", "PROBLEM", 682, 692], ["reduction", "OBSERVATION_MODIFIER", 9, 18], ["arterial", "ANATOMY_MODIFIER", 22, 30], ["oxygen partial", "OBSERVATION", 31, 45], ["pressure", "OBSERVATION_MODIFIER", 46, 54], ["oxygen", "OBSERVATION_MODIFIER", 70, 76], ["air PaO2", "OBSERVATION", 89, 97], ["hypercapnia", "OBSERVATION", 104, 115], ["high oxygen", "OBSERVATION", 148, 159], ["neutrophil elastase", "OBSERVATION", 289, 308], ["ARDS", "OBSERVATION", 401, 405], ["ALI", "OBSERVATION", 406, 409], ["Pulmonary", "ANATOMY", 589, 598], ["fluid", "OBSERVATION", 599, 604], ["lung", "ANATOMY", 682, 686], ["edema", "OBSERVATION", 687, 692]]], ["Regulator factors include cystic fibrosis transmembrane conductance regulators, sodium-and potassium\u2212activated adenosine triphophatase (Na+-K+-ATPase), protein kinases, aclenylate cyclase, and cyclic adenosine monophosphate (cAMP).[12],[29],[107],[108]Possible therapeutic regimenThe treatment of ARDS/ALI is difficult and complex.", [["fibrosis", "DISEASE", 33, 41], ["sodium", "CHEMICAL", 80, 86], ["adenosine", "CHEMICAL", 111, 120], ["cyclic adenosine monophosphate", "CHEMICAL", 193, 223], ["cAMP", "CHEMICAL", 225, 229], ["ARDS", "DISEASE", 297, 301], ["ALI", "DISEASE", 302, 305], ["sodium", "CHEMICAL", 80, 86], ["adenosine", "CHEMICAL", 111, 120], ["cyclic adenosine monophosphate", "CHEMICAL", 193, 223], ["cAMP", "CHEMICAL", 225, 229], ["sodium", "SIMPLE_CHEMICAL", 80, 86], ["potassium\u2212activated adenosine triphophatase", "GENE_OR_GENE_PRODUCT", 91, 134], ["Na+-K+-ATPase", "GENE_OR_GENE_PRODUCT", 136, 149], ["aclenylate cyclase", "GENE_OR_GENE_PRODUCT", 169, 187], ["cyclic adenosine monophosphate", "GENE_OR_GENE_PRODUCT", 193, 223], ["cAMP", "SIMPLE_CHEMICAL", 225, 229], ["[29]", "SIMPLE_CHEMICAL", 236, 240], ["[107]", "SIMPLE_CHEMICAL", 241, 246], ["[108]", "SIMPLE_CHEMICAL", 247, 252], ["Regulator factors", "PROTEIN", 0, 17], ["cystic fibrosis transmembrane conductance regulators", "PROTEIN", 26, 78], ["sodium-and potassium\u2212activated adenosine triphophatase", "PROTEIN", 80, 134], ["Na+-K+-ATPase", "PROTEIN", 136, 149], ["protein kinases", "PROTEIN", 152, 167], ["aclenylate cyclase", "PROTEIN", 169, 187], ["Regulator factors", "TEST", 0, 17], ["cystic fibrosis transmembrane conductance regulators", "PROBLEM", 26, 78], ["sodium", "TEST", 80, 86], ["potassium\u2212activated adenosine triphophatase", "TEST", 91, 134], ["ATPase", "TEST", 143, 149], ["protein kinases", "TEST", 152, 167], ["aclenylate cyclase", "TEST", 169, 187], ["cyclic adenosine monophosphate (cAMP)", "TREATMENT", 193, 230], ["therapeutic regimen", "TREATMENT", 261, 280], ["ARDS", "PROBLEM", 297, 301], ["ALI", "PROBLEM", 302, 305], ["cystic", "OBSERVATION_MODIFIER", 26, 32], ["fibrosis", "OBSERVATION", 33, 41], ["ARDS", "OBSERVATION", 297, 301], ["ALI", "OBSERVATION", 302, 305]]], ["Several review articles and monographs have addressed the issue of possible therapeutic regimen.", [["therapeutic regimen", "TREATMENT", 76, 95]]], ["The modalities include extracorporeal membrane oxygenation, prone position, mechanical ventilation with appropriate tidal volume and respiratory pressure, fluid and hemodynamic management and permissive hypercapnic acidosis.[68],[100],[109]\u2013[119]Possible therapeutic regimenOther pharmacological treatments are anti-inflammatory and/or antimicrobial agents to control infection and to abrogate sepsis, adequate nutrition, surfactant therapy, inhalation of NO and other vasodilators, glucocorticoids and other nonsteroid anti-inflammatory drugs, agents that accelerate lung water resolution and ion transports.[68],[102],[120]\u2013[124] Although most animal experimentations on these pharmacological options showed favorable results, the effectiveness and outcomes in clinical studies or trials were conflicting.Possible therapeutic regimenBeta agonists to facilitate water removal and ion transport have been shown to be promising.", [["extracorporeal membrane", "ANATOMY", 23, 46], ["respiratory", "ANATOMY", 133, 144], ["lung", "ANATOMY", 568, 572], ["acidosis", "DISEASE", 215, 223], ["infection", "DISEASE", 368, 377], ["sepsis", "DISEASE", 394, 400], ["NO", "CHEMICAL", 456, 458], ["glucocorticoids", "CHEMICAL", 483, 498], ["NO", "CHEMICAL", 456, 458], ["extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 23, 46], ["[100]", "SIMPLE_CHEMICAL", 229, 234], ["[109]\u2013[119]", "SIMPLE_CHEMICAL", 235, 246], ["surfactant", "SIMPLE_CHEMICAL", 422, 432], ["NO", "SIMPLE_CHEMICAL", 456, 458], ["glucocorticoids", "SIMPLE_CHEMICAL", 483, 498], ["lung", "ORGAN", 568, 572], ["[102]", "SIMPLE_CHEMICAL", 614, 619], ["[120]\u2013[124]", "SIMPLE_CHEMICAL", 620, 631], ["water", "SIMPLE_CHEMICAL", 863, 868], ["ion", "SIMPLE_CHEMICAL", 881, 884], ["extracorporeal membrane oxygenation", "TREATMENT", 23, 58], ["prone position", "TREATMENT", 60, 74], ["mechanical ventilation", "TREATMENT", 76, 98], ["appropriate tidal volume", "TREATMENT", 104, 128], ["respiratory pressure", "TEST", 133, 153], ["fluid", "TREATMENT", 155, 160], ["hemodynamic management", "TREATMENT", 165, 187], ["permissive hypercapnic acidosis", "PROBLEM", 192, 223], ["therapeutic regimenOther pharmacological treatments", "TREATMENT", 255, 306], ["anti-inflammatory", "TREATMENT", 311, 328], ["antimicrobial agents", "TREATMENT", 336, 356], ["infection", "PROBLEM", 368, 377], ["sepsis", "PROBLEM", 394, 400], ["surfactant therapy", "TREATMENT", 422, 440], ["inhalation", "TREATMENT", 442, 452], ["other vasodilators", "TREATMENT", 463, 481], ["glucocorticoids", "TREATMENT", 483, 498], ["other nonsteroid anti-inflammatory drugs", "TREATMENT", 503, 543], ["agents", "TREATMENT", 545, 551], ["clinical studies", "TEST", 763, 779], ["therapeutic regimenBeta agonists", "TREATMENT", 816, 848], ["water removal", "TREATMENT", 863, 876], ["extracorporeal membrane oxygenation", "OBSERVATION", 23, 58], ["mechanical ventilation", "OBSERVATION", 76, 98], ["tidal volume", "OBSERVATION", 116, 128], ["respiratory pressure", "OBSERVATION", 133, 153], ["permissive", "OBSERVATION_MODIFIER", 192, 202], ["hypercapnic acidosis", "OBSERVATION", 203, 223], ["lung", "ANATOMY", 568, 572]]], ["These agents may also stimulate secretion of surfactant and have no serious side effects.", [["surfactant", "TREATMENT", 45, 55], ["serious side effects", "PROBLEM", 68, 88]]], ["There were several reports on the pharmacological and molecular actions of beta agonists, surfactant and vascular endothelial growth factor and related molecules as well as angiotensin-converting enzyme (ACE).[107],[125],[126]Nonpharmacological and pharmacological therapeutic for ALI and ARDS from recent studies in our laboratoryIn addition to the experimental studies and clinical investigations on the pathogenesis of ALI/ARDS, our laboratory has carried out several experimentations on the therapeutic regimen for this serious disorder.", [["angiotensin", "CHEMICAL", 173, 184], ["ALI", "DISEASE", 281, 284], ["ARDS", "DISEASE", 289, 293], ["ALI", "DISEASE", 422, 425], ["ARDS", "DISEASE", 426, 430], ["beta agonists", "GENE_OR_GENE_PRODUCT", 75, 88], ["surfactant", "SIMPLE_CHEMICAL", 90, 100], ["vascular endothelial growth factor", "GENE_OR_GENE_PRODUCT", 105, 139], ["angiotensin-converting enzyme", "GENE_OR_GENE_PRODUCT", 173, 202], ["ACE", "GENE_OR_GENE_PRODUCT", 204, 207], ["[125]", "SIMPLE_CHEMICAL", 215, 220], ["[126]", "SIMPLE_CHEMICAL", 221, 226], ["vascular endothelial growth factor", "PROTEIN", 105, 139], ["angiotensin-converting enzyme", "PROTEIN", 173, 202], ["ACE", "PROTEIN", 204, 207], ["beta agonists", "TREATMENT", 75, 88], ["surfactant", "TREATMENT", 90, 100], ["vascular endothelial growth factor", "PROBLEM", 105, 139], ["related molecules", "PROBLEM", 144, 161], ["angiotensin", "TREATMENT", 173, 184], ["Nonpharmacological", "TREATMENT", 226, 244], ["ALI", "PROBLEM", 281, 284], ["ARDS", "PROBLEM", 289, 293], ["recent studies", "TEST", 299, 313], ["the experimental studies", "TEST", 346, 370], ["clinical investigations", "TEST", 375, 398], ["ALI", "PROBLEM", 422, 425], ["ARDS", "PROBLEM", 426, 430], ["the therapeutic regimen", "TREATMENT", 491, 514], ["this serious disorder", "PROBLEM", 519, 540], ["vascular endothelial", "ANATOMY", 105, 125], ["ARDS", "OBSERVATION", 289, 293], ["ARDS", "OBSERVATION", 426, 430]]], ["In conscious rats, regular exercise training attenuates septic responses such as systemic hypotension, increases in plasma nitrate/nitrite, methyl guanidine, blood urea nitrogen, creatinine, amylase, lipase, asparate aminotransferase, alanine aminotransferase, creatine phosphokinase, lactic dehydrogenase, TNF\u03b1, and IL\u03b2.", [["plasma", "ANATOMY", 116, 122], ["blood", "ANATOMY", 158, 163], ["septic", "DISEASE", 56, 62], ["hypotension", "DISEASE", 90, 101], ["nitrate", "CHEMICAL", 123, 130], ["nitrite", "CHEMICAL", 131, 138], ["methyl guanidine", "CHEMICAL", 140, 156], ["blood urea nitrogen", "CHEMICAL", 158, 177], ["creatinine", "CHEMICAL", 179, 189], ["asparate", "CHEMICAL", 208, 216], ["alanine", "CHEMICAL", 235, 242], ["creatine", "CHEMICAL", 261, 269], ["nitrate", "CHEMICAL", 123, 130], ["nitrite", "CHEMICAL", 131, 138], ["methyl guanidine", "CHEMICAL", 140, 156], ["urea", "CHEMICAL", 164, 168], ["nitrogen", "CHEMICAL", 169, 177], ["creatinine", "CHEMICAL", 179, 189], ["asparate", "CHEMICAL", 208, 216], ["alanine", "CHEMICAL", 235, 242], ["creatine", "CHEMICAL", 261, 269], ["lactic", "CHEMICAL", 285, 291], ["rats", "ORGANISM", 13, 17], ["plasma", "ORGANISM_SUBSTANCE", 116, 122], ["nitrate", "SIMPLE_CHEMICAL", 123, 130], ["nitrite", "SIMPLE_CHEMICAL", 131, 138], ["methyl guanidine", "SIMPLE_CHEMICAL", 140, 156], ["blood", "ORGANISM_SUBSTANCE", 158, 163], ["urea nitrogen", "SIMPLE_CHEMICAL", 164, 177], ["creatinine", "SIMPLE_CHEMICAL", 179, 189], ["amylase", "GENE_OR_GENE_PRODUCT", 191, 198], ["lipase", "GENE_OR_GENE_PRODUCT", 200, 206], ["asparate aminotransferase", "GENE_OR_GENE_PRODUCT", 208, 233], ["alanine", "AMINO_ACID", 235, 242], ["aminotransferase", "GENE_OR_GENE_PRODUCT", 243, 259], ["creatine phosphokinase", "GENE_OR_GENE_PRODUCT", 261, 283], ["lactic dehydrogenase", "GENE_OR_GENE_PRODUCT", 285, 305], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 307, 311], ["IL\u03b2", "GENE_OR_GENE_PRODUCT", 317, 320], ["amylase", "PROTEIN", 191, 198], ["lipase", "PROTEIN", 200, 206], ["asparate aminotransferase", "PROTEIN", 208, 233], ["alanine aminotransferase", "PROTEIN", 235, 259], ["creatine phosphokinase", "PROTEIN", 261, 283], ["lactic dehydrogenase", "PROTEIN", 285, 305], ["TNF\u03b1", "PROTEIN", 307, 311], ["IL\u03b2", "PROTEIN", 317, 320], ["rats", "SPECIES", 13, 17], ["regular exercise training", "TREATMENT", 19, 44], ["septic responses", "PROBLEM", 56, 72], ["systemic hypotension", "PROBLEM", 81, 101], ["plasma nitrate", "TREATMENT", 116, 130], ["nitrite", "TREATMENT", 131, 138], ["methyl guanidine", "TREATMENT", 140, 156], ["blood urea nitrogen", "TEST", 158, 177], ["creatinine", "TEST", 179, 189], ["amylase", "TEST", 191, 198], ["lipase", "TEST", 200, 206], ["asparate", "TEST", 208, 216], ["aminotransferase", "TEST", 217, 233], ["alanine aminotransferase", "TEST", 235, 259], ["creatine phosphokinase", "TEST", 261, 283], ["lactic dehydrogenase", "TEST", 285, 305], ["TNF\u03b1", "TREATMENT", 307, 311], ["septic", "OBSERVATION", 56, 62], ["hypotension", "OBSERVATION", 90, 101], ["amylase", "ANATOMY", 191, 198], ["lipase", "ANATOMY", 200, 206]]], ["Exercise training also abrogates the cardiac, hepatic and pulmonary injuries caused by endotoxemia.[124] Insulin exerts anti-inflammatory effects on the ALI and associated biochemical changes following intravenous administration of lipopolysaccharide (LPS).[127] Propofol (2,6-diisopropylphenol) has been commonly used for sedation in critically ill patients.[128] This anesthetic has rapid onset, short duration and rapid elimination.[129] Propofol protects the anesthetized rats from ALI caused by endotoxin.[65] In conscious rats, oleic acid results in sepsis-like responses including ALI, inflammatory reactions and increased in neutrophil-derived factors (neutrophil elastase, myeloperoxidase and malondialdehyde), nitrate/nitrite, methyl guanidine, inflammatory cytokines.", [["cardiac", "ANATOMY", 37, 44], ["hepatic", "ANATOMY", 46, 53], ["pulmonary", "ANATOMY", 58, 67], ["intravenous", "ANATOMY", 202, 213], ["neutrophil", "ANATOMY", 633, 643], ["neutrophil", "ANATOMY", 661, 671], ["cardiac, hepatic and pulmonary injuries", "DISEASE", 37, 76], ["endotoxemia", "DISEASE", 87, 98], ["Insulin", "CHEMICAL", 105, 112], ["ALI", "DISEASE", 153, 156], ["lipopolysaccharide", "CHEMICAL", 232, 250], ["LPS", "CHEMICAL", 252, 255], ["Propofol", "CHEMICAL", 263, 271], ["2,6-diisopropylphenol", "CHEMICAL", 273, 294], ["critically ill", "DISEASE", 335, 349], ["Propofol", "CHEMICAL", 441, 449], ["ALI", "DISEASE", 486, 489], ["endotoxin", "CHEMICAL", 500, 509], ["oleic acid", "CHEMICAL", 534, 544], ["sepsis", "DISEASE", 556, 562], ["ALI", "DISEASE", 588, 591], ["malondialdehyde", "CHEMICAL", 702, 717], ["nitrate", "CHEMICAL", 720, 727], ["nitrite", "CHEMICAL", 728, 735], ["methyl guanidine", "CHEMICAL", 737, 753], ["[127] Propofol", "CHEMICAL", 257, 271], ["2,6-diisopropylphenol", "CHEMICAL", 273, 294], ["[129] Propofol", "CHEMICAL", 435, 449], ["oleic acid", "CHEMICAL", 534, 544], ["malondialdehyde", "CHEMICAL", 702, 717], ["nitrate", "CHEMICAL", 720, 727], ["nitrite", "CHEMICAL", 728, 735], ["methyl guanidine", "CHEMICAL", 737, 753], ["cardiac", "ORGAN", 37, 44], ["hepatic", "MULTI-TISSUE_STRUCTURE", 46, 53], ["pulmonary", "ORGAN", 58, 67], ["[124] Insulin", "SIMPLE_CHEMICAL", 99, 112], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 202, 213], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 232, 250], ["LPS", "SIMPLE_CHEMICAL", 252, 255], ["[127] Propofol", "SIMPLE_CHEMICAL", 257, 271], ["2,6-diisopropylphenol", "SIMPLE_CHEMICAL", 273, 294], ["patients", "ORGANISM", 350, 358], ["[129] Propofol", "SIMPLE_CHEMICAL", 435, 449], ["rats", "ORGANISM", 476, 480], ["endotoxin", "SIMPLE_CHEMICAL", 500, 509], ["rats", "ORGANISM", 528, 532], ["oleic acid", "SIMPLE_CHEMICAL", 534, 544], ["neutrophil-derived factors", "GENE_OR_GENE_PRODUCT", 633, 659], ["neutrophil elastase", "GENE_OR_GENE_PRODUCT", 661, 680], ["myeloperoxidase", "SIMPLE_CHEMICAL", 682, 697], ["malondialdehyde", "SIMPLE_CHEMICAL", 702, 717], ["nitrate", "SIMPLE_CHEMICAL", 720, 727], ["nitrite", "SIMPLE_CHEMICAL", 728, 735], ["methyl guanidine", "SIMPLE_CHEMICAL", 737, 753], ["neutrophil-derived factors", "PROTEIN", 633, 659], ["neutrophil elastase", "PROTEIN", 661, 680], ["myeloperoxidase", "PROTEIN", 682, 697], ["inflammatory cytokines", "PROTEIN", 755, 777], ["patients", "SPECIES", 350, 358], ["rats", "SPECIES", 476, 480], ["rats", "SPECIES", 528, 532], ["Exercise training", "TREATMENT", 0, 17], ["the cardiac, hepatic and pulmonary injuries", "PROBLEM", 33, 76], ["endotoxemia", "PROBLEM", 87, 98], ["Insulin", "TREATMENT", 105, 112], ["anti-inflammatory effects", "TREATMENT", 120, 145], ["the ALI", "PROBLEM", 149, 156], ["intravenous administration of lipopolysaccharide (LPS)", "TREATMENT", 202, 256], ["Propofol", "TREATMENT", 263, 271], ["diisopropylphenol", "TREATMENT", 277, 294], ["sedation", "TREATMENT", 323, 331], ["This anesthetic", "TREATMENT", 365, 380], ["short duration", "PROBLEM", 398, 412], ["Propofol", "TREATMENT", 441, 449], ["ALI", "PROBLEM", 486, 489], ["conscious rats", "TEST", 518, 532], ["oleic acid", "TEST", 534, 544], ["sepsis", "PROBLEM", 556, 562], ["ALI", "PROBLEM", 588, 591], ["inflammatory reactions", "PROBLEM", 593, 615], ["neutrophil", "TEST", 633, 643], ["neutrophil elastase", "TEST", 661, 680], ["myeloperoxidase", "TEST", 682, 697], ["malondialdehyde)", "TREATMENT", 702, 718], ["nitrate", "TREATMENT", 720, 727], ["nitrite", "TREATMENT", 728, 735], ["methyl guanidine", "TREATMENT", 737, 753], ["inflammatory cytokines", "PROBLEM", 755, 777], ["cardiac", "ANATOMY", 37, 44], ["hepatic", "ANATOMY", 46, 53], ["pulmonary", "ANATOMY", 58, 67], ["injuries", "OBSERVATION", 68, 76], ["endotoxemia", "OBSERVATION", 87, 98], ["ALI", "ANATOMY", 153, 156], ["short duration", "OBSERVATION_MODIFIER", 398, 412], ["sepsis", "OBSERVATION", 556, 562], ["ALI", "ANATOMY", 588, 591], ["inflammatory", "OBSERVATION_MODIFIER", 593, 605], ["increased", "OBSERVATION_MODIFIER", 620, 629], ["inflammatory cytokines", "OBSERVATION", 755, 777]]], ["It depresses the sodium-and potassium-activated ATPase, but upregulates the iNOS mRNA expression.", [["sodium", "CHEMICAL", 17, 23], ["potassium", "CHEMICAL", 28, 37], ["sodium", "CHEMICAL", 17, 23], ["potassium", "CHEMICAL", 28, 37], ["sodium", "SIMPLE_CHEMICAL", 17, 23], ["potassium", "SIMPLE_CHEMICAL", 28, 37], ["ATPase", "GENE_OR_GENE_PRODUCT", 48, 54], ["iNOS", "GENE_OR_GENE_PRODUCT", 76, 80], ["potassium-activated ATPase", "PROTEIN", 28, 54], ["iNOS mRNA", "RNA", 76, 85], ["the sodium", "TEST", 13, 23], ["potassium", "TEST", 28, 37], ["iNOS mRNA expression", "OBSERVATION", 76, 96]]], ["Pretreatment and posttreatment with propofol alleviates or reverses the oleic acid-induced lung pathology and associated biochemical changes.[54] Pentobarbital, an anesthetic agent commonly used in experimental studies and a hypnotic for patients improves the pulmonary and other organ functions following LPS administration.", [["lung", "ANATOMY", 91, 95], ["pulmonary", "ANATOMY", 260, 269], ["organ", "ANATOMY", 280, 285], ["propofol", "CHEMICAL", 36, 44], ["oleic acid-", "CHEMICAL", 72, 83], ["Pentobarbital", "CHEMICAL", 146, 159], ["LPS", "CHEMICAL", 306, 309], ["propofol", "CHEMICAL", 36, 44], ["oleic acid-", "CHEMICAL", 72, 83], ["[54] Pentobarbital", "CHEMICAL", 141, 159], ["propofol", "SIMPLE_CHEMICAL", 36, 44], ["oleic acid-", "SIMPLE_CHEMICAL", 72, 83], ["lung", "ORGAN", 91, 95], ["[54] Pentobarbital", "SIMPLE_CHEMICAL", 141, 159], ["patients", "ORGANISM", 238, 246], ["pulmonary", "ORGAN", 260, 269], ["organ", "ORGAN", 280, 285], ["LPS", "SIMPLE_CHEMICAL", 306, 309], ["patients", "SPECIES", 238, 246], ["Pretreatment", "TREATMENT", 0, 12], ["propofol", "TREATMENT", 36, 44], ["the oleic acid-induced lung pathology", "PROBLEM", 68, 105], ["associated biochemical changes", "PROBLEM", 110, 140], ["Pentobarbital", "TREATMENT", 146, 159], ["an anesthetic agent", "TREATMENT", 161, 180], ["experimental studies", "TEST", 198, 218], ["LPS administration", "TREATMENT", 306, 324], ["lung", "ANATOMY", 91, 95], ["pathology", "OBSERVATION", 96, 105], ["biochemical changes", "OBSERVATION", 121, 140], ["pulmonary", "ANATOMY", 260, 269]]], ["It also increases the survival rate.[15] A later study by Yang et al.[130] further revealed that pentobarbital suppressed the expression of tumor necrosis factor\u03b1, which might result from decrease in the activities of nuclear factor-\u03ba\u03b2 and activator protein 1 and reduction in expression of P38 mitogen-activated protein kinase.", [["pentobarbital", "CHEMICAL", 97, 110], ["tumor", "DISEASE", 140, 145], ["necrosis", "DISEASE", 146, 154], ["pentobarbital", "CHEMICAL", 97, 110], ["pentobarbital", "SIMPLE_CHEMICAL", 97, 110], ["tumor necrosis factor\u03b1", "GENE_OR_GENE_PRODUCT", 140, 162], ["nuclear factor-\u03ba\u03b2", "GENE_OR_GENE_PRODUCT", 218, 235], ["activator protein 1", "GENE_OR_GENE_PRODUCT", 240, 259], ["P38 mitogen-activated protein kinase", "GENE_OR_GENE_PRODUCT", 291, 327], ["tumor necrosis factor\u03b1", "PROTEIN", 140, 162], ["nuclear factor-\u03ba\u03b2", "PROTEIN", 218, 235], ["activator protein 1", "PROTEIN", 240, 259], ["P38 mitogen-activated protein kinase", "PROTEIN", 291, 327], ["A later study", "TEST", 41, 54], ["pentobarbital", "TREATMENT", 97, 110], ["tumor necrosis factor\u03b1", "PROBLEM", 140, 162], ["nuclear factor", "TEST", 218, 232], ["activator protein", "TEST", 240, 257], ["P38 mitogen", "TEST", 291, 302], ["activated protein kinase", "TEST", 303, 327], ["increases", "OBSERVATION_MODIFIER", 8, 17], ["survival", "OBSERVATION_MODIFIER", 22, 30], ["tumor necrosis", "OBSERVATION", 140, 154], ["decrease", "OBSERVATION_MODIFIER", 188, 196]]], ["In vivo examination of cytotoxic effects of LPS disclosed that LPS caused multiple organ dysfunctions.", [["organ", "ANATOMY", 83, 88], ["LPS", "CHEMICAL", 44, 47], ["LPS", "CHEMICAL", 63, 66], ["organ dysfunctions", "DISEASE", 83, 101], ["LPS", "SIMPLE_CHEMICAL", 44, 47], ["LPS", "SIMPLE_CHEMICAL", 63, 66], ["organ", "ORGAN", 83, 88], ["vivo examination", "TEST", 3, 19], ["LPS", "TREATMENT", 44, 47], ["LPS", "PROBLEM", 63, 66], ["multiple organ dysfunctions", "PROBLEM", 74, 101], ["multiple", "OBSERVATION_MODIFIER", 74, 82], ["organ", "ANATOMY", 83, 88], ["dysfunctions", "OBSERVATION", 89, 101]]], ["These changes were attenuated by pentobarbital.", [["pentobarbital", "CHEMICAL", 33, 46], ["pentobarbital", "CHEMICAL", 33, 46], ["pentobarbital", "SIMPLE_CHEMICAL", 33, 46], ["pentobarbital", "TREATMENT", 33, 46]]], ["Pentobarbital also reduced the cell aptosis caused by deforoxamine-induced hypoxia.", [["cell", "ANATOMY", 31, 35], ["Pentobarbital", "CHEMICAL", 0, 13], ["deforoxamine", "CHEMICAL", 54, 66], ["hypoxia", "DISEASE", 75, 82], ["Pentobarbital", "CHEMICAL", 0, 13], ["deforoxamine", "CHEMICAL", 54, 66], ["Pentobarbital", "SIMPLE_CHEMICAL", 0, 13], ["cell", "CELL", 31, 35], ["deforoxamine", "SIMPLE_CHEMICAL", 54, 66], ["Pentobarbital", "TREATMENT", 0, 13], ["the cell aptosis", "PROBLEM", 27, 43], ["deforoxamine", "PROBLEM", 54, 66], ["hypoxia", "PROBLEM", 75, 82], ["cell aptosis", "OBSERVATION", 31, 43], ["hypoxia", "OBSERVATION", 75, 82]]], ["Nicotinamide or niacinamide (compound of soluble B complex) abrogates the ALI caused by ischemic/reperfusion or endotoxin by mechanism through inhibition on poly (ADP-ribose) synthase or permerase cytoxic enzyme and subsequent suppression of iNOS, NO, free radicals and proinflammatory cytokines with restoration of adenosine triphosphate ATP.[48],[53]N-acetylcysteine, an antioxidant and cytoprotective agent with scavenging action on reactive oxygen species and inhibitory effects on proinflammatory cytokines ameliorated organ dysfunctions due to sepsis in conscious rats.[131],[132] In a similar endotoxin-induced ALI model, we found that N-acetylcysteine improved the LPS-induced systemic hypotension and leukocytopenia.", [["organ", "ANATOMY", 524, 529], ["Nicotinamide", "CHEMICAL", 0, 12], ["niacinamide", "CHEMICAL", 16, 27], ["ALI", "DISEASE", 74, 77], ["endotoxin", "CHEMICAL", 112, 121], ["poly (ADP-ribose", "CHEMICAL", 157, 173], ["NO", "CHEMICAL", 248, 250], ["adenosine", "CHEMICAL", 316, 325], ["ATP", "CHEMICAL", 339, 342], ["[53]N-acetylcysteine", "CHEMICAL", 348, 368], ["oxygen", "CHEMICAL", 445, 451], ["organ dysfunctions", "DISEASE", 524, 542], ["sepsis", "DISEASE", 550, 556], ["endotoxin", "CHEMICAL", 600, 609], ["ALI", "DISEASE", 618, 621], ["N-acetylcysteine", "CHEMICAL", 643, 659], ["LPS", "CHEMICAL", 673, 676], ["hypotension", "DISEASE", 694, 705], ["leukocytopenia", "DISEASE", 710, 724], ["Nicotinamide", "CHEMICAL", 0, 12], ["niacinamide", "CHEMICAL", 16, 27], ["poly (ADP-ribose)", "CHEMICAL", 157, 174], ["NO", "CHEMICAL", 248, 250], ["adenosine triphosphate", "CHEMICAL", 316, 338], ["ATP", "CHEMICAL", 339, 342], ["[48],[53]N-acetylcysteine", "CHEMICAL", 343, 368], ["oxygen", "CHEMICAL", 445, 451], ["N-acetylcysteine", "CHEMICAL", 643, 659], ["Nicotinamide", "SIMPLE_CHEMICAL", 0, 12], ["niacinamide", "SIMPLE_CHEMICAL", 16, 27], ["soluble B complex", "GENE_OR_GENE_PRODUCT", 41, 58], ["endotoxin", "SIMPLE_CHEMICAL", 112, 121], ["poly (ADP-ribose) synthase", "GENE_OR_GENE_PRODUCT", 157, 183], ["permerase cytoxic enzyme", "GENE_OR_GENE_PRODUCT", 187, 211], ["iNOS", "GENE_OR_GENE_PRODUCT", 242, 246], ["NO", "SIMPLE_CHEMICAL", 248, 250], ["free radicals", "SIMPLE_CHEMICAL", 252, 265], ["adenosine triphosphate ATP", "SIMPLE_CHEMICAL", 316, 342], ["[53]N-acetylcysteine", "SIMPLE_CHEMICAL", 348, 368], ["reactive oxygen species", "SIMPLE_CHEMICAL", 436, 459], ["organ", "ORGAN", 524, 529], ["rats", "ORGANISM", 570, 574], ["endotoxin", "SIMPLE_CHEMICAL", 600, 609], ["N-acetylcysteine", "SIMPLE_CHEMICAL", 643, 659], ["LPS", "SIMPLE_CHEMICAL", 673, 676], ["soluble B complex", "PROTEIN", 41, 58], ["poly (ADP-ribose) synthase", "PROTEIN", 157, 183], ["permerase cytoxic enzyme", "PROTEIN", 187, 211], ["iNOS", "PROTEIN", 242, 246], ["proinflammatory cytokines", "PROTEIN", 270, 295], ["proinflammatory cytokines", "PROTEIN", 486, 511], ["rats", "SPECIES", 570, 574], ["Nicotinamide", "TREATMENT", 0, 12], ["niacinamide", "TREATMENT", 16, 27], ["soluble B complex)", "TREATMENT", 41, 59], ["the ALI", "PROBLEM", 70, 77], ["endotoxin", "TREATMENT", 112, 121], ["poly (ADP-ribose) synthase", "TREATMENT", 157, 183], ["permerase cytoxic enzyme", "PROBLEM", 187, 211], ["iNOS", "PROBLEM", 242, 246], ["free radicals and proinflammatory cytokines", "PROBLEM", 252, 295], ["adenosine triphosphate ATP", "TREATMENT", 316, 342], ["-acetylcysteine", "TREATMENT", 353, 368], ["an antioxidant", "TREATMENT", 370, 384], ["cytoprotective agent", "TREATMENT", 389, 409], ["scavenging action", "TREATMENT", 415, 432], ["reactive oxygen species", "TREATMENT", 436, 459], ["inhibitory effects", "PROBLEM", 464, 482], ["proinflammatory cytokines", "PROBLEM", 486, 511], ["organ dysfunctions", "PROBLEM", 524, 542], ["sepsis in conscious rats", "PROBLEM", 550, 574], ["N-acetylcysteine", "TREATMENT", 643, 659], ["the LPS", "PROBLEM", 669, 676], ["systemic hypotension", "PROBLEM", 685, 705], ["leukocytopenia", "PROBLEM", 710, 724], ["ALI", "ANATOMY", 74, 77], ["ischemic", "OBSERVATION", 88, 96], ["reperfusion", "OBSERVATION", 97, 108], ["adenosine triphosphate ATP", "OBSERVATION", 316, 342], ["reactive", "OBSERVATION_MODIFIER", 436, 444], ["oxygen species", "OBSERVATION", 445, 459], ["sepsis", "OBSERVATION", 550, 556], ["systemic", "OBSERVATION_MODIFIER", 685, 693], ["hypotension", "OBSERVATION", 694, 705], ["leukocytopenia", "OBSERVATION", 710, 724]]], ["It also reduced the extent of ALI, as evidenced by reductions in lung weight changes, exhaled NO and lung pathology.", [["lung", "ANATOMY", 65, 69], ["lung", "ANATOMY", 101, 105], ["ALI", "DISEASE", 30, 33], ["NO", "CHEMICAL", 94, 96], ["NO", "CHEMICAL", 94, 96], ["lung", "ORGAN", 65, 69], ["NO", "SIMPLE_CHEMICAL", 94, 96], ["lung", "ORGAN", 101, 105], ["ALI", "PROBLEM", 30, 33], ["lung weight changes", "PROBLEM", 65, 84], ["lung pathology", "PROBLEM", 101, 115], ["reduced", "OBSERVATION_MODIFIER", 8, 15], ["extent", "OBSERVATION_MODIFIER", 20, 26], ["ALI", "OBSERVATION", 30, 33], ["reductions", "OBSERVATION_MODIFIER", 51, 61], ["lung", "ANATOMY", 65, 69], ["weight", "OBSERVATION", 70, 76], ["lung", "ANATOMY", 101, 105], ["pathology", "OBSERVATION", 106, 115]]], ["In addition, N-acetylcysteine diminished the LPS-induced increases in nitrate/nitrite, TNF\u03b1, and IL\u03b2[64] In isolated lungs, N-acetylcysteine attenuated the ALI caused by phorbol myristate acetate.[86] In a recent study, we reported that posttreatment with N-acetylcysteine prevented the ALI caused by fat embolism.[50] Our series of experimental studies provided results in favor of N-acetylcysteine.", [["lungs", "ANATOMY", 117, 122], ["fat", "ANATOMY", 301, 304], ["N-acetylcysteine", "CHEMICAL", 13, 29], ["LPS", "CHEMICAL", 45, 48], ["nitrate", "CHEMICAL", 70, 77], ["nitrite", "CHEMICAL", 78, 85], ["N-acetylcysteine", "CHEMICAL", 124, 140], ["ALI", "DISEASE", 156, 159], ["phorbol myristate acetate", "CHEMICAL", 170, 195], ["N-acetylcysteine", "CHEMICAL", 256, 272], ["ALI", "DISEASE", 287, 290], ["fat embolism", "DISEASE", 301, 313], ["N-acetylcysteine", "CHEMICAL", 383, 399], ["N-acetylcysteine", "CHEMICAL", 13, 29], ["nitrate", "CHEMICAL", 70, 77], ["nitrite", "CHEMICAL", 78, 85], ["N-acetylcysteine", "CHEMICAL", 124, 140], ["phorbol myristate acetate", "CHEMICAL", 170, 195], ["N-acetylcysteine", "CHEMICAL", 256, 272], ["N-acetylcysteine", "CHEMICAL", 383, 399], ["N-acetylcysteine", "SIMPLE_CHEMICAL", 13, 29], ["LPS", "SIMPLE_CHEMICAL", 45, 48], ["nitrate", "SIMPLE_CHEMICAL", 70, 77], ["nitrite", "SIMPLE_CHEMICAL", 78, 85], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 87, 91], ["IL\u03b2[64]", "SIMPLE_CHEMICAL", 97, 104], ["lungs", "ORGAN", 117, 122], ["N-acetylcysteine", "SIMPLE_CHEMICAL", 124, 140], ["phorbol myristate acetate", "SIMPLE_CHEMICAL", 170, 195], ["N-acetylcysteine", "SIMPLE_CHEMICAL", 256, 272], ["fat", "TISSUE", 301, 304], ["N-acetylcysteine", "SIMPLE_CHEMICAL", 383, 399], ["TNF\u03b1", "PROTEIN", 87, 91], ["N-acetylcysteine", "TREATMENT", 13, 29], ["the LPS", "TEST", 41, 48], ["nitrate/nitrite", "TREATMENT", 70, 85], ["TNF", "TEST", 87, 90], ["-acetylcysteine", "TREATMENT", 125, 140], ["the ALI", "PROBLEM", 152, 159], ["phorbol myristate acetate", "TREATMENT", 170, 195], ["a recent study", "TEST", 204, 218], ["N-acetylcysteine", "TREATMENT", 256, 272], ["the ALI", "PROBLEM", 283, 290], ["fat embolism", "PROBLEM", 301, 313], ["experimental studies", "TEST", 333, 353], ["N-acetylcysteine", "TREATMENT", 383, 399], ["diminished", "OBSERVATION", 30, 40], ["lungs", "ANATOMY", 117, 122], ["ALI", "ANATOMY", 287, 290], ["fat embolism", "OBSERVATION", 301, 313]]], ["The conflicting results and practice guidelines from clinical studies in the recommendation of N-acetylcysteine in critically ill patients[133],[134] were commented and analyzed by Moln\u00e1r.[135] The clinical application of results from animal studies requires further investigations.SummaryARDS or ALI is a serious clinical problem with high mortality.", [["N-acetylcysteine", "CHEMICAL", 95, 111], ["critically ill", "DISEASE", 115, 129], ["SummaryARDS", "DISEASE", 282, 293], ["ALI", "DISEASE", 297, 300], ["N-acetylcysteine", "CHEMICAL", 95, 111], ["N-acetylcysteine", "SIMPLE_CHEMICAL", 95, 111], ["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 130, 138], ["clinical studies", "TEST", 53, 69], ["N-acetylcysteine", "TREATMENT", 95, 111], ["animal studies", "TEST", 235, 249], ["further investigations", "TEST", 259, 281], ["ALI", "PROBLEM", 297, 300], ["a serious clinical problem", "PROBLEM", 304, 330], ["high mortality", "PROBLEM", 336, 350]]], ["The risk factors leading to ALI/ARDS include head injury, intracranial disorders, sepsis and infections.", [["head", "ANATOMY", 45, 49], ["intracranial", "ANATOMY", 58, 70], ["ALI", "DISEASE", 28, 31], ["ARDS", "DISEASE", 32, 36], ["head injury", "DISEASE", 45, 56], ["intracranial disorders", "DISEASE", 58, 80], ["sepsis", "DISEASE", 82, 88], ["infections", "DISEASE", 93, 103], ["head", "ORGANISM_SUBDIVISION", 45, 49], ["The risk factors", "PROBLEM", 0, 16], ["ALI", "PROBLEM", 28, 31], ["ARDS", "PROBLEM", 32, 36], ["head injury", "PROBLEM", 45, 56], ["intracranial disorders", "PROBLEM", 58, 80], ["sepsis", "PROBLEM", 82, 88], ["infections", "PROBLEM", 93, 103], ["ARDS", "OBSERVATION", 32, 36], ["head", "ANATOMY", 45, 49], ["injury", "OBSERVATION", 50, 56], ["intracranial", "ANATOMY", 58, 70], ["disorders", "OBSERVATION", 71, 80], ["sepsis", "OBSERVATION", 82, 88], ["infections", "OBSERVATION", 93, 103]]], ["Pulmonary embolic disorders such as fat and air embolism are less common causes.", [["Pulmonary", "ANATOMY", 0, 9], ["fat", "ANATOMY", 36, 39], ["Pulmonary embolic disorders", "DISEASE", 0, 27], ["fat and air embolism", "DISEASE", 36, 56], ["fat", "TISSUE", 36, 39], ["Pulmonary embolic disorders", "PROBLEM", 0, 27], ["air embolism", "PROBLEM", 44, 56], ["embolic", "OBSERVATION", 10, 17], ["fat", "ANATOMY", 36, 39], ["air embolism", "OBSERVATION", 44, 56], ["less common", "OBSERVATION_MODIFIER", 61, 72]]], ["Ischemia/reperfusion lung injury may develop as a consequence of several pulmonary disorders such as lung transplantation.", [["lung", "ANATOMY", 21, 25], ["pulmonary", "ANATOMY", 73, 82], ["lung", "ANATOMY", 101, 105], ["Ischemia", "DISEASE", 0, 8], ["lung injury", "DISEASE", 21, 32], ["pulmonary disorders", "DISEASE", 73, 92], ["lung", "ORGAN", 21, 25], ["pulmonary", "ORGAN", 73, 82], ["lung", "ORGAN", 101, 105], ["Ischemia", "PROBLEM", 0, 8], ["reperfusion lung injury", "PROBLEM", 9, 32], ["several pulmonary disorders", "PROBLEM", 65, 92], ["lung transplantation", "TREATMENT", 101, 121], ["reperfusion", "OBSERVATION_MODIFIER", 9, 20], ["lung", "ANATOMY", 21, 25], ["injury", "OBSERVATION", 26, 32], ["several", "OBSERVATION_MODIFIER", 65, 72], ["pulmonary", "ANATOMY", 73, 82], ["disorders", "OBSERVATION", 83, 92], ["lung", "ANATOMY", 101, 105], ["transplantation", "OBSERVATION", 106, 121]]], ["Gastric aspiration occurs frequently in several conditions such as anesthesia, trauma and pregnancy.", [["Gastric", "ANATOMY", 0, 7], ["trauma", "DISEASE", 79, 85], ["Gastric", "ORGAN", 0, 7], ["Gastric aspiration", "PROBLEM", 0, 18], ["anesthesia", "TREATMENT", 67, 77], ["trauma", "PROBLEM", 79, 85], ["pregnancy", "PROBLEM", 90, 99], ["aspiration", "OBSERVATION", 8, 18]]], ["The ventilator-induced ALI has been attributed to the deleterious effects on capillary stress due to alveolar overdistension.", [["capillary", "ANATOMY", 77, 86], ["alveolar", "ANATOMY", 101, 109], ["ALI", "DISEASE", 23, 26], ["capillary", "TISSUE", 77, 86], ["alveolar", "MULTI-TISSUE_STRUCTURE", 101, 109], ["ALI", "PROBLEM", 23, 26], ["the deleterious effects", "PROBLEM", 50, 73], ["capillary stress", "PROBLEM", 77, 93], ["alveolar overdistension", "PROBLEM", 101, 124], ["ALI", "OBSERVATION", 23, 26], ["deleterious", "OBSERVATION", 54, 65], ["alveolar", "ANATOMY_MODIFIER", 101, 109], ["overdistension", "OBSERVATION", 110, 124]]], ["In experimental studies, phorbol myristate acetate and oleic acid have been employed to induce ALI.SummaryThe pathogenesis of ARDS/ALI is complex.", [["phorbol myristate acetate", "CHEMICAL", 25, 50], ["oleic acid", "CHEMICAL", 55, 65], ["ALI", "DISEASE", 95, 98], ["ARDS", "DISEASE", 126, 130], ["ALI", "DISEASE", 131, 134], ["phorbol myristate acetate", "CHEMICAL", 25, 50], ["oleic acid", "CHEMICAL", 55, 65], ["phorbol myristate acetate", "SIMPLE_CHEMICAL", 25, 50], ["oleic acid", "SIMPLE_CHEMICAL", 55, 65], ["experimental studies", "TEST", 3, 23], ["phorbol myristate acetate", "TREATMENT", 25, 50], ["oleic acid", "TREATMENT", 55, 65], ["ALI", "PROBLEM", 95, 98], ["ARDS", "PROBLEM", 126, 130], ["ALI", "PROBLEM", 131, 134], ["ALI", "OBSERVATION", 95, 98], ["ARDS", "OBSERVATION", 126, 130], ["ALI", "OBSERVATION", 131, 134], ["complex", "OBSERVATION_MODIFIER", 138, 145]]], ["Experimental studies and clinical investigations from our and other laboratories have indicated the detrimental role of nitric NO through inducible NO synthase (iNOS).", [["nitric NO", "CHEMICAL", 120, 129], ["NO", "CHEMICAL", 148, 150], ["nitric NO", "CHEMICAL", 120, 129], ["NO", "CHEMICAL", 148, 150], ["nitric NO", "SIMPLE_CHEMICAL", 120, 129], ["inducible NO synthase", "GENE_OR_GENE_PRODUCT", 138, 159], ["iNOS", "GENE_OR_GENE_PRODUCT", 161, 165], ["NO synthase", "PROTEIN", 148, 159], ["iNOS", "PROTEIN", 161, 165], ["Experimental studies", "TEST", 0, 20], ["clinical investigations", "TEST", 25, 48], ["nitric", "TREATMENT", 120, 126]]], ["Activation and recruitment of neutrophils that lead to release of neutrophil elastase, myeloperoxidase, malondialdehyde and pro-inflammatory cytokines may play an initial role in the pathogenesis of ALI/ARDS.SummaryThe possible therapeutic regimen for ALI/ARDS include extracorporeal membrane oxygenation, prone position, fluid and hemodynamic management and permissive hypercapnic acidosis etc. Other pharmacological treatments are anti-inflammatory and/or antimicrobial agents, inhalation of NO, glucocorticoids, surfactant therapy and agents that facilitate lung water resolution and ion transports.", [["neutrophils", "ANATOMY", 30, 41], ["neutrophil", "ANATOMY", 66, 76], ["extracorporeal membrane", "ANATOMY", 269, 292], ["fluid", "ANATOMY", 322, 327], ["lung", "ANATOMY", 561, 565], ["malondialdehyde", "CHEMICAL", 104, 119], ["ALI", "DISEASE", 199, 202], ["ARDS", "DISEASE", 203, 207], ["ALI", "DISEASE", 252, 255], ["ARDS", "DISEASE", 256, 260], ["acidosis", "DISEASE", 382, 390], ["NO", "CHEMICAL", 494, 496], ["malondialdehyde", "CHEMICAL", 104, 119], ["NO", "CHEMICAL", 494, 496], ["neutrophils", "CELL", 30, 41], ["neutrophil elastase", "GENE_OR_GENE_PRODUCT", 66, 85], ["myeloperoxidase", "SIMPLE_CHEMICAL", 87, 102], ["malondialdehyde", "SIMPLE_CHEMICAL", 104, 119], ["extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 269, 292], ["NO", "SIMPLE_CHEMICAL", 494, 496], ["glucocorticoids", "SIMPLE_CHEMICAL", 498, 513], ["surfactant", "SIMPLE_CHEMICAL", 515, 525], ["lung", "ORGAN", 561, 565], ["neutrophils", "CELL_TYPE", 30, 41], ["neutrophil elastase", "PROTEIN", 66, 85], ["myeloperoxidase", "PROTEIN", 87, 102], ["pro-inflammatory cytokines", "PROTEIN", 124, 150], ["recruitment of neutrophils", "PROBLEM", 15, 41], ["neutrophil elastase", "TEST", 66, 85], ["myeloperoxidase", "TEST", 87, 102], ["malondialdehyde and pro-inflammatory cytokines", "PROBLEM", 104, 150], ["ALI", "PROBLEM", 199, 202], ["ARDS", "PROBLEM", 203, 207], ["therapeutic regimen", "TREATMENT", 228, 247], ["ALI", "PROBLEM", 252, 255], ["ARDS", "PROBLEM", 256, 260], ["extracorporeal membrane oxygenation", "TREATMENT", 269, 304], ["prone position", "TREATMENT", 306, 320], ["fluid", "TREATMENT", 322, 327], ["hemodynamic management", "TREATMENT", 332, 354], ["permissive hypercapnic acidosis", "PROBLEM", 359, 390], ["Other pharmacological treatments", "TREATMENT", 396, 428], ["anti-inflammatory", "TREATMENT", 433, 450], ["antimicrobial agents", "TREATMENT", 458, 478], ["inhalation", "TREATMENT", 480, 490], ["glucocorticoids", "TREATMENT", 498, 513], ["surfactant therapy", "TREATMENT", 515, 533], ["agents", "TREATMENT", 538, 544], ["lung water resolution", "TREATMENT", 561, 582], ["neutrophil elastase", "OBSERVATION", 66, 85], ["pro-inflammatory cytokines", "OBSERVATION", 124, 150], ["ALI", "ANATOMY", 199, 202], ["ARDS", "OBSERVATION", 203, 207], ["possible", "UNCERTAINTY", 219, 227], ["ARDS", "OBSERVATION", 256, 260], ["extracorporeal membrane oxygenation", "OBSERVATION", 269, 304], ["hypercapnic acidosis", "OBSERVATION", 370, 390], ["lung", "ANATOMY", 561, 565]]], ["Adrenergic beta agonists are able to accelerate lung fluid and ion removal and to stimulate surfactant secretion.", [["lung fluid", "ANATOMY", 48, 58], ["Adrenergic beta", "GENE_OR_GENE_PRODUCT", 0, 15], ["lung", "ORGAN", 48, 52], ["ion", "SIMPLE_CHEMICAL", 63, 66], ["surfactant", "SIMPLE_CHEMICAL", 92, 102], ["Adrenergic beta agonists", "TREATMENT", 0, 24], ["ion removal", "TREATMENT", 63, 74], ["surfactant secretion", "PROBLEM", 92, 112], ["lung", "ANATOMY", 48, 52], ["fluid", "OBSERVATION", 53, 58]]], ["There are reports on the actions of vascular endothelial growth factor and related molecules as well as angiotensin-converting enzyme.SummaryOur laboratory has reported experimental studies on the effectiveness of several regimen for ALI/ARDS.", [["angiotensin", "CHEMICAL", 104, 115], ["ALI", "DISEASE", 234, 237], ["ARDS", "DISEASE", 238, 242], ["vascular endothelial growth factor", "GENE_OR_GENE_PRODUCT", 36, 70], ["angiotensin-converting enzyme", "GENE_OR_GENE_PRODUCT", 104, 133], ["vascular endothelial growth factor", "PROTEIN", 36, 70], ["angiotensin-converting enzyme", "PROTEIN", 104, 133], ["vascular endothelial growth factor", "PROBLEM", 36, 70], ["related molecules", "PROBLEM", 75, 92], ["angiotensin", "TREATMENT", 104, 115], ["experimental studies", "TEST", 169, 189], ["several regimen", "TREATMENT", 214, 229], ["ALI", "PROBLEM", 234, 237], ["ARDS", "PROBLEM", 238, 242], ["vascular endothelial", "ANATOMY", 36, 56], ["ARDS", "OBSERVATION", 238, 242]]], ["In conscious rats, regular exercise training alleviates the endotoxin-induced ALI.", [["endotoxin", "CHEMICAL", 60, 69], ["ALI", "DISEASE", 78, 81], ["rats", "ORGANISM", 13, 17], ["endotoxin", "SIMPLE_CHEMICAL", 60, 69], ["rats", "SPECIES", 13, 17], ["regular exercise training", "TREATMENT", 19, 44], ["the endotoxin-induced ALI", "PROBLEM", 56, 81], ["ALI", "OBSERVATION", 78, 81]]], ["Propofol and N-acetylcysteine exert protective effect on the ALI causes by endotoxin, oleic acid and phorbol myristate acetate.", [["Propofol", "CHEMICAL", 0, 8], ["N-acetylcysteine", "CHEMICAL", 13, 29], ["ALI", "DISEASE", 61, 64], ["endotoxin", "CHEMICAL", 75, 84], ["oleic acid", "CHEMICAL", 86, 96], ["phorbol myristate acetate", "CHEMICAL", 101, 126], ["Propofol", "CHEMICAL", 0, 8], ["N-acetylcysteine", "CHEMICAL", 13, 29], ["oleic acid", "CHEMICAL", 86, 96], ["phorbol myristate acetate", "CHEMICAL", 101, 126], ["Propofol", "SIMPLE_CHEMICAL", 0, 8], ["N-acetylcysteine", "SIMPLE_CHEMICAL", 13, 29], ["endotoxin", "SIMPLE_CHEMICAL", 75, 84], ["oleic acid", "SIMPLE_CHEMICAL", 86, 96], ["phorbol myristate acetate", "SIMPLE_CHEMICAL", 101, 126], ["Propofol", "TREATMENT", 0, 8], ["N-acetylcysteine", "TREATMENT", 13, 29], ["endotoxin", "TREATMENT", 75, 84], ["oleic acid", "TREATMENT", 86, 96], ["phorbol myristate acetate", "TREATMENT", 101, 126], ["protective effect", "OBSERVATION_MODIFIER", 36, 53], ["ALI", "ANATOMY", 61, 64]]], ["We have also provided evidence that insulin possesses anti-inflammatory effect.", [["insulin", "GENE_OR_GENE_PRODUCT", 36, 43], ["insulin", "PROTEIN", 36, 43], ["insulin possesses anti-inflammatory effect", "TREATMENT", 36, 78]]], ["Pentobarbital is capable of reducing the endotoxin-induced ALI and associated changes.", [["Pentobarbital", "CHEMICAL", 0, 13], ["endotoxin", "CHEMICAL", 41, 50], ["ALI", "DISEASE", 59, 62], ["Pentobarbital", "CHEMICAL", 0, 13], ["Pentobarbital", "SIMPLE_CHEMICAL", 0, 13], ["endotoxin", "SIMPLE_CHEMICAL", 41, 50], ["Pentobarbital", "TREATMENT", 0, 13], ["the endotoxin", "TREATMENT", 37, 50], ["ALI", "OBSERVATION", 59, 62]]], ["In addition, nicotinamide or niacinamide (soluble B complex) abrogates the ALI caused by ischemia/reperfusion or endotoxemia.", [["nicotinamide", "CHEMICAL", 13, 25], ["niacinamide", "CHEMICAL", 29, 40], ["ALI", "DISEASE", 75, 78], ["ischemia", "DISEASE", 89, 97], ["endotoxemia", "DISEASE", 113, 124], ["nicotinamide", "CHEMICAL", 13, 25], ["niacinamide", "CHEMICAL", 29, 40], ["nicotinamide", "SIMPLE_CHEMICAL", 13, 25], ["niacinamide", "SIMPLE_CHEMICAL", 29, 40], ["soluble B complex", "GENE_OR_GENE_PRODUCT", 42, 59], ["soluble B complex", "PROTEIN", 42, 59], ["nicotinamide", "TREATMENT", 13, 25], ["niacinamide (soluble B complex)", "TREATMENT", 29, 60], ["the ALI", "PROBLEM", 71, 78], ["ischemia", "PROBLEM", 89, 97], ["reperfusion", "PROBLEM", 98, 109], ["endotoxemia", "PROBLEM", 113, 124], ["ALI", "ANATOMY", 75, 78], ["ischemia", "OBSERVATION", 89, 97], ["reperfusion", "OBSERVATION", 98, 109], ["endotoxemia", "OBSERVATION", 113, 124]]], ["These nonpharmacological and pharmacological therapeutic strategies require further investigations for clinical application.", [["further investigations", "TEST", 76, 98], ["clinical application", "TREATMENT", 103, 123]]]], "e6426cb3b8b7df2b4fc14f1550a94efc5a935900": [["SARS originated in November 2002 in the Guangdong Province of China, and by February 2003, had spread to Hong Kong and subsequently to 32 other countries or regions, infecting 8096 patients and resulting in 774 deaths.", [["SARS", "DISEASE", 0, 4], ["deaths", "DISEASE", 211, 217], ["patients", "ORGANISM", 181, 189], ["patients", "SPECIES", 181, 189], ["SARS", "PROBLEM", 0, 4]]], ["2, 3 SARS is unique in several aspects.", [["SARS", "DISEASE", 5, 9]]], ["SARS was the first emerging infectious disease for which WHO issued a global alert, on March 12, 2003 .", [["SARS", "DISEASE", 0, 4], ["infectious", "OBSERVATION", 28, 38]]], ["It illustrated dramatically the potential of air travel and globalization for the dissemination of an emerging infectious disease.", [["infectious disease", "DISEASE", 111, 129], ["an emerging infectious disease", "PROBLEM", 99, 129], ["dramatically", "OBSERVATION_MODIFIER", 15, 27], ["air travel", "OBSERVATION", 45, 55], ["infectious", "OBSERVATION", 111, 121]]], ["The concentration of cases in previously healthy adults and the proportion of patients requiring intensive care was particularly alarming.", [["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["intensive care", "TREATMENT", 97, 111], ["concentration", "OBSERVATION_MODIFIER", 4, 17]]], ["[4] [5] [6] [7] SARS caused morbidity and mortality in healthcare workers (HCWs) and intrahospital transmission amplified regional outbreaks and augmented spread of the illness into the community.", [["[4] [5] [6", "CHEMICAL", 0, 10], ["SARS", "DISEASE", 16, 20], ["illness", "DISEASE", 169, 176], ["[4] [5] [6] [7] SARS", "SIMPLE_CHEMICAL", 0, 20], ["intrahospital transmission amplified regional outbreaks", "PROBLEM", 85, 140]]], ["2, 3 All added a tremendous burden to healthcare systems in the absence of natural disaster or war.", [["tremendous", "OBSERVATION_MODIFIER", 17, 27], ["burden", "OBSERVATION", 28, 34]]], ["The cost of SARS was substantial: a 4% drop in GDP in Hong Kong (> 6 billion US dollars) was estimated by the Asian Development Bank.", [["SARS", "DISEASE", 12, 16], ["GDP", "CHEMICAL", 47, 50], ["GDP", "SIMPLE_CHEMICAL", 47, 50], ["SARS", "PROBLEM", 12, 16], ["a 4% drop in GDP", "PROBLEM", 34, 50]]], ["8 From SARS, we know that an infectious disease in one country is a threat to all.", [["SARS", "DISEASE", 7, 11], ["infectious disease", "DISEASE", 29, 47], ["an infectious disease", "PROBLEM", 26, 47], ["infectious", "OBSERVATION", 29, 39]]], ["An infectious disease outbreak reveals weaknesses in the public health infrastructure.", [["An infectious disease outbreak", "PROBLEM", 0, 30], ["weaknesses", "PROBLEM", 39, 49], ["infectious", "OBSERVATION", 3, 13]]], ["Emerging infectious diseases can be contained with a high level of government commitment and international collaboration.", [["infectious diseases", "DISEASE", 9, 28], ["Emerging infectious diseases", "PROBLEM", 0, 28], ["infectious", "OBSERVATION", 9, 19]]], ["In our ever-shrinking world, widespread media coverage of infections-ranging from SARS and influenza in Asia to acute gastroenteritis due to norovirus on cruise ships in Europe and the outbreak due to Escherichia coli 0157 in the United States-has raised public interest in contagious diseases to new heights.", [["infections", "DISEASE", 58, 68], ["SARS", "DISEASE", 82, 86], ["influenza", "DISEASE", 91, 100], ["gastroenteritis", "DISEASE", 118, 133], ["norovirus", "DISEASE", 141, 150], ["Escherichia coli 0157", "CHEMICAL", 201, 222], ["Escherichia coli", "ORGANISM", 201, 217], ["0157", "ORGANISM", 218, 222], ["Escherichia coli", "SPECIES", 201, 217], ["Escherichia coli", "SPECIES", 201, 217], ["infections", "PROBLEM", 58, 68], ["SARS", "PROBLEM", 82, 86], ["influenza", "PROBLEM", 91, 100], ["acute gastroenteritis", "PROBLEM", 112, 133], ["norovirus", "PROBLEM", 141, 150], ["Escherichia coli", "PROBLEM", 201, 217], ["contagious diseases to new heights", "PROBLEM", 274, 308], ["infections", "OBSERVATION", 58, 68], ["acute", "OBSERVATION_MODIFIER", 112, 117], ["gastroenteritis", "OBSERVATION", 118, 133], ["norovirus", "OBSERVATION", 141, 150], ["Escherichia coli", "OBSERVATION", 201, 217], ["contagious diseases", "OBSERVATION", 274, 293], ["new", "OBSERVATION_MODIFIER", 297, 300], ["heights", "OBSERVATION_MODIFIER", 301, 308]]], ["11 Recent experiences with the highly pathogenic avian influenza A/H5N1 have given the world its first advance warning that another influenza pandemic may be imminent.", [["avian influenza A/H5N1", "DISEASE", 49, 71], ["influenza", "DISEASE", 132, 141], ["avian", "ORGANISM", 49, 54], ["influenza A/H5N1", "ORGANISM", 55, 71], ["avian influenza A/H5N1", "SPECIES", 49, 71], ["A/H5N1", "SPECIES", 65, 71], ["H5N1", "PROBLEM", 67, 71], ["another influenza pandemic", "PROBLEM", 124, 150]]], ["1, 12, 13 To prevent the potential serious consequences of a pandemic, timely implementation of pharmaceutical and non-pharmaceutical interventions locally within the outbreak area is the key to minimizing global spread.", [["a pandemic", "PROBLEM", 59, 69], ["pharmaceutical and non-pharmaceutical interventions", "TREATMENT", 96, 147], ["minimizing", "OBSERVATION_MODIFIER", 195, 205], ["global", "OBSERVATION_MODIFIER", 206, 212], ["spread", "OBSERVATION", 213, 219]]], ["12, 14 As air travel and global trade are now commonplace and have facilitated the international spread of emerging infectious diseases within a very short period of time, a review of the lessons learned from the latest outbreak of SARS is important.Transmissibility and Containment StrategiesSARS is a zoonotic disease caused by a new coronavirus (SARS-CoV).", [["infectious diseases", "DISEASE", 116, 135], ["SARS", "DISEASE", 232, 236], ["Transmissibility", "DISEASE", 250, 266], ["zoonotic disease", "DISEASE", 303, 319], ["SARS", "DISEASE", 349, 353], ["coronavirus", "ORGANISM", 336, 347], ["SARS-CoV", "ORGANISM", 349, 357], ["SARS-CoV", "SPECIES", 349, 357], ["emerging infectious diseases", "PROBLEM", 107, 135], ["SARS", "PROBLEM", 232, 236], ["a zoonotic disease", "PROBLEM", 301, 319], ["a new coronavirus (SARS", "PROBLEM", 330, 353], ["infectious", "OBSERVATION", 116, 126], ["Containment", "OBSERVATION_MODIFIER", 271, 282], ["zoonotic", "OBSERVATION_MODIFIER", 303, 311], ["new", "OBSERVATION_MODIFIER", 332, 335], ["coronavirus", "OBSERVATION", 336, 347]]], ["2, 9, 15, 16 SARS-CoV evolved consistently and rapidly within its animal and human hosts, while both the infectivity of the virus and the severity of the disease varied, along with the variation/adaptation of the virus to its hosts.", [["SARS-CoV", "ORGANISM", 13, 21], ["human", "ORGANISM", 77, 82], ["human", "SPECIES", 77, 82], ["SARS-CoV", "SPECIES", 13, 21], ["human", "SPECIES", 77, 82], ["16 SARS-CoV", "PROBLEM", 10, 21], ["the virus", "PROBLEM", 120, 129], ["the disease", "PROBLEM", 150, 161], ["the virus", "PROBLEM", 209, 218], ["virus", "OBSERVATION", 124, 129], ["severity", "OBSERVATION_MODIFIER", 138, 146], ["disease", "OBSERVATION", 154, 161]]], ["16 Transmissibility refers to the capacity of an infectious agent to spread from one person to another, and risk of infection depends on the conditions of exposure.", [["infection", "DISEASE", 116, 125], ["person", "SPECIES", 85, 91], ["an infectious agent", "TREATMENT", 46, 65], ["infection", "PROBLEM", 116, 125], ["infectious", "OBSERVATION", 49, 59], ["infection", "OBSERVATION", 116, 125]]], ["17 Lipsitch et al 18 and Riley et al 19 calculated that the basic case reproduction number (R 0 )-the fundamental epidemiologic quantity that determines the potential for disease spread-is of the order of 2-4 (excluding superspreading events).", [["disease spread", "PROBLEM", 171, 185]]], ["Both studies suggested that an achievable combination of control measures, including hand washing, the use of an appropriate and well-fitted facemask, isolation of SARS cases, enhanced surveillance and effective contact tracing and quarantine of asymptomatic contacts (shortening the time from symptom onset to isolation of patients), can be effective in containing SARS, as mentioned previously.", [["hand", "ANATOMY", 85, 89], ["SARS", "DISEASE", 164, 168], ["SARS", "DISEASE", 366, 370], ["hand", "ORGANISM_SUBDIVISION", 85, 89], ["patients", "ORGANISM", 324, 332], ["patients", "SPECIES", 324, 332], ["Both studies", "TEST", 0, 12], ["control measures", "TREATMENT", 57, 73], ["hand washing", "TREATMENT", 85, 97], ["facemask", "TREATMENT", 141, 149], ["enhanced surveillance", "TEST", 176, 197], ["effective contact tracing", "TEST", 202, 227], ["asymptomatic contacts", "PROBLEM", 246, 267], ["SARS", "PROBLEM", 366, 370]]], ["7, 20 Transmission rates fell during the epidemic: R 0 fell from a mean of 7 in the first week of the Singapore outbreak to a mean of 1.6 in the second week, to a mean below 1 in most weeks thereafter.", [["Transmission rates", "TEST", 6, 24]]], ["18 Molecular epidemiologic studies indicated that viruses from the outbreaks in Hong Kong, Vietnam, Singapore, Toronto, and Taiwan are clonally related.", [["Molecular epidemiologic studies", "TEST", 3, 34], ["viruses", "PROBLEM", 50, 57], ["viruses", "OBSERVATION", 50, 57]]], ["[21] [22] [23] [24] Compliance with standard precautions, alertness and using inline suction for the undiagnosed SARS patient (first SARS patient in Taiwan) who had respiratory failure and was intubated in the emergency room (ER) were the reasons that no HCWs became seropositive and no intrahospital spread occurred before implementation of specific infection control strategies at the National Taiwan University Hospital (NTUH).", [["respiratory", "ANATOMY", 165, 176], ["SARS", "DISEASE", 113, 117], ["SARS", "DISEASE", 133, 137], ["respiratory failure", "DISEASE", 165, 184], ["infection", "DISEASE", 351, 360], ["patient", "ORGANISM", 118, 125], ["patient", "ORGANISM", 138, 145], ["patient", "SPECIES", 118, 125], ["patient", "SPECIES", 138, 145], ["standard precautions", "TREATMENT", 36, 56], ["inline suction", "TREATMENT", 78, 92], ["the undiagnosed SARS", "PROBLEM", 97, 117], ["respiratory failure", "PROBLEM", 165, 184], ["intubated", "TREATMENT", 193, 202], ["HCWs", "PROBLEM", 255, 259], ["seropositive", "PROBLEM", 267, 279], ["intrahospital spread", "PROBLEM", 287, 307], ["specific infection control strategies", "TREATMENT", 342, 379], ["respiratory", "ANATOMY", 165, 176], ["failure", "OBSERVATION", 177, 184]]], ["25 Unexpectedly, the good performance of NTUH during the initial phase of the SARS epidemic in Taiwan resulted in underestimation of the continuous risk of transmission from the neighboring affected areas into Taiwan.", [["NTUH", "CHEMICAL", 41, 45], ["SARS", "DISEASE", 78, 82], ["the SARS epidemic", "PROBLEM", 74, 91]]], ["[26] [27] [28] A similar situation developed in Canada and resulted in a second wave of the epidemic.", [["[26] [27] [28] A", "SIMPLE_CHEMICAL", 0, 16], ["the epidemic", "PROBLEM", 88, 100], ["epidemic", "OBSERVATION", 92, 100]]], ["29Super-spreading EventsExperts were concerned about the evident heterogeneity in transmission.", [["heterogeneity", "OBSERVATION", 65, 78]]], ["30 In extreme instances of SARS, there were super-spreading events, where single individuals apparently infected as many as 300 others.", [["SARS", "DISEASE", 27, 31], ["SARS", "PROBLEM", 27, 31], ["super-spreading events", "PROBLEM", 44, 66], ["SARS", "OBSERVATION", 27, 31], ["infected", "OBSERVATION", 104, 112]]], ["29, 31, 32 Understanding and quantifying these super-spreading events is clearly vital for the containment of SARS.", [["SARS", "DISEASE", 110, 114], ["SARS", "PROBLEM", 110, 114]]], ["30 However, it remains difficult to differentiate such superspreading events that are due to persons secreting an exceptionally high amount of infectious material, from those with an environmental factor working to amplify transmission at some key phase of virus shedding.", [["persons", "ORGANISM", 93, 100], ["persons", "SPECIES", 93, 100], ["superspreading events", "PROBLEM", 55, 76], ["infectious material", "PROBLEM", 143, 162], ["virus shedding", "PROBLEM", 257, 271], ["high amount", "OBSERVATION_MODIFIER", 128, 139], ["infectious", "OBSERVATION", 143, 153]]], ["For example, aerosolgenerating procedures and environmental contamination may have contributed to a large intrahospital spread in the epidemic of SARS.", [["SARS", "DISEASE", 146, 150], ["aerosolgenerating procedures", "TREATMENT", 13, 41], ["environmental contamination", "PROBLEM", 46, 73], ["a large intrahospital spread", "PROBLEM", 98, 126], ["large", "OBSERVATION_MODIFIER", 100, 105], ["intrahospital", "OBSERVATION_MODIFIER", 106, 119], ["spread", "OBSERVATION_MODIFIER", 120, 126]]], ["6, 33 A recent study revealed that the independent risk factors associated with nosocomial outbreaks of SARS among hospital wards in Guangzhou and Hong Kong, China, included a distance between beds of \u2264 1 m, lack of availability of washing or changing facilities for staff (protective), resuscitation performed in the ward, staff members working while experiencing symptoms, host patient (index patient or the first patient with SARS admitted to a ward) requiring oxygen therapy, and host patient requiring bi-level positive airway pressure ventilation.", [["airway", "ANATOMY", 525, 531], ["SARS", "DISEASE", 104, 108], ["SARS", "DISEASE", 429, 433], ["oxygen", "CHEMICAL", 464, 470], ["oxygen", "CHEMICAL", 464, 470], ["patient", "ORGANISM", 380, 387], ["patient", "ORGANISM", 395, 402], ["patient", "ORGANISM", 416, 423], ["oxygen", "SIMPLE_CHEMICAL", 464, 470], ["patient", "ORGANISM", 489, 496], ["airway", "MULTI-TISSUE_STRUCTURE", 525, 531], ["patient", "SPECIES", 380, 387], ["patient", "SPECIES", 395, 402], ["patient", "SPECIES", 416, 423], ["patient", "SPECIES", 489, 496], ["A recent study", "TEST", 6, 20], ["resuscitation", "TREATMENT", 287, 300], ["symptoms", "PROBLEM", 365, 373], ["SARS", "PROBLEM", 429, 433], ["oxygen therapy", "TREATMENT", 464, 478], ["bi-level positive airway pressure ventilation", "TREATMENT", 507, 552], ["airway pressure", "OBSERVATION", 525, 540]]], ["34 Two aforementioned phenomena warrant caution when we are facing emerging pandemic influenza: travel and super-spreading events.", [["influenza", "DISEASE", 85, 94], ["Two aforementioned phenomena", "PROBLEM", 3, 31], ["phenomena", "OBSERVATION", 22, 31]]], ["35, 36 It is anticipated that adults undertaking international travel might be infected and spread the disease worldwide, as noted during the SARS epidemic.", [["SARS", "DISEASE", 142, 146], ["the SARS epidemic", "PROBLEM", 138, 155], ["infected", "OBSERVATION", 79, 87], ["disease", "OBSERVATION", 103, 110]]], ["4 Once the elderly and persons with chronic illnesses are infected, the clinical presentation might be atypical and masked by comorbidities.", [["chronic illnesses are infected", "DISEASE", 36, 66], ["persons", "ORGANISM", 23, 30], ["persons", "SPECIES", 23, 30], ["chronic illnesses", "PROBLEM", 36, 53], ["infected", "PROBLEM", 58, 66], ["comorbidities", "PROBLEM", 126, 139]]], ["Furthermore, viral load might be high and viral shedding might be prolonged in immunocompromised hosts, resulting in a high chance of spread.", [["viral load", "TEST", 13, 23], ["viral shedding", "PROBLEM", 42, 56], ["immunocompromised hosts", "PROBLEM", 79, 102], ["viral load", "OBSERVATION", 13, 23], ["prolonged", "OBSERVATION_MODIFIER", 66, 75], ["spread", "OBSERVATION", 134, 140]]], ["37 Thus, super-spreading events should be taken into consideration during preparedness for a pandemic.", [["a pandemic", "PROBLEM", 91, 101]]], ["The community, patients and visitors should be educated in addition to HCWs.Mode of Transmission and Infection Control StrategiesThe major mode of transmission of SARS-CoV is through close contact, in particular, through exposure to droplets of respiratory secretions from an infected person.", [["respiratory secretions", "ANATOMY", 245, 267], ["Infection", "DISEASE", 101, 110], ["SARS", "DISEASE", 163, 167], ["patients", "ORGANISM", 15, 23], ["SARS-CoV", "ORGANISM", 163, 171], ["patients", "SPECIES", 15, 23], ["person", "SPECIES", 285, 291], ["SARS-CoV", "SPECIES", 163, 171], ["Infection Control Strategies", "TREATMENT", 101, 129], ["SARS", "PROBLEM", 163, 167], ["respiratory secretions", "PROBLEM", 245, 267], ["Infection", "OBSERVATION", 101, 110], ["respiratory", "ANATOMY", 245, 256], ["secretions", "OBSERVATION", 257, 267], ["infected", "OBSERVATION", 276, 284]]], ["However, two overlapping sets of disease signs and symptoms have been reported, with some patients having varying degrees of enteric disease.", [["enteric disease", "DISEASE", 125, 140], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["disease signs", "PROBLEM", 33, 46], ["symptoms", "PROBLEM", 51, 59], ["enteric disease", "PROBLEM", 125, 140], ["disease", "OBSERVATION", 33, 40], ["varying degrees", "OBSERVATION_MODIFIER", 106, 121], ["enteric disease", "OBSERVATION", 125, 140]]], ["Diarrhea developed early in the course of disease.", [["Diarrhea", "DISEASE", 0, 8], ["Diarrhea", "PROBLEM", 0, 8], ["disease", "PROBLEM", 42, 49], ["disease", "OBSERVATION", 42, 49]]], ["38, 39 Up to seven of the first 10 patients at NTUH 38 and five of the first 10 patients in Canada 40 had diarrhea.", [["diarrhea", "DISEASE", 106, 114], ["patients", "ORGANISM", 35, 43], ["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 35, 43], ["patients", "SPECIES", 80, 88], ["diarrhea", "PROBLEM", 106, 114]]], ["Although a review of data from China, Hong Kong, Canada and Singapore showed that only 20.1% of patients had diarrhea, 2 up to 73.3% of 75 patients treated with ribavirin and steroids had watery diarrhea.", [["diarrhea", "DISEASE", 109, 117], ["ribavirin", "CHEMICAL", 161, 170], ["steroids", "CHEMICAL", 175, 183], ["watery diarrhea", "DISEASE", 188, 203], ["ribavirin", "CHEMICAL", 161, 170], ["steroids", "CHEMICAL", 175, 183], ["patients", "ORGANISM", 96, 104], ["patients", "ORGANISM", 139, 147], ["ribavirin", "SIMPLE_CHEMICAL", 161, 170], ["steroids", "SIMPLE_CHEMICAL", 175, 183], ["patients", "SPECIES", 96, 104], ["patients", "SPECIES", 139, 147], ["diarrhea", "PROBLEM", 109, 117], ["ribavirin", "TREATMENT", 161, 170], ["steroids", "TREATMENT", 175, 183], ["watery diarrhea", "PROBLEM", 188, 203]]], ["In our cohort, diarrhea developed before the occurrence of cough [42] [43] [44] and became exacerbated in parallel to desaturation in the second week of illness.", [["diarrhea", "DISEASE", 15, 23], ["cough", "DISEASE", 59, 64], ["desaturation", "DISEASE", 118, 130], ["diarrhea", "PROBLEM", 15, 23], ["cough", "PROBLEM", 59, 64], ["parallel to desaturation", "PROBLEM", 106, 130], ["illness", "PROBLEM", 153, 160], ["desaturation", "OBSERVATION", 118, 130]]], ["38, 41 SARS-CoV in feces was identified by RT-PCR in 97% at day 14 and positivity rates were highest in feces, followed by nasopharyngeal aspirates and urine samples.", [["feces", "ANATOMY", 104, 109], ["nasopharyngeal aspirates", "ANATOMY", 123, 147], ["urine samples", "ANATOMY", 152, 165], ["SARS-CoV", "ORGANISM", 7, 15], ["feces", "ORGANISM", 19, 24], ["feces", "ORGANISM_SUBSTANCE", 104, 109], ["nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 123, 147], ["urine samples", "ORGANISM_SUBSTANCE", 152, 165], ["SARS-CoV", "SPECIES", 7, 15], ["CoV in feces", "TEST", 12, 24], ["RT", "TEST", 43, 45], ["PCR", "TEST", 46, 49], ["positivity rates", "TEST", 71, 87], ["nasopharyngeal aspirates", "TEST", 123, 147], ["urine samples", "TEST", 152, 165], ["nasopharyngeal", "ANATOMY", 123, 137], ["aspirates", "OBSERVATION", 138, 147]]], ["41 The virus is stable in feces and urine and can survive after drying on surfaces.", [["feces", "ANATOMY", 26, 31], ["urine", "ANATOMY", 36, 41], ["feces", "ORGANISM_SUBSTANCE", 26, 31], ["urine", "ORGANISM_SUBSTANCE", 36, 41], ["The virus", "PROBLEM", 3, 12], ["virus", "OBSERVATION", 7, 12], ["stable", "OBSERVATION_MODIFIER", 16, 22], ["feces", "OBSERVATION", 26, 31]]], ["45, 46 Thus, contamination of the environment by infectious respiratory secretions or other body fluids (e.g. saliva, tears, urine, feces) may play a role in disease transmission.", [["respiratory", "ANATOMY", 60, 71], ["body fluids", "ANATOMY", 92, 103], ["saliva", "ANATOMY", 110, 116], ["tears", "ANATOMY", 118, 123], ["urine", "ANATOMY", 125, 130], ["feces", "ANATOMY", 132, 137], ["body", "ORGANISM_SUBDIVISION", 92, 96], ["saliva", "ORGANISM_SUBSTANCE", 110, 116], ["tears", "ORGANISM_SUBDIVISION", 118, 123], ["urine", "ORGANISM_SUBSTANCE", 125, 130], ["feces", "ORGANISM_SUBDIVISION", 132, 137], ["infectious respiratory secretions", "PROBLEM", 49, 82], ["other body fluids", "TEST", 86, 103], ["saliva, tears, urine, feces", "TEST", 110, 137]]], ["28, 33 Thus, educating HCWs, patients, caregivers and visitors to maintain both hand hygiene and environmental hygiene together are important.", [["hand", "ANATOMY", 80, 84], ["patients", "ORGANISM", 29, 37], ["hand", "ORGANISM_SUBDIVISION", 80, 84], ["patients", "SPECIES", 29, 37]]], ["SARS-CoV is completely inactivated by \u2264 5 minutes of exposure to 75% ethanol, 500 ppm hypochlorite, and household detergent.", [["SARS", "DISEASE", 0, 4], ["ethanol", "CHEMICAL", 69, 76], ["hypochlorite", "CHEMICAL", 86, 98], ["ethanol", "CHEMICAL", 69, 76], ["hypochlorite", "CHEMICAL", 86, 98], ["SARS-CoV", "ORGANISM", 0, 8], ["ethanol", "SIMPLE_CHEMICAL", 69, 76], ["hypochlorite", "SIMPLE_CHEMICAL", 86, 98], ["SARS-CoV", "SPECIES", 0, 8], ["SARS", "PROBLEM", 0, 4], ["hypochlorite", "TREATMENT", 86, 98]]], ["45, 46 Disinfection and disinfestations are important in healthcare settings and households.", [["disinfestations", "PROBLEM", 24, 39]]], ["Disinfection of the sewage system, elimination of rodents and cockroaches, and proper garbage disposal are also important.Mode of Transmission and Infection Control StrategiesInfluenza is transmitted through close contact via large droplets, direct or indirect.", [["Infection", "DISEASE", 147, 156], ["Influenza", "DISEASE", 175, 184], ["the sewage system", "TEST", 16, 33], ["cockroaches", "TREATMENT", 62, 73], ["Infection Control", "TREATMENT", 147, 164], ["Influenza", "PROBLEM", 175, 184], ["sewage system", "OBSERVATION", 20, 33], ["Infection", "OBSERVATION", 147, 156]]], ["Fine droplet inhalational transmission may also occur.", [["Fine droplet inhalational transmission", "TREATMENT", 0, 38], ["droplet inhalational", "OBSERVATION", 5, 25]]], ["12, 13, 35, 36 Adults infected by seasonal influenza virus are typically infectious at or before the onset of illness.", [["influenza virus", "DISEASE", 43, 58], ["illness", "DISEASE", 110, 117], ["seasonal influenza virus", "ORGANISM", 34, 58], ["seasonal influenza virus", "SPECIES", 34, 58], ["seasonal influenza virus", "SPECIES", 34, 58], ["seasonal influenza virus", "PROBLEM", 34, 58], ["illness", "PROBLEM", 110, 117], ["seasonal", "OBSERVATION_MODIFIER", 34, 42], ["influenza virus", "OBSERVATION", 43, 58]]], ["Young children and immunocompromised persons can shed the virus for longer than healthy adults.", [["children", "ORGANISM", 6, 14], ["persons", "ORGANISM", 37, 44], ["children", "SPECIES", 6, 14], ["persons", "SPECIES", 37, 44]]], ["Contagiousness of influenza varies inversely with the level of immunity in the population.", [["influenza", "DISEASE", 18, 27], ["influenza", "PROBLEM", 18, 27], ["influenza", "OBSERVATION", 18, 27]]], ["17, 37 Thus, the containment or attenuation of pandemic influenza before the availability of an effective vaccination depends on early detection and before large numbers are involved.", [["influenza", "DISEASE", 56, 65], ["pandemic influenza", "PROBLEM", 47, 65], ["an effective vaccination", "TREATMENT", 93, 117], ["early detection", "TEST", 129, 144], ["attenuation", "OBSERVATION_MODIFIER", 32, 43]]], ["12 Recently, a case report described a human H5N1 infection with fever and diarrhea but no respiratory symptoms.", [["respiratory", "ANATOMY", 91, 102], ["H5N1 infection", "DISEASE", 45, 59], ["fever", "DISEASE", 65, 70], ["diarrhea", "DISEASE", 75, 83], ["respiratory symptoms", "DISEASE", 91, 111], ["human", "ORGANISM", 39, 44], ["H5N1", "ORGANISM", 45, 49], ["human", "SPECIES", 39, 44], ["human H5N1", "SPECIES", 39, 49], ["a human H5N1 infection", "PROBLEM", 37, 59], ["fever", "PROBLEM", 65, 70], ["diarrhea", "PROBLEM", 75, 83], ["respiratory symptoms", "PROBLEM", 91, 111], ["no", "UNCERTAINTY", 88, 90], ["respiratory", "ANATOMY", 91, 102], ["symptoms", "OBSERVATION", 103, 111]]], ["47 Avian influenza virus can survive in the environment for days, but it can be inactivated by standard hospital disinfectants.", [["influenza virus", "DISEASE", 9, 24], ["47", "ORGANISM", 0, 2], ["Avian influenza virus", "ORGANISM", 3, 24], ["Avian influenza virus", "SPECIES", 3, 24], ["Avian influenza virus", "SPECIES", 3, 24], ["Avian influenza virus", "PROBLEM", 3, 24], ["influenza virus", "OBSERVATION", 9, 24]]], ["36 Once again, the importance of routine cleaning and disinfection following standard procedures for the healthcare environment cannot be overemphasized.Implicit Cases and Patients with Dual DiagnosisUnrecognized cases of SARS are probably the most important factor that led to intrahospital spread and cases among HCWs.", [["SARS", "DISEASE", 222, 226], ["Patients", "ORGANISM", 172, 180], ["Patients", "SPECIES", 172, 180], ["routine cleaning", "TREATMENT", 33, 49], ["disinfection", "TREATMENT", 54, 66], ["standard procedures", "TREATMENT", 77, 96], ["SARS", "PROBLEM", 222, 226]]], ["6, 27, 28, 48 The nonspecific signs and symptoms, long incubation period (mean, 6.4 days), long time between onset of symptoms and hospital admission (from 3-5 days), 32 and lack of a reliable diagnostic test in the early phase of the illness can lead to potential transmission to frontline HCWs and the community.", [["The nonspecific signs and symptoms", "PROBLEM", 14, 48], ["symptoms", "PROBLEM", 118, 126], ["a reliable diagnostic test", "TEST", 182, 208], ["nonspecific", "OBSERVATION_MODIFIER", 18, 29]]], ["Early diagnosis relies on known history of potential exposure to SARS.", [["SARS", "DISEASE", 65, 69], ["SARS", "PROBLEM", 65, 69]]], ["High vigilance is needed and clinicians must be familiar with the rapidly changing epidemiology of this infection.Implicit Cases and Patients with Dual DiagnosisDespite efforts in developing rapid laboratory assays for SARS, the sensitivity of RT-PCR for samples collected during the first 3 days of illness is inadequate for infection control purposes.", [["samples", "ANATOMY", 255, 262], ["infection", "DISEASE", 104, 113], ["SARS", "DISEASE", 219, 223], ["infection", "DISEASE", 326, 335], ["Patients", "ORGANISM", 133, 141], ["Patients", "SPECIES", 133, 141], ["this infection", "PROBLEM", 99, 113], ["rapid laboratory assays", "TEST", 191, 214], ["SARS", "PROBLEM", 219, 223], ["RT-PCR", "TEST", 244, 250], ["samples", "TEST", 255, 262], ["illness", "PROBLEM", 300, 307], ["infection control purposes", "PROBLEM", 326, 352], ["infection", "OBSERVATION", 104, 113]]], ["Yet it is not practical and cost-effective to screen every patient with febrile illness when the incidence of disease is relatively low or when the epidemic becomes overwhelming.", [["febrile illness", "DISEASE", 72, 87], ["patient", "ORGANISM", 59, 66], ["patient", "SPECIES", 59, 66], ["febrile illness", "PROBLEM", 72, 87], ["disease", "PROBLEM", 110, 117], ["disease", "OBSERVATION", 110, 117]]], ["Screening tools using easily available symptomatic and laboratory items are highly desirable.", [["Screening tools", "TEST", 0, 15], ["symptomatic and laboratory items", "PROBLEM", 39, 71]]], ["A 6-item clinical score was developed for triaging patients with febrile illness in the emergency room.", [["febrile illness", "DISEASE", 65, 80], ["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["febrile illness", "PROBLEM", 65, 80]]], ["[42] [43] [44] The sensitivity reached 92.6% and the specificity 71.2%.", [["[42] [43] [44]", "SIMPLE_CHEMICAL", 0, 14], ["The sensitivity", "TEST", 15, 30], ["the specificity", "TEST", 49, 64]]], ["42 In this model, we emphasize the sequential development of symptoms and diarrhea in addition to cough.", [["diarrhea", "DISEASE", 74, 82], ["cough", "DISEASE", 98, 103], ["symptoms", "PROBLEM", 61, 69], ["diarrhea", "PROBLEM", 74, 82], ["cough", "PROBLEM", 98, 103], ["cough", "OBSERVATION", 98, 103]]], ["44 As this scoring system was implemented irrespective of the epidemiological link, it was useful when SARS was spreading in the community.", [["SARS", "DISEASE", 103, 107], ["SARS", "PROBLEM", 103, 107]]], ["As this discrimination system was generated during non-influenza seasons and the majority of patients in the deprivation cohort were otherwise healthy adults, the predictive value decreased in the validation cohort when patients with comorbidity acquired SARS.", [["SARS", "DISEASE", 255, 259], ["patients", "ORGANISM", 93, 101], ["patients", "ORGANISM", 220, 228], ["patients", "SPECIES", 93, 101], ["patients", "SPECIES", 220, 228], ["the predictive value", "TEST", 159, 179], ["comorbidity acquired SARS", "PROBLEM", 234, 259]]], ["43 The predictive value is anticipated to decrease in those without immunity to seasonal influenza during the influenza season.Implicit Cases and Patients with Dual DiagnosisEarly in the SARS epidemic, a case definition was generated for epidemiological purposes.", [["influenza", "DISEASE", 89, 98], ["influenza", "DISEASE", 110, 119], ["SARS", "DISEASE", 187, 191], ["Patients", "ORGANISM", 146, 154], ["Patients", "SPECIES", 146, 154], ["The predictive value", "TEST", 3, 23], ["seasonal influenza", "PROBLEM", 80, 98], ["epidemiological purposes", "TEST", 238, 262]]], ["49 Despite a global alert, several cases remained unrecognized and outbreak investigation found these implicit cases with either atypical presentation or in the early stage of infection, comorbidity or old age.", [["infection", "DISEASE", 176, 185], ["outbreak investigation", "TEST", 67, 89], ["infection", "PROBLEM", 176, 185], ["early stage", "OBSERVATION_MODIFIER", 161, 172], ["infection", "OBSERVATION", 176, 185]]], ["All evidence suggests that heightened vigilance and infection-control measures should be maintained routinely.Implicit Cases and Patients with Dual DiagnosisThe index case causing intrahospital spread in Southern Taiwan was admitted under the diagnosis of acute pyelonephritis.", [["infection", "DISEASE", 52, 61], ["pyelonephritis", "DISEASE", 262, 276], ["Patients", "ORGANISM", 129, 137], ["Patients", "SPECIES", 129, 137], ["heightened vigilance", "PROBLEM", 27, 47], ["infection", "PROBLEM", 52, 61], ["control measures", "TREATMENT", 62, 78], ["acute pyelonephritis", "PROBLEM", 256, 276], ["heightened", "OBSERVATION_MODIFIER", 27, 37], ["vigilance", "OBSERVATION_MODIFIER", 38, 47], ["infection", "OBSERVATION", 52, 61], ["acute", "OBSERVATION_MODIFIER", 256, 261], ["pyelonephritis", "OBSERVATION", 262, 276]]], ["48 Taipei (the first intrahospital spread of SARS in Taiwan) was not obtained until an infectious disease specialist was consulted for persistent fever.", [["SARS", "DISEASE", 45, 49], ["fever", "DISEASE", 146, 151], ["persistent fever", "PROBLEM", 135, 151]]], ["The index case causing the NTUH ER outbreak was a 73-year-old man with chronic cardiopulmonary and renal diseases.", [["cardiopulmonary", "ANATOMY", 79, 94], ["renal", "ANATOMY", 99, 104], ["chronic cardiopulmonary and renal diseases", "DISEASE", 71, 113], ["ER", "GENE_OR_GENE_PRODUCT", 32, 34], ["man", "ORGANISM", 62, 65], ["renal", "ORGAN", 99, 104], ["ER", "PROTEIN", 32, 34], ["man", "SPECIES", 62, 65], ["chronic cardiopulmonary and renal diseases", "PROBLEM", 71, 113], ["chronic", "OBSERVATION_MODIFIER", 71, 78], ["cardiopulmonary", "ANATOMY", 79, 94], ["renal", "ANATOMY", 99, 104], ["diseases", "OBSERVATION", 105, 113]]], ["He had dyspnea and orthopnea.", [["dyspnea", "DISEASE", 7, 14], ["orthopnea", "DISEASE", 19, 28], ["dyspnea", "PROBLEM", 7, 14], ["orthopnea", "PROBLEM", 19, 28], ["dyspnea", "OBSERVATION", 7, 14], ["orthopnea", "OBSERVATION", 19, 28]]], ["28 The first patient linked to the second phase of the Ontario outbreak was a 96-year-old man admitted with a fractured pelvis.", [["pelvis", "ANATOMY", 120, 126], ["patient", "ORGANISM", 13, 20], ["man", "ORGANISM", 90, 93], ["pelvis", "ORGAN", 120, 126], ["patient", "SPECIES", 13, 20], ["man", "SPECIES", 90, 93], ["a fractured pelvis", "PROBLEM", 108, 126], ["fractured", "OBSERVATION", 110, 119], ["pelvis", "ANATOMY", 120, 126]]], ["29 He had no apparent contact with a patient or an HCW with SARS, and aspiration pneumonia and Clostridium difficile-associated diarrhea appeared to be probable explanations for his symptoms.", [["SARS", "DISEASE", 60, 64], ["pneumonia", "DISEASE", 81, 90], ["Clostridium difficile", "DISEASE", 95, 116], ["diarrhea", "DISEASE", 128, 136], ["patient", "ORGANISM", 37, 44], ["Clostridium difficile", "ORGANISM", 95, 116], ["patient", "SPECIES", 37, 44], ["Clostridium difficile", "SPECIES", 95, 116], ["Clostridium difficile", "SPECIES", 95, 116], ["SARS", "PROBLEM", 60, 64], ["aspiration pneumonia", "PROBLEM", 70, 90], ["Clostridium difficile", "PROBLEM", 95, 116], ["associated diarrhea", "PROBLEM", 117, 136], ["his symptoms", "PROBLEM", 178, 190], ["no apparent", "UNCERTAINTY", 10, 21], ["pneumonia", "OBSERVATION", 81, 90]]], ["Both elderly patients developed fever and new pulmonary infiltration during hospitalization.Implicit Cases and Patients with Dual DiagnosisFisher et al were the first to report four patients with atypical presentations of SARS.", [["pulmonary", "ANATOMY", 46, 55], ["fever", "DISEASE", 32, 37], ["pulmonary infiltration", "DISEASE", 46, 68], ["SARS", "DISEASE", 222, 226], ["patients", "ORGANISM", 13, 21], ["pulmonary", "ORGAN", 46, 55], ["Patients", "ORGANISM", 111, 119], ["patients", "ORGANISM", 182, 190], ["patients", "SPECIES", 13, 21], ["Patients", "SPECIES", 111, 119], ["patients", "SPECIES", 182, 190], ["fever", "PROBLEM", 32, 37], ["new pulmonary infiltration", "PROBLEM", 42, 68], ["SARS", "PROBLEM", 222, 226], ["fever", "OBSERVATION", 32, 37], ["new", "OBSERVATION_MODIFIER", 42, 45], ["pulmonary", "ANATOMY", 46, 55], ["infiltration", "OBSERVATION", 56, 68]]], ["50 All had chronic cardiopulmonary diseases and three were elderly patients.", [["cardiopulmonary", "ANATOMY", 19, 34], ["chronic cardiopulmonary diseases", "DISEASE", 11, 43], ["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["chronic cardiopulmonary diseases", "PROBLEM", 11, 43], ["chronic", "OBSERVATION_MODIFIER", 11, 18], ["cardiopulmonary", "ANATOMY", 19, 34], ["diseases", "OBSERVATION", 35, 43]]], ["According to the updated interim US CDC case definition for SARS on July 16, 2003, the clinical criteria of SARS include asymptomatic or mild respiratory illness, moderate respiratory illness, and severe respiratory illness.", [["respiratory", "ANATOMY", 142, 153], ["respiratory", "ANATOMY", 172, 183], ["respiratory", "ANATOMY", 204, 215], ["SARS", "DISEASE", 60, 64], ["SARS", "DISEASE", 108, 112], ["respiratory illness", "DISEASE", 142, 161], ["respiratory illness", "DISEASE", 172, 191], ["respiratory illness", "DISEASE", 204, 223], ["SARS", "PROBLEM", 60, 64], ["SARS", "PROBLEM", 108, 112], ["asymptomatic or mild respiratory illness", "PROBLEM", 121, 161], ["moderate respiratory illness", "PROBLEM", 163, 191], ["severe respiratory illness", "PROBLEM", 197, 223], ["mild", "OBSERVATION_MODIFIER", 137, 141], ["respiratory illness", "OBSERVATION", 142, 161], ["moderate", "OBSERVATION_MODIFIER", 163, 171], ["respiratory illness", "OBSERVATION", 172, 191], ["severe", "OBSERVATION_MODIFIER", 197, 203], ["respiratory illness", "OBSERVATION", 204, 223]]], ["51 This guideline emphasized that clinical judgment should be used when evaluating patients for whom a measured temperature of > 38\u00b0C has not been documented.", [["patients", "ORGANISM", 83, 91], ["C", "GENE_OR_GENE_PRODUCT", 132, 133], ["patients", "SPECIES", 83, 91], ["a measured temperature", "TEST", 101, 123]]], ["Factors that might be considered include patient self-report of fever, use of antipyretics, presence of immunocompromising conditions or therapies, lack of access to healthcare, or inability to obtain a measured temperature.Implicit Cases and Patients with Dual DiagnosisAsymptomatic or mild cases, though limited in numbers, were documented.", [["fever", "DISEASE", 64, 69], ["patient", "ORGANISM", 41, 48], ["Patients", "ORGANISM", 243, 251], ["patient", "SPECIES", 41, 48], ["Patients", "SPECIES", 243, 251], ["fever", "PROBLEM", 64, 69], ["antipyretics", "TREATMENT", 78, 90], ["immunocompromising conditions", "PROBLEM", 104, 133], ["therapies", "TREATMENT", 137, 146], ["a measured temperature", "PROBLEM", 201, 223], ["Dual DiagnosisAsymptomatic or mild cases", "PROBLEM", 257, 297], ["mild", "OBSERVATION_MODIFIER", 287, 291], ["cases", "OBSERVATION", 292, 297]]], ["[52] [53] [54] [55] [56] [57] The seroprevalence of antibody to SARS-CoV in cohorts of HCWs with subclinical infection in SARS and non-SARS medical wards was 2.3% and 0%, respectively.", [["[52] [53] [54", "CHEMICAL", 0, 13], ["SARS", "DISEASE", 64, 68], ["infection", "DISEASE", 109, 118], ["SARS", "DISEASE", 122, 126], ["[52] [53] [54] [55] [56] [57]", "SIMPLE_CHEMICAL", 0, 29], ["SARS-CoV", "ORGANISM", 64, 72], ["HCWs", "ORGANISM", 87, 91], ["SARS-CoV", "SPECIES", 64, 72], ["antibody", "TEST", 52, 60], ["SARS", "PROBLEM", 64, 68], ["CoV", "PROBLEM", 69, 72], ["subclinical infection in SARS", "PROBLEM", 97, 126], ["subclinical", "OBSERVATION_MODIFIER", 97, 108], ["infection", "OBSERVATION", 109, 118]]], ["57 A seroprevalence survey in Guangzhou identified its presence in 40% of animal traders, 20% of animal slaughterers, 5% of vegetable traders and 0% of controls.", [["slaughterers", "DISEASE", 104, 116], ["vegetable", "ORGANISM_SUBDIVISION", 124, 133]]], ["15 Che et al 52 recently reported the first case of asymptomatic SARS with antigenemia and seroconversion who worked in the same restaurant with one of the four community-acquired cases of SARS.What We Know for CertainAlthough it is impossible to predict the individual emergence in time and place, we can be confident that new microbial diseases will emerge.", [["SARS", "DISEASE", 65, 69], ["antigenemia", "DISEASE", 75, 86], ["SARS", "DISEASE", 189, 193], ["microbial diseases", "DISEASE", 328, 346], ["asymptomatic SARS", "PROBLEM", 52, 69], ["antigenemia", "PROBLEM", 75, 86], ["seroconversion", "TREATMENT", 91, 105], ["SARS", "PROBLEM", 189, 193], ["new microbial diseases", "PROBLEM", 324, 346]]], ["Every one of us should work together to build a stronger, more flexible healthcare and public health system that is well-prepared to respond to known disease problems, as well as to address the unexpected, whether it be an influenza pandemic, a disease caused by an unknown organism, or a bioterrorist attack.What We Know for CertainSARS and highly pathogenic avian influenza are two important emergent infections with pandemic potential.", [["influenza pandemic", "DISEASE", 223, 241], ["avian influenza", "DISEASE", 360, 375], ["infections", "DISEASE", 403, 413], ["pandemic", "DISEASE", 419, 427], ["avian influenza", "ORGANISM", 360, 375], ["avian influenza", "SPECIES", 360, 375], ["known disease problems", "PROBLEM", 144, 166], ["an influenza pandemic", "PROBLEM", 220, 241], ["a disease", "PROBLEM", 243, 252], ["an unknown organism", "PROBLEM", 263, 282], ["CertainSARS", "PROBLEM", 326, 337], ["highly pathogenic avian influenza", "PROBLEM", 342, 375], ["influenza", "OBSERVATION", 223, 232], ["infections", "OBSERVATION", 403, 413]]], ["Both infections have crossed the species barrier to infect humans.", [["infections", "DISEASE", 5, 15], ["humans", "ORGANISM", 59, 65], ["humans", "SPECIES", 59, 65], ["humans", "SPECIES", 59, 65], ["Both infections", "PROBLEM", 0, 15], ["infections", "OBSERVATION", 5, 15]]], ["As with the outbreak of SARS, the development of sensitive and accurate early diagnostic tests is extremely important for successful control of the outbreak at source.", [["SARS", "DISEASE", 24, 28], ["SARS", "PROBLEM", 24, 28], ["diagnostic tests", "TEST", 78, 94]]], ["The availability of isolation facilities, the stockpiling of antiviral agents and effective and safe vaccination will be extremely important in minimizing the damage of a new influenza pandemic.", [["influenza", "DISEASE", 175, 184], ["isolation facilities", "TREATMENT", 20, 40], ["antiviral agents", "TREATMENT", 61, 77], ["safe vaccination", "TREATMENT", 96, 112], ["a new influenza pandemic", "PROBLEM", 169, 193], ["new", "OBSERVATION_MODIFIER", 171, 174], ["influenza", "OBSERVATION", 175, 184]]], ["However, there are important differences in the dynamics of infection between SARS and influenza A/H5N1 which have had an impact on infection control (Table) .", [["infection", "DISEASE", 60, 69], ["SARS", "DISEASE", 78, 82], ["influenza A/H5N1", "DISEASE", 87, 103], ["infection", "DISEASE", 132, 141], ["influenza A/H5N1", "ORGANISM", 87, 103], ["influenza A/H5N1", "SPECIES", 87, 103], ["influenza A/H5N1", "SPECIES", 87, 103], ["infection", "PROBLEM", 60, 69], ["SARS", "PROBLEM", 78, 82], ["influenza A/H5N1", "PROBLEM", 87, 103], ["infection control", "TREATMENT", 132, 149], ["infection", "OBSERVATION", 60, 69], ["infection", "OBSERVATION", 132, 141]]], ["[58] [59] [60] [61] [62] [63] [64]Reinforcement of infection control measures and compliance monitoring on a regular basisStandard precautions should be applied to every patient and education should be given to everyone in healthcare facilities.", [["infection", "DISEASE", 51, 60], ["[58] [59] [60] [61] [62] [63]", "CHEMICAL", 0, 29], ["[58] [59] [60] [61] [62] [63] [64]", "SIMPLE_CHEMICAL", 0, 34], ["patient", "ORGANISM", 170, 177], ["patient", "SPECIES", 170, 177], ["infection control measures", "TREATMENT", 51, 77], ["compliance monitoring", "TEST", 82, 103], ["Standard precautions", "TREATMENT", 122, 142], ["infection", "OBSERVATION", 51, 60]]], ["25 HCWs, caregivers and even the patient should follow hand hygiene practices (e.g. washing hands before and after touching a patient or the environment, even when no epidemic is apparent).", [["hand", "ANATOMY", 55, 59], ["patient", "ORGANISM", 33, 40], ["hand", "ORGANISM_SUBDIVISION", 55, 59], ["patient", "ORGANISM", 126, 133], ["patient", "SPECIES", 33, 40], ["patient", "SPECIES", 126, 133], ["hand hygiene practices", "TREATMENT", 55, 77]]], ["Following the SARS outbreak in a nearby hospital, HCWs at NTUH ER wear N-95 respirators for all patient care.", [["SARS", "DISEASE", 14, 18], ["patient", "ORGANISM", 96, 103], ["patient", "SPECIES", 96, 103], ["all patient care", "TREATMENT", 92, 108]]], ["However, masks do not prevent acquisition of SARS from a contaminated environment.", [["SARS", "DISEASE", 45, 49], ["masks", "TREATMENT", 9, 14], ["SARS", "PROBLEM", 45, 49]]], ["28, 65 Furthermore, it is likely the spread of SARS was facilitated by lack of proper hand washing after taking care of unrecognized SARS patients.", [["hand", "ANATOMY", 86, 90], ["SARS", "DISEASE", 47, 51], ["SARS", "DISEASE", 133, 137], ["hand", "ORGANISM_SUBDIVISION", 86, 90], ["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 138, 146], ["SARS", "PROBLEM", 47, 51], ["proper hand washing", "TREATMENT", 79, 98], ["is likely", "UNCERTAINTY", 23, 32]]], ["34 Compliance monitoring and reinforcement are needed for maximal effectiveness of infection control measures.Respiratory hygiene/cough etiquetteHealthcare facilities should promote respiratory hygiene/cough etiquette by educating HCWs, patients, caregivers, and visitors on the importance of containing respiratory spray and secretions to help prevent the transmission of influenza and other respiratory viruses.", [["Respiratory", "ANATOMY", 110, 121], ["respiratory", "ANATOMY", 182, 193], ["respiratory", "ANATOMY", 304, 315], ["infection", "DISEASE", 83, 92], ["influenza", "DISEASE", 373, 382], ["respiratory viruses", "DISEASE", 393, 412], ["patients", "ORGANISM", 237, 245], ["patients", "SPECIES", 237, 245], ["Compliance monitoring", "TEST", 3, 24], ["reinforcement", "TREATMENT", 29, 42], ["infection control measures", "TREATMENT", 83, 109], ["respiratory spray", "TREATMENT", 304, 321], ["secretions", "TREATMENT", 326, 336], ["influenza", "PROBLEM", 373, 382], ["other respiratory viruses", "PROBLEM", 387, 412], ["infection", "OBSERVATION", 83, 92], ["respiratory viruses", "OBSERVATION", 393, 412]]], ["14, 36, 66 Healthcare facilities should post signs requesting that patients and family members with acute febrile respiratory illness use respiratory hygiene/cough etiquette and provide resources for hand hygiene in common areas.", [["respiratory", "ANATOMY", 114, 125], ["respiratory", "ANATOMY", 138, 149], ["hand", "ANATOMY", 200, 204], ["febrile respiratory illness", "DISEASE", 106, 133], ["patients", "ORGANISM", 67, 75], ["hand", "ORGANISM_SUBDIVISION", 200, 204], ["patients", "SPECIES", 67, 75], ["acute febrile respiratory illness", "PROBLEM", 100, 133], ["respiratory hygiene", "TREATMENT", 138, 157], ["cough etiquette", "TREATMENT", 158, 173], ["hand hygiene", "TREATMENT", 200, 212]]], ["It is likely that some aerosol-generating medical procedures (such as endotracheal intubation, open suctioning, nebulizer treatment, bronchoscopy, and positive airway pressure devices) could increase the potential for generation of small aerosols in the immediate vicinity of the patient and may inadvertently spread the disease.", [["endotracheal", "ANATOMY", 70, 82], ["airway", "ANATOMY", 160, 166], ["airway", "MULTI-TISSUE_STRUCTURE", 160, 166], ["patient", "ORGANISM", 280, 287], ["patient", "SPECIES", 280, 287], ["some aerosol", "TREATMENT", 18, 30], ["medical procedures", "TREATMENT", 42, 60], ["endotracheal intubation", "TREATMENT", 70, 93], ["open suctioning", "TREATMENT", 95, 110], ["nebulizer treatment", "TREATMENT", 112, 131], ["bronchoscopy", "TREATMENT", 133, 145], ["positive airway pressure devices", "TREATMENT", 151, 183], ["small aerosols", "PROBLEM", 232, 246], ["the disease", "PROBLEM", 317, 328], ["is likely", "UNCERTAINTY", 3, 12], ["airway", "ANATOMY", 160, 166], ["small", "OBSERVATION_MODIFIER", 232, 237], ["aerosols", "OBSERVATION", 238, 246], ["disease", "OBSERVATION", 321, 328]]], ["34 Thus, these procedures should be performed with precautions and kept in mind for emerging diseases, tuberculosis and other respiratory infectious diseases.", [["respiratory", "ANATOMY", 126, 137], ["tuberculosis", "DISEASE", 103, 115], ["respiratory infectious diseases", "DISEASE", 126, 157], ["these procedures", "TREATMENT", 9, 25], ["precautions", "TREATMENT", 51, 62], ["emerging diseases", "PROBLEM", 84, 101], ["tuberculosis", "PROBLEM", 103, 115], ["other respiratory infectious diseases", "PROBLEM", 120, 157], ["tuberculosis", "OBSERVATION", 103, 115], ["respiratory", "ANATOMY", 126, 137], ["infectious", "OBSERVATION", 138, 148]]], ["In addition, aerosol-generating procedures should be performed in an airborne isolation environment.", [["aerosol-generating procedures", "TREATMENT", 13, 42], ["an airborne isolation environment", "TREATMENT", 66, 99]]], ["36Recognition of a new disease or a cluster of infectionA repeated theme in reviewing emergent outbreaks is that it is essential that astute clinicians with sufficient experience recognize and distinguish something new.", [["a new disease", "PROBLEM", 17, 30], ["infectionA", "PROBLEM", 47, 57], ["new", "OBSERVATION_MODIFIER", 19, 22], ["disease", "OBSERVATION", 23, 30], ["cluster", "OBSERVATION_MODIFIER", 36, 43]]], ["25, 36 Appropriate history taking when a patient with a fever is seen, to obtain important information, such as recent travel history, occupation, contacts with possibly infected persons, persons with similar symptoms, sick or dead animals, or a cluster of persons with similar symptoms, could help to quickly identify people at risk and reduce spread.Immediate source and contact tracing, quarantine and isolationSource and contact tracing should rapidly identify possible early secondary cases and any unrecognized sources of infection for persons without epidemiologic links.", [["fever", "DISEASE", 56, 61], ["infection", "DISEASE", 528, 537], ["patient", "ORGANISM", 41, 48], ["persons", "ORGANISM", 179, 186], ["persons", "ORGANISM", 188, 195], ["persons", "ORGANISM", 257, 264], ["people", "ORGANISM", 319, 325], ["persons", "ORGANISM", 542, 549], ["patient", "SPECIES", 41, 48], ["persons", "SPECIES", 179, 186], ["persons", "SPECIES", 188, 195], ["persons", "SPECIES", 257, 264], ["people", "SPECIES", 319, 325], ["persons", "SPECIES", 542, 549], ["a fever", "PROBLEM", 54, 61], ["similar symptoms", "PROBLEM", 201, 217], ["similar symptoms", "PROBLEM", 270, 286], ["contact tracing", "TEST", 373, 388], ["isolationSource", "TREATMENT", 405, 420], ["contact tracing", "TEST", 425, 440], ["early secondary cases", "PROBLEM", 474, 495], ["infection", "PROBLEM", 528, 537], ["infection", "OBSERVATION", 528, 537]]], ["Regarding risk of intrahospital spread of a highly contagious disease, infectioncontrol teams may additionally institute passive or active surveillance for pneumonia or fever among staff and patients, combined with diagnostic testing for the infectious agent.", [["pneumonia", "DISEASE", 156, 165], ["fever", "DISEASE", 169, 174], ["patients", "ORGANISM", 191, 199], ["patients", "SPECIES", 191, 199], ["a highly contagious disease", "PROBLEM", 42, 69], ["infectioncontrol teams", "TREATMENT", 71, 93], ["active surveillance", "TEST", 132, 151], ["pneumonia", "PROBLEM", 156, 165], ["fever", "PROBLEM", 169, 174], ["diagnostic testing", "TEST", 215, 233], ["the infectious agent", "TREATMENT", 238, 258], ["pneumonia", "OBSERVATION", 156, 165], ["infectious", "OBSERVATION", 242, 252]]], ["Specific infection control measures were implemented for patients with SARS, H5N1, or other highly contagious diseases.", [["infection", "DISEASE", 9, 18], ["SARS", "DISEASE", 71, 75], ["H5N1", "DISEASE", 77, 81], ["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["Specific infection control measures", "TREATMENT", 0, 35], ["SARS", "PROBLEM", 71, 75], ["H5N1", "PROBLEM", 77, 81], ["other highly contagious diseases", "PROBLEM", 86, 118], ["infection", "OBSERVATION", 9, 18]]], ["14, 25, 28, 36 In non-SARS areas, infection control measures were upgraded stepwise in response to possible healthcare associated transmission and the increasing possibility of community spread of SARS.", [["infection", "DISEASE", 34, 43], ["SARS", "DISEASE", 197, 201], ["infection control measures", "TREATMENT", 34, 60], ["community spread of SARS", "PROBLEM", 177, 201], ["infection", "OBSERVATION", 34, 43]]], ["On the other hand, personal protective equipment in hospital services caring for SARS or avian influenza, and its disposition were stratified based on the risk assessment because resources might be limited.", [["SARS", "DISEASE", 81, 85], ["influenza", "DISEASE", 95, 104], ["avian", "SPECIES", 89, 94], ["SARS", "PROBLEM", 81, 85], ["avian influenza", "PROBLEM", 89, 104], ["the risk assessment", "TEST", 151, 170]]], ["12, 67 In response to inadequate capacity of the negative pressure isolation room within the intensive care facility, intubated patients whose airway secretions, stool and urine become negative for SARS-CoV or H5N1 RNA should be removed from the negative pressure isolation rooms.", [["airway secretions", "ANATOMY", 143, 160], ["stool", "ANATOMY", 162, 167], ["urine", "ANATOMY", 172, 177], ["SARS", "DISEASE", 198, 202], ["patients", "ORGANISM", 128, 136], ["airway secretions", "MULTI-TISSUE_STRUCTURE", 143, 160], ["stool", "ORGANISM_SUBSTANCE", 162, 167], ["urine", "ORGANISM_SUBSTANCE", 172, 177], ["SARS-CoV", "ORGANISM", 198, 206], ["H5N1", "ORGANISM", 210, 214], ["patients", "SPECIES", 128, 136], ["SARS-CoV", "SPECIES", 198, 206], ["H5N1", "SPECIES", 210, 214], ["intubated", "TREATMENT", 118, 127], ["airway secretions", "TEST", 143, 160], ["stool and urine", "TEST", 162, 177], ["SARS", "PROBLEM", 198, 202], ["CoV", "PROBLEM", 203, 206], ["H5N1 RNA", "TREATMENT", 210, 218], ["airway", "ANATOMY", 143, 149], ["secretions", "OBSERVATION", 150, 160]]], ["Droplet and contact precautions and inline suction should be performed in single rooms.Risk assessmentIn facing emerging infectious diseases, WHO emphasizes risk assessment, including burden assessment and needs assessment.", [["infectious diseases", "DISEASE", 121, 140], ["Droplet", "TREATMENT", 0, 7], ["contact precautions", "TREATMENT", 12, 31], ["inline suction", "TREATMENT", 36, 50], ["risk assessment", "TEST", 157, 172], ["burden assessment", "TEST", 184, 201], ["assessment", "TEST", 212, 222]]], ["12 Disease pattern, population at risk and factors affecting transmission pattern and control activities will be determined or characterized.", [["12 Disease pattern", "PROBLEM", 0, 18], ["population at risk", "PROBLEM", 20, 38], ["Disease", "OBSERVATION", 3, 10], ["population", "OBSERVATION_MODIFIER", 20, 30]]], ["The scale of interventions required to control an epidemic depends on the number of infectious cases present at the time the control measures are instituted and on logistical constraints, such as availability of isolation facilities.", [["interventions", "TREATMENT", 13, 26], ["an epidemic depends", "PROBLEM", 47, 66], ["infectious cases", "PROBLEM", 84, 100], ["isolation facilities", "TREATMENT", 212, 232], ["infectious", "OBSERVATION", 84, 94]]], ["Furthermore, isolation and quarantine procedures will be less effective as more cases accrue.", [["isolation", "TREATMENT", 13, 22], ["quarantine procedures", "TREATMENT", 27, 48]]], ["68 Therefore, stringent measures implemented early in the course of the epidemic prevent the need for more stringent measures as the epidemic spreads.", [["stringent measures", "TREATMENT", 14, 32], ["more stringent measures", "TREATMENT", 102, 125]]], ["18 Nevertheless, it is practical and most feasible that routine infection control strategies and traditional, standard interventions used during outbreak control should be applied immediately before laboratory confirmation of the causative agent.", [["infection", "DISEASE", 64, 73], ["routine infection control strategies", "TREATMENT", 56, 92], ["standard interventions", "TREATMENT", 110, 132], ["outbreak control", "TREATMENT", 145, 161], ["laboratory confirmation", "TEST", 199, 222], ["infection", "OBSERVATION", 64, 73]]], ["Hand and respiratory hygiene should be promoted.", [["respiratory", "ANATOMY", 9, 20], ["respiratory hygiene", "TREATMENT", 9, 28], ["respiratory", "ANATOMY", 9, 20], ["hygiene", "OBSERVATION", 21, 28]]], ["Domestic cleaning using household cleaning products, to reduce transmission via fomites and from infectious respiratory secretions on surfaces, is important as well.", [["respiratory", "ANATOMY", 108, 119], ["Domestic cleaning", "TREATMENT", 0, 17], ["household cleaning products", "TREATMENT", 24, 51], ["transmission via fomites", "PROBLEM", 63, 87], ["infectious respiratory secretions", "PROBLEM", 97, 130], ["infectious", "OBSERVATION_MODIFIER", 97, 107], ["respiratory secretions", "OBSERVATION", 108, 130]]], ["The environment surrounding an outbreak is unique in public health.", [["outbreak", "OBSERVATION_MODIFIER", 31, 39]]], ["Outbreaks are frequently marked by uncertainty, confusion and a sense of urgency.", [["confusion", "DISEASE", 48, 57], ["Outbreaks", "PROBLEM", 0, 9], ["confusion", "PROBLEM", 48, 57], ["urgency", "PROBLEM", 73, 80], ["marked", "OBSERVATION_MODIFIER", 25, 31]]], ["Communication failures delay outbreak control, undermine public trust and compliance, and unnecessarily prolong economic, social and political turmoil.", [["Communication failures", "PROBLEM", 0, 22]]], ["If implemented effectively, guidelines for outbreak communication will result in greater public resilience and guide appropriate public participation to support the rapid containment of an outbreak, thus limiting morbidity and mortality.", [["an outbreak", "PROBLEM", 186, 197]]], ["69 In addition, effective outbreak communication will minimize the damage to a nation's international standing, its economy and its public health infrastructure.", [["the damage", "PROBLEM", 63, 73]]], ["However, the decisions and actions of public health officials have a greater effect on trust and public risk perception than communication.ConclusionThe population-dense regions of Southeast Asia are the epicenter of many emerging diseases, as evidenced by the outbreak of SARS, avian influenza A/H5N1, dengue, and enterovirus 71 in this region in the past decade.", [["SARS", "DISEASE", 273, 277], ["influenza A/H5N1, dengue, and enterovirus 71", "DISEASE", 285, 329], ["avian influenza A/H5N1", "ORGANISM", 279, 301], ["enterovirus 71", "ORGANISM", 315, 329], ["avian influenza", "SPECIES", 279, 294], ["A/H5N1", "SPECIES", 295, 301], ["dengue", "SPECIES", 303, 309], ["many emerging diseases", "PROBLEM", 217, 239], ["SARS", "PROBLEM", 273, 277], ["avian influenza A/H5N1", "PROBLEM", 279, 301], ["dengue", "PROBLEM", 303, 309], ["enterovirus", "PROBLEM", 315, 326], ["population", "OBSERVATION_MODIFIER", 153, 163], ["dense", "OBSERVATION_MODIFIER", 164, 169], ["regions", "OBSERVATION_MODIFIER", 170, 177], ["Southeast Asia", "OBSERVATION", 181, 195], ["epicenter", "OBSERVATION_MODIFIER", 204, 213], ["many", "OBSERVATION_MODIFIER", 217, 221], ["emerging", "OBSERVATION_MODIFIER", 222, 230], ["diseases", "OBSERVATION", 231, 239]]], ["Rapid identification, epidemiologic surveillance, and prevention of transmission are major challenges in ensuring public health safety.", [["Rapid identification", "TEST", 0, 20], ["epidemiologic surveillance", "TEST", 22, 48]]], ["Pandemic prevention strategies must be based on preparing for the unexpected and being capable of reacting accordingly.ConclusionStrategies for survival in the face of emerging pathogens include biotechnology (chemoprophylaxis, vaccines, treatment), public health (for foodborne, water-borne and fecal-borne diseases), and behavior modification (for sexually transmitted diseases).", [["fecal-borne diseases", "DISEASE", 296, 316], ["sexually transmitted diseases", "DISEASE", 350, 379], ["fecal", "ORGANISM_SUBDIVISION", 296, 301], ["Pandemic prevention strategies", "TREATMENT", 0, 30], ["survival", "TREATMENT", 144, 152], ["emerging pathogens", "PROBLEM", 168, 186], ["biotechnology (chemoprophylaxis", "TREATMENT", 195, 226], ["vaccines", "TREATMENT", 228, 236], ["treatment", "TREATMENT", 238, 247], ["foodborne", "PROBLEM", 269, 278], ["fecal-borne diseases", "PROBLEM", 296, 316], ["sexually transmitted diseases", "PROBLEM", 350, 379], ["fecal", "ANATOMY", 296, 301]]], ["70 However, prevention of airborne transmission of microbes remains a challenge.ConclusionThe primary role of an infection-control program is to reduce the risk of healthcare-associated infection, thereby protecting patients, HCWs and visitors.", [["infection", "DISEASE", 113, 122], ["infection", "DISEASE", 186, 195], ["patients", "ORGANISM", 216, 224], ["patients", "SPECIES", 216, 224], ["an infection-control program", "TREATMENT", 110, 138], ["healthcare-associated infection", "PROBLEM", 164, 195], ["infection", "OBSERVATION", 113, 122], ["infection", "OBSERVATION", 186, 195]]], ["Prevention of transmission of a contagious infectious disease is thus an important guard for the whole society.", [["infectious disease", "DISEASE", 43, 61], ["a contagious infectious disease", "PROBLEM", 30, 61]]], ["Healthy habits can protect everyone from getting germs or spreading germs at home, school or work.", [["germs", "ANATOMY", 49, 54], ["germs", "ANATOMY", 68, 73], ["germs", "ORGAN", 68, 73]]], ["Simple actions, like covering your mouth and nose and washing your hands often, can stop germs and prevent illnesses.", [["mouth", "ANATOMY", 35, 40], ["nose", "ANATOMY", 45, 49], ["mouth", "ORGANISM_SUBDIVISION", 35, 40], ["nose", "ORGANISM_SUBDIVISION", 45, 49], ["Simple actions", "PROBLEM", 0, 14], ["your mouth and nose", "PROBLEM", 30, 49], ["illnesses", "PROBLEM", 107, 116], ["mouth", "ANATOMY", 35, 40], ["nose", "ANATOMY", 45, 49]]], ["66 Emerging infectious diseases can be contained with high-level government commitment and international collaboration to strengthen infectious disease surveillance and response, improve methods for gathering and evaluating surveillance data, ensure the use of surveillance data to improve public health practice and medical treatment, strengthen a nation's capacity to monitor and respond to emerging infectious diseases, implement, support, and evaluate programs for the prevention and control of emerging infectious diseases, and to develop, evaluate, and promote strategies to help healthcare providers and other persons change behavior that facilitates disease transmission.", [["infectious diseases", "DISEASE", 12, 31], ["infectious disease", "DISEASE", 133, 151], ["infectious diseases", "DISEASE", 402, 421], ["infectious diseases", "DISEASE", 508, 527], ["persons", "ORGANISM", 617, 624], ["persons", "SPECIES", 617, 624], ["Emerging infectious diseases", "PROBLEM", 3, 31], ["surveillance data", "TEST", 224, 241], ["surveillance data", "TEST", 261, 278], ["public health practice", "TREATMENT", 290, 312], ["medical treatment", "TREATMENT", 317, 334], ["emerging infectious diseases", "PROBLEM", 393, 421], ["emerging infectious diseases", "PROBLEM", 499, 527], ["infectious", "OBSERVATION", 12, 22]]], ["The mobilization and coordination of efforts at all levels of government and private sectors are also important.", [["The mobilization", "TREATMENT", 0, 16], ["mobilization", "OBSERVATION_MODIFIER", 4, 16]]], ["Furthermore, international collaboration and resource and information sharing are also essential for the control of emerging diseases worldwide.ConclusionHowever, challenges remain, including how best to allocate limited medical and public health resources for preparedness planning.", [["preparedness planning", "TREATMENT", 261, 282]]], ["Whether avian influenza will become a pandemic or SARS will become a recurring problem is uncertain, but lessons learned while preparing for that eventuality will be important for other global infectious disease outbreaks.", [["avian influenza", "DISEASE", 8, 23], ["SARS", "DISEASE", 50, 54], ["infectious disease", "DISEASE", 193, 211], ["avian influenza", "ORGANISM", 8, 23], ["avian", "SPECIES", 8, 13], ["avian influenza", "PROBLEM", 8, 23], ["a pandemic", "PROBLEM", 36, 46], ["SARS", "PROBLEM", 50, 54], ["a recurring problem", "PROBLEM", 67, 86], ["other global infectious disease outbreaks", "PROBLEM", 180, 221], ["infectious", "OBSERVATION", 193, 203]]]], "5e08b5cac534329f901fda71f98fe298db61f972": [["On 11 th March 2020, the World Health Organisation (WHO) declared Coronavirus (COVID-19) a pandemic.", [["Coronavirus", "PROBLEM", 66, 77], ["COVID", "TEST", 79, 84], ["a pandemic", "PROBLEM", 89, 99]]], ["As of 16 th May 2020, 188 countries/regions were hit with 4,570,370 infected cases and 308,317 deaths (Dong, 2020) .", [["deaths", "DISEASE", 95, 101], ["hit", "PROBLEM", 49, 52]]], ["Northern Italy has had the most impact with Lombardy having the highest prevalence of COVID-19 infections (84,119, 15,411 deaths) and Veneto having the fourthhighest prevalence (18,889, 1,762 deaths) (Ministero Della Salute, 2020).", [["infections", "DISEASE", 95, 105], ["deaths", "DISEASE", 122, 128], ["deaths", "DISEASE", 192, 198], ["COVID", "TEST", 86, 91]]]]}